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Maranda K. Thompson, Ph.D.
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Normal pregnancy relies on inflammation for implantation, placentation, and
parturition, but uncontrolled it can lead to poor infant outcomes. Maternal diet is one
modifiable factor that can impact inflammation. Omega-3 and omega-6 fatty acids have
been shown to be metabolized into bioactive metabolites that effect inflammation. The
presence and importance of these metabolites at the time of delivery are not well
understood. Therefore, the purpose of this dissertation was to first quantify omega-3 and
omega-6 metabolites in maternal plasma, cord plasma, and placental tissue. Then the
relationships between metabolites and infant outcomes, including birth weight percentile,
length percentile, head circumferences percentile, prematurity and admission to the
Neonatal Intensive Care Unit were explored. Lastly, the associations of GPR18 receptor
expression and prematurity were explored. An IRB-approved cross-sectional study
enrolled 120 maternal-infant pairs for infants born at Nebraska Medicine Hospital.
Placental tissue, maternal blood and umbilical cord blood samples were collected and
analyzed for metabolite concentrations. Mothers completed a food frequency
questionnaire to identify usual intake. Demographic and birth outcome data were
collected from the electronic medical record. Omega-3 and Omega-6 metabolites from
the enzymatic lipoxygenase pathway are present at delivery. Birth length percentile was
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positively associated with cord metabolites 9-hydroxyoctadecadienoic acid (HODE), 13HODE, 13-ketooctadecadienoic acid (KODE), and 5-hydroxyeicosapentaenoic acid
(HEPE). Birth weight percentiles were negatively predicted by maternal 5,15dihydroxyeicosatetraenoic acid (DiHETE), maternal 7-hydroxydocosahexaenoic acid
(HDHA), and placental leukotriene B4 (LTB4). Further, maternal lipoxin A4 (LXA4)
reduced the odds of admission to the neonatal intensive care unit (NICU), while cord
14,15-dihydroxyeicosatrienoic acid (DiHET) reduced the odds of prematurity. In the
setting of prematurity, the expression of specialized pro-resolving mediator resolvin D2’s
G-coupled-protein receptor was lower in in placental vascular smooth muscle cells
relative to term placentas. Conclusively from this study, a diverse group of omega-3 and
omega-6 metabolites were identified at delivery. Further, these results highlight roles of
oxylipins in fetal growth, with potential benefits conferred to the developing infant.
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CHAPTER 1: Introduction

2
Inflammation is necessary to defend our bodies against infections and other
noxious insults. There are five signs of inflammation, including fever, pain, redness,
swelling, and loss of function. Chemokines and cytokines are mediators of inflammation
that act on blood vessels, nerves, and tissue to contribute to the five classical signs.1,2
Inflammation serves to resolve injury, remove debris, initiate tissue repair and
regeneration, and suppress and prevent infection. The inflammatory response has been
shown to be regulated by pro- and anti-inflammatory molecules. Previously,
inflammation resolution was thought to be a passive process where pro-inflammatory
molecules became diluted over time. However, studies have now demonstrated that
anti-inflammatory molecules are synthesized at the same time and help to resolve the
inflammation and restore the tissue to homeostasis.2–6
Diet is a modifiable factor in inflammation resolution. Omega-3 (n-3) and n-6 fatty
acids (FA) have several important structural and functional roles in the body, and their
bioactive fatty acid metabolites are important in the inflammation system regulation.7
Omega-3 and n-6 FAs are incorporated into the phospholipid bilayer and released from
the membrane to influence downstream pathways.8 The essential fatty acids that must
be obtained from the diet are linoleic acid (LA) and alpha-linolenic acid (ALA). LA is the
parent nutrient for arachidonic acid (AA) and dihomo g-linolenic acid (DGLA).
Docosahexaenoic (DHA) and eicosapentaenoic acid (EPA) are synthesized from ALA.
However, less than ten percent of ALA can be converted to DHA and EPA, making
preformed DHA and EPA consumption through the diet and supplementation necessary
to reach recommended intakes.9 Omega-3 and n-6 FAs influence the inflammation
cascade through their metabolism into bioactive metabolites. These metabolites are
necessary for normal physiology but can also have a role in human disease.

3
The influence of n-3 and n-6 metabolites during pregnancy and their role in
normal and adverse outcomes is a newer body of research. Little is known about the role
of these diverse eicosanoids and how they contribute throughout gestation to maternalinfant outcomes. Therefore, understanding the interactions between controlled
inflammation, the presence of n-3 and n-6 metabolites, and areas of dysfunction
between the two in pregnancy is imperative to create useful preventative and treatment
measures.

The following sections will detail physiological processes throughout

gestation, areas of dysfunction, and the role n-3 and n-6 metabolites have in both. Then
to bring it all together, prematurity and pre-eclampsia will be discussed due to their
relation to inflammation and the recent literature beginning to show the presence of
metabolites in these high-risk outcomes.

1.1. The Relationship between Inflammation and Nutrition during Normal
Pregnancy
Normal pregnancies rely on controlled inflammation from implantation of the
blastocyst to parturition. Mor et al. categorized pregnancy into three immunological
events, denoted as Stage 1-3 in Figures 1 and 2.10 Early pregnancy is the first stage
which includes the first and second trimester when implantation and placentation occur.
During this stage, the body relies heavily on inflammation. The second stage is midpregnancy, where rapid fetal growth and development occur within a characteristically
anti-inflammatory environment. Lastly, late pregnancy is an inflammatory process as
mothers

begin

to

prepare

for

delivery.11–13
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Figure 1: Mor et al. Stage 1 of Immunological Events Occurring During Pregnancy
Implantation relies on the presence of inflammatory cytokines, chemokines and other mediators to invade the uterine wall. During
placentation there is a dynamic relationship between the uterine wall and the placenta for trophoblast differentiation and proper placental
development. Inflammation is indicated by the red dots in the figure. Figure created in BioRender.
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Figure 2: Mor et al. Stages 2-3 of Immunological Events Occurring During Pregnancy
Stage 2 is defined by a balance between pro- and anti-inflammatory mediators, with a shift towards an anti-inflammatory environment.
Inflammation is needed to prevent infection and rejection of the fetus. Stage 3 is a pro-inflammatory state with preparation for labor and
delivery. Cytokines and mediators remodel the cervix and infiltrate the uterus to participate in uterine contractions. Blue dots represent antinflammatory and red dots represent pro-inflammatory molecules. Figure was created in Biorender.
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During pregnancy, both n-3 and n-6 FAs are necessary for proper fetal
development, and their role in the different stages of inflammation described by Mor et
al. For example, the n-3 fatty acid, DHA, is essential for the proper development of the
fetal nervous system and retina. Arachidonic acid, an n-6 FA, also accumulates in the
fetal brain.14 However, imbalance in n-3 and n-6 intake can influence the homeostatic
equilibrium within the mother’s body. During pregnancy, there are no consistent
guidelines for recommended daily intake of n-3 FAs, but generally, around 200
milligrams of EPA + DHA per day is suggested.15 In the United States, the Western diet
is high in n-6 and low in n-3 intake. Research has demonstrated that mothers do not
reach the suggested daily intake in pregnancy,15,16 potentially putting them at risk for
poor maternal-infant outcomes due to dysregulated inflammation. Therefore, a balance
between intakes of n-3 and n-6 FAs is necessary for normal pregnancy.
More recently, the role of n-6 and n-3 FAs have been attributed to their
metabolism into bioactive metabolites involved in the inflammatory cascade.2 The parent
n-6s and n-3s compete for the lipoxygenase (LOX), cyclo-oxygenase (COX), or
cytochrome P450 enzymes (CYP450), creating eicosanoids. More specifically, these
eicosanoids are called oxylipins when metabolized through these three pathways.
Omega-6 FAs generally produce pro-inflammatory eicosanoids, while n-3 FA
metabolites are anti-inflammatory. The amount of n-6 to n-3 FAs influences the types of
FAs that are metabolized and ultimately determines which eicosanoids are produced.17
These eicosanoids either enhance the pro-inflammatory environment or move the
process towards repair and resolution. Because eicosanoids also have a role in
regulating inflammation during pregnancy, more research is needed to understand how
these metabolites function “normally.”
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1.1.1. Specialized Pro-Resolving Mediators in Pregnancy
Specialized pro-resolving mediators (SPMs) are eicosanoids of particular interest
in pregnancy due to their anti-inflammatory, repair, and resolution properties.4
Eicosapentaenoic acid (EPA) is metabolized into the SPM Resolvin E series [RvE-].
Docosahexaenoic acid creates maresins, protectins, and the Resovlin D series [RvD-].2
SPMs bind to their specific g-coupled protein receptors (GPRs) to influence downstream
physiological processes.5 SPMs act either within the cell (autocrine) or locally
(paracrine). In non-pregnant adults, the concentrations of SPMs and pathway precursors
are reported in picogram per milliliter range, and levels have been reported as not
detectable to concentrations in the low thousands in healthy adults.6,18,19
More recently, studies have begun to detail the presence of SPMs and their
intermediates in the context of pregnancy. A study by Mozurkewich et al. described the
differences in metabolite levels across pregnancy and demonstrated omega-3
supplementation augmented 17-HDHA but no other metabolites.20 Keelan et al.
investigated the effects of maternal n-3 fatty acid supplementation on placental
cytokines, SPMs, and their intermediates. DHA and EPA SPMs and intermediates were
present in the placenta, and supplementation increased 17-HDHA and 18-HEPE relative
to controls.21 Lastly, randomized clinical trials have studied the effects of pre- and
postnatal n-3 fatty acid supplementation. Prenatal supplementation starting at 20 weeks
of gestation and continued until birth resulted in increases in cord blood 18-HEPE and
17-HDHA. At 12 years of age, the metabolites were present, but the higher
concentration of 18-HEPE were not sustained between supplementation groups.22 This
is potentially due to changes in dietary intakes across ages. Postnatal supplementation
of infants from birth to 6 months of age, demonstrated an increase in 18-HEPE at six
months of age in the supplement group compared to placebo. These effects were not
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sustained at 1 year or 5 years after supplementation was ceased at 6 months of age.23
The presence of these SPMs during pregnancy, at birth, and six months postnatal
demonstrate relevant functions of these metabolites to newborn health.
1.1.2. The Importance of Inflammation and Metabolites in Implantation
Using Mor et al. stages of pregnancy, implantation is part of the first stage, which
requires inflammation to assist in blastocyst adherence to the uterine wall and initiation
of processes that establish a maternal-fetal connection.12,13 The fertilized egg, now a
blastocyst, must attach to the uterine wall and achieves this through the recruitment of
immune cells to the implantation site. Immune cells assist the blastocyst in getting
through the epithelial lining of the uterus to the endometrium to implant.12 In addition,
immune cells also help replace the endothelium and vascular smooth muscle cells of the
maternal blood vessels to establish blood flow from the placenta to the fetus.24 The
decidua houses critical immune cells such as natural killer (NK) cells, macrophages, and
dendritic cells (DCs). Polarized macrophages (Th-1) and cytokines (e.g., IL-6, IL-8, and
TNF-alpha) are important inflammatory players.13 The communication between the
uterus and the blastocysts establishes pregnancy.

9
Evidence suggests that the different enzymatic pathways are key modulators of
inflammation during implantation.25 12/15-LOX enzymatic derivatives influence uterine
function during implantation. Li et al. reported in a mouse model an increase in 12HETE, 15-HETE, and 13-HODE on day 4 of implantation, but 9-HODE remained low.26
The potential mechanism is a sequence of events with upregulation of LOX pathway
enzymes by progesterone during implantation, ultimately leading to an increase in the
production of eicosanoids locally like 12-HETE and 15-HETE. Then the metabolites
activate uterine peroxisome proliferator-activated receptors (PPARs), triggering further
expression and the differentiation of cells that regulate the implantation process.

25,26

Lipoxins, synthesized from 13-HODE using the LOX pathway, are also important during
implantation as they allow vessel remodeling and placental abruption due to their ability
to separate inflammation and angiogenesis.27,28 In 12/15 LOX knockout mice,
implantation did not occur due to the necessity of spontaneous inflammation for vessel
remodeling and trophoblasts anchoring.26
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Arachidonic acid (AA) metabolites in the COX pathway have been shown to
influence implantation. COX-1 deficient mice were fertile but had a higher incidence of
fetal malformations compared to control. Sun et al. suggest this is due to the reduced
levels of thromboxane A2 (TXA2) synthesized from the AA COX pathway, which affects
on platelet aggregation and vasoconstriction.29 Studies involving COX-2 deficiency have
yielded contradictory results. One study found a failure of implantation and
decidualization,29 whereas another study did not observe implantation failures in the
presences of COX-2 deficiency.30 However, ovulation and fertilization rates were lower
with COX-2 insufficiency. Studies performed in a monkey model by Sun et al. and
colleagues, suggest that endometrial COX-1 is responsible for prostaglandin (PG)
synthesis, and COX-2 may impact the preparation of a receptive endometrium for
implantation.29
Omega-3 and n-6 metabolites undergo final metabolism through CYP450
monooxygenase pathway. Polymorphisms may participate in pregnancy and are
implicated in many diseases, including cancer and cardiovascular diseases and may
play a role in establishing and maintaining pregnancy.31 Zhou et al. described an
increase in CYP2C11, CYP2C23, and CYP2J2 expression in mice on days 6,12, and 19
of pregnancy.32 The isoforms CYP2C8 and CYP2C9 contribute to vasodilating epoxyeicosatrienoic acid (EETs), while CYP2C8, CYP2C9, and CYP2J2 create antiinflammatory metabolites.31 CYP2J2 also mediates the formation of anti-inflammatory
EETs. However, CYP11A1 overexpression causes a decrease in trophoblast
proliferation.33,34 A unique balance of pro-inflammatory metabolites from the different
pathways is necessary for the implantation of the blastocysts.
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In the presence of dysfunctional inflammation, many complications can occur,
resulting in improper implantation. Macrophages are immune cells that are either Th1
(pro-inflammatory) or Th2 (anti-inflammatory) predominant, and in pregnancy, the
Th1/Th2 balance is shifted heavily toward Th2.35 A shift towards Th1 is associated with
increased pro-inflammatory cytokines IL-6, interferon-gamma (IFN- g), IFN beta-1beta
(IFN-b) and TNF-alpha (a), with lower levels of anti-inflammatory interleukin (IL)-4 and
IL-10 cytokines being associated with spontaneous abortion and preterm deliveries.

36

Oxylipins can influence pathology through the transformation of AA via the COX pathway
to produce prostaglandins and thromboxane related to inflammation and fetal growth.
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The first trimester is the critical period for an uneventful course of pregnancy, in which
implantation, trophoblast invasion, and placental development occur.36
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1.1.3. Trophoblast Cells, Placental Unit, and Metabolites During Pregnancy
The proper development of the placenta is essential to establish communication
and nutrient transfer between the mother and fetus. Placental development is
considered part of Mor et al. stage 1 of pregnancy, which relies on physiological
inflammation to induce immune cell differentiation into phenotypes beneficial for
trophoblasts.13 Support for this idea comes from Fest et al., who discovered media
conditioned from trophoblasts, induced immune cells to release pro-inflammatory
cytokines essential for trophoblast development and function.37
Trophoblast cell development influences placental development by modulating
the maternal immune response through steps referred to as attraction, education. and
response.12 First, trophoblast cells attract immune cells to the implantation site through
secretion of cytokines such as TNF-a, IL-6, and IL-8. Next, trophoblasts educate cells
through the release of regulatory cytokines to modulate the differentiation of immune
cells. Lastly, educated immune cells can respond to signals from the local environment.
Fetal-derived trophoblasts and membranes remain in contact with maternal immune
effector cells in the decidua, allowing for communication between the mother and fetus.38
A “normal” pregnancy course and fetal development rely on the proper development of
the placenta because of its role in regulating communication between mother and baby.
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The placenta is a modulator and can influence both the maternal and fetal
immune systems. The response of the mother and fetus is mediated by the type of
response initiated by the placenta. For example, strong inflammatory responses initiated
by placental infections have led to pro-inflammatory cytokines ( TNF-a, INF-g, IL-12, and
IL-6), causing placenta damage, abortion, and preterm labor.10 Trophoblast cell invasion
and fusion are hindered by TNF-a and demonstrate increased apoptosis and
prostaglandin and cortisol production.39 However, a mild inflammatory response may not
terminate the pregnancy but can still activate the fetal and maternal immune system.10
Abnormal inflammation can influence trophoblast cells’ ability to invade maternal
arteries, leading to poor placental perfusion and precipitation of poor maternal-fetal
outcomes like pre-eclampsia.40 Strong inflammatory responses can lead to premature
rupture of the membranes and preterm birth.
Studies are beginning to describe the presence and meaning of n-3 and n-6
metabolites in regulating fetal and placental health. Mozurkewich, Keelan, Jones et al.
have started to describe the relationship of some n-3 oxylipins like 14-HDHA, 17-HDHA,
and 18-HEPE, in pregnancy and the placenta as SPM producing tissue.20,21,41 Other
studies have identified n-6 metabolites produced in the placenta (12-HETE and LTB4),
which have been suggested to influence the myometrium and progesterone synthesis.
Studies also highlight significant concentrations of CYP enzymes in placental tissue.42–44
However, the mechanisms, production, and transport of oxylipins and SPMs through the
placenta remain largely unexplored.
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1.1.4. Balance between Anti- and Pro- Inflammatory Mediators in the Middle of
Pregnancy
An anti-inflammatory environment characterizes the second stage of pregnancy
defined by Mor. Normal pregnancy relies on a balance between the pro- and antiinflammatory levels. With the progression of pregnancy, placental activity and the
production of reactive oxygen species increases due to increased fetal oxygen demand
and typical development. Sufficient amounts of anti-inflammatory mediators are
necessary to maintain uterine quiescence and prevent uncontrolled inflammation.45
Although, inflammation is needed to fight infection and allow the mother to maintain the
fetus, but it must be modulated. An intrauterine environment shifted towards proinflammation at this stage can lead to intrauterine growth restriction and altered fetal
growth.46 Nutrition during pregnancy programs metabolism and physiological responses
in the fetus. 45 As discussed, this is the period of rapid growth where n-3 and n-6 FAs are
a part of brain development. There are few studies describing metabolites’ roles in fetal
development in this stage. More studies are needed to understand baseline levels and
their role in maintenance.
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1.1.5. Inflammation in Late Stages of Pregnancy and Parturition
The late stages of pregnancy are characterized as the third and final stage of
Mor et al. categorizations, as the mother begins to prepare for delivery. Inflammation in
the mother and placenta ready the body by initiating uterine contraction, ripening and
dilating the cervix, and causing membrane rupture.

Prostaglandins, COX pathway

metabolites, are vital mediators causing these changes. Both PGE2 and PGF2a induce
contractions, cervical maturation, and fetal membrane rupture. In a cattle model, 12HETE and 15-HETre were related to the regular course of pregnancy.47 Further, in the
setting of prematurity, umbilical cord 11-HETE and 15-HETrE were higher compared to
term delivery. In post-term neonates, 5-HETE levels were lower, while 11-HETE was
lower than that of preterm and term deliveries.48 These findings suggest that lower levels
of 5-HETE may delay labor, with 11-HETE and 15-HETrE accelerating it.25 As shown by
these studies, the contribution of metabolites to inflammation is necessary. However,
dysregulation begins to expose the infant to a harmful environment that may increase
the risk of morbidity and mortality. The following sections will discuss inflammation and
metabolites in the context of specific pregnancy outcomes.
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1.2. Pregnancy Outcomes and How They Relate to Inflammation and
Oxylipins
1.2.1 Preterm Labor and Delivery
Currently, approximately 10% of infants are born prematurely in the United
States.49 Many different mechanisms are known to cause of preterm labor; however,
chemokines and cytokines have been highlighted as central to inflammation/infectioninduced preterm labor.46 There is increasing evidence that inflammation in early
development may have lifelong impacts on the offspring.50 For example, infants exposed
to intrauterine inflammation had higher rates of chronic lung disease, retinopathy of
prematurity, intraventricular hemorrhage, periventricular leukomalacia, and necrotizing
enterocolitis than infants born equally preterm without inflammatory exposures.51–53 To
reduce the morbidity and mortality that inflammation-induced prematurity causes, the
underlying mechanisms must be better understood.
Inflammation can be caused by infections or other signals in the intra-uterine
environment. Increases in pro-inflammatory cytokines and chemokines have been
implicated in preterm labor and delivery,13 whereas the anti-inflammatory cytokines IL-10
and IL-4 are reduced.1,54 Intrauterine inflammation can be due to microbes or by sterile
intra-amniotic inflammation that can occur without the presence of a pathological
infection. Sterile inflammation is significantly greater for women with preterm labor and
intact membranes.55 This could be due to other alarm signals within the intrauterine
environment, which activate intracellular pathways leading to the same cytokine
mediators being released as an infection.56 One possible contribution to the mechanisms
leading to sterile inflammation is an imbalance in nutrition and oxylipin levels.
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Due to the role of inflammation in prematurity and the link between oxylipins and
inflammation, studies have started to elucidate the influence of n-6 and n-3 oxylipins on
early delivery. Oxylipins derived from AA have been implicated in multiple studies to be
associated with prematurity.48,57 Ramsden et al. showed that at 14 weeks of gestation, 5LOX derivatives-5-HETE and 4-HDHA-above the median had higher risks of
spontaneous preterm birth. Two other LOX derivatives demonstrated greater odds of
prematurity, with levels of 15-HETE above the median and 9-HODE below the median
were associated with preterm delivery.58 Further, maternal and cord plasma had
elevated SPM levels in the presence of prematurity.59 Taken together, oxylipins from n-6
and n-3 fatty acids are tightly related to inflammation which can become unregulated in
preterm birth.
The morbidity and mortality caused by inflammation-mediated prematurity have
led to an interest in targeting inflammation by upregulation of anti-inflammatory
mediators, blocking pro-inflammatory cytokines, or administering anti-inflammatory
agents. Clinically, progesterone is used to reduce preterm delivery incidence. However,
progesterone cannot block infection-induced inflammation, and concerns remain with
route administration, bioavailability, and association with stillbirths.60 Other drugs such
as

cytokine-suppressive

anti-inflammatory

drugs

(CSAIDS),

anti-inflammatory

prostaglandin 15-deoxy-D (12,14) prostaglandin J2 (15dPGJ2), and antibody-based
TNF-a biologics are being studied for their ability to modulate inflammatory pathways
and influence prematurity.13

A large gap remains in the effective prevention and

treatment of preterm labor. In a mouse model, administration of RvE3, but not its
precursor 18-HEPE, was associated with a lower incidence of preterm birth in the
presence of lipopolysaccharide (LPS).61 By studying the effect of n-3 and n-6 mediators
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concentrations on prematurity, this research could identify a mediator that could be
targeted for use in at-risk pregnancies.
1.2.2. Pre-eclampsia
Pre-eclampsia (PE) is a clinical diagnosis characterized by inflammation,
proteinuria, thrombosis, endothelial dysfunction, and placental defects in the second
trimester of pregnancy.13 Studies have shown that the pro-inflammatory cytokines are
similar between normal and pre-eclamptic pregnancies. However, in pre-eclampsia, the
inflammatory response is exaggerated, and this seems to be due to a lack of antiinflammatory cytokines.62–64 In dysfunctional inflammation, trophoblast invasion and
spiral artery remodeling are insufficient, causing altered blood flow and elevated mean
arterial pressures. TNF-a expression, for example, has been shown to alter
prostaglandin

production,

oxidant/antioxidant

balance,

and

adhesion

molecule

expression in blood vessels.39 The subsequent cascade of insufficient perfusion,
hypoxia, placental stress, and release of placental factors into the maternal circulation
causes more inflammation and endothelial dysfunction. Activation of various pathways
can lead to inflammatory cytokine release and ultimately placental dysfunction leading to
pre-eclampsia. Pre-eclampsia often results in preterm delivery since the only cure for
pre-eclampsia is delivering the fetus and removing the placenta.
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Mainly, n-6 FA metabolites have been described in plasma and placental
samples in the setting of pre-eclampsia. The following research highlights the
metabolites that have been called out. HETEs are AA metabolites that may result in poor
placental profusion. At 20 weeks of gestation, maternal levels of 5-, 8-, 12- and 15-HETE
were higher in pregnancies later diagnosed with PE. In placentas, 15-HETE and 12HETE were increased in pre-eclamptic pregnancies relative to control, with trophoblast
cells demonstrating the same relationships.

35,65,66

In addition, 15-HETE was also found

in umbilical cord blood and caused increased constriction of the arteries. However,
Plenty et al. found no significant increase in 15-HETE in women with PE.67 Therefore,
dysregulation of HETE as a group of metabolites may be underlying PE.
Currently, two studies present contradictory results regarding the role of lipoxins,
also an AA metabolite, in modulating pre-eclampsia. The anti-inflammatory n-6 oxylipin,
lipoxin A4 (LXA4), regulates the cytokine milieu, inhibits leukocyte chemotaxis, and limits
oxygen species generation. Xu et al. highlighted a decrease in plasma LXA4, its receptor
formyl- peptide-receptor 2 (FPR2)/ lipoxin A4 (ALX), and the enzyme for synthesizing
LXA4 for mothers with pre-eclampsia.68 Rats treated with LXA4 had improved PE
symptoms, a decrease in LPS-induced pro-inflammatory cytokines, and an increase in
anti-inflammatory cytokines. Conversely, rats with blocked LXA4 signaling developed
symptoms of pre-eclampsia. In contrast, Dong et al. found women with pre-eclampsia
had significantly increased levels of LXA4, TNF-a, and IL-1Beta.59,69 Together, these two
studies provide seemingly different results, highlighting the need for a better
understanding of the enzymatic pathways in women with PE.
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1.3. Specific Aims and Hypothesis
Review of the available literature shows that much remains unexplored in the
context of oxylipins and SPMs during pregnancy, especially at delivery. Therefore, the
overall objective of my dissertation work was to identify SPMs and their intermediates as
possible targets to improve infant outcomes. To address this objective, specific aims for
this study are as follows (Figure 3):
1. Quantify a diverse panel of oxylipins in maternal plasma, cord plasma, and placental
tissue at the time of delivery. Explore associations of oxylipins between tissue samples
and their relationship with infant outcomes.
2. Identify how prematurity influences SPM-responsive cellular targets at the maternalfetal placental interface.
Based on information obtained from the literature review, the hypotheses of the
listed specific aims are as follows. 1) Oxylipin levels will be identified at higher levels in
maternal plasma compared to cord plasma and placental tissues. Further, n-3 FA
metabolites will improve infant outcomes, while n-6 metabolites are harmful. 2) GPR18
expression will be lower in vascular smooth muscle cells and extra-villous trophoblasts in
preterm placentas relative to term placentas.
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Figure 3: Graphical Representation of Specific Aims for the Dissertation
SA 1 is to quantify oxylipins in tissue samples and then explore oxylipins’
relationships between tissues and with infant outcomes. SA 2 focuses on identifying
GPR18 expression in vascular smooth muscle cells and extra-villous trophoblasts
from term and preterm deliveries. In addition, GPR18 expression and regulation with
SPM treatment is the bases for current research and future exploration. Figure
created in BioRender.

22

CHAPTER 2: The Presence of LOX
Pathway Oxylipins at Delivery and their
Relationship with Infant Growth Metrics
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2.1. INTRODUCTION
Pregnancy is a period of rapid fetal growth and cell differentiation in the womb,
where diverse insults can lead to acute diseases with long-term consequences. The
fetus is susceptible to inflammatory stimulation that may affect embryonic growth,
placental development, organ development, and regulation of immune responses.70 An
inflammatory uterine environment can increase the risk of premature infants developing
various diseases at later life stages. Examples include chronic lung diseases,
retinopathy of prematurity, intraventricular hemorrhage, periventricular leukomalacia,
and necrotizing enterocolitis.51,51,52 These considerations underscore the importance of
identifying modifiable factors that can reduce and limit the negative consequences of
inflammation in the intrauterine environment.
Maternal nutrition is a modifiable factor that impacts infant outcomes;71,72 for
example, fatty acids (FAs) are essential for proper pregnancy progression and normal
fetal growth.73,74 Omega n-3 FAs are necessary for fetal brain and eye development.70 In
addition, dietary n-3 supplementation in pregnancy has been shown to reduce preterm
births,75–79 intrauterine growth restriction,73 and admission to the neonatal intensive care
unit.80,15 A phase III randomized controlled trial in which a cohort of women received
supplemental n-3 FAs during pregnancy revealed that this intervention increased infant
birth weight, length, and head circumference.81 Omega n-6 FAs are essential nutrients
that become incorporated into the phospholipid bilayer. These lipids play vital roles in
organ development and function, although their effects are mixed.70 The Western diet is
high in n-6 FAs and relatively low in n-3 FAs; notably, pregnant women have reported
lower intakes of n-3 FAs compared to non-pregnant women.15,16 Excess n-6 FA
consumption has been associated with increased anxiety in animal models,70 early-life
onset of obesity and metabolic diseases,82 and fetal cardiovascular health.83
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Mechanistically, excess maternal intake of n-6 FAs can limit the metabolism of beneficial
n-3 FAs as all FAs compete for the same metabolic enzymes. This competition impacts
the balance of n-3 and n-6 FAs available to the fetus and may adversely affect fetal
growth and pregnancy outcomes.84
Accumulating evidence suggests that n-6 and n-3 FAs affect maternal and fetal
health through their metabolism into biologically active eicosanoids. The generation of
these signaling molecules is catalyzed by lipoxygenase (LOX), cyclooxygenase (COX),
and cytochrome-P-450 (CYP450)-dependent oxygenases. Omega-6 FA metabolism
generates pro-inflammatory eicosanoids such as lipoxins and leukotrienes. In contrast,
n-3 FAs are precursors of anti-inflammatory eicosanoids and specialized pro-resolving
mediators (SPMs) that exhibit protective functions. Eicosanoids and their bioactive
metabolites play central roles at all stages of inflammation, including initiation,
progression, and resolution.
While a large body of work has advanced our understanding of the biological role
of eicosanoids, the impact of the LOX pathway and its metabolites in pregnancy remains
to be established. A study by Mozurkewich et al. demonstrated that n-3 supplementation
during pregnancy augments LOX pathway metabolites.20 However, most reports are
limited to analyses of metabolite levels up to 35 weeks of gestation, do not analyze
potential relationships between metabolite levels in maternal and umbilical cord plasma,
or investigate their impact on birth outcomes. This study characterized LOX pathway
metabolites in maternal and umbilical cord plasma at the time of delivery and
investigated the relationship between LOX metabolites levels and birth outcomes.
Through these investigations, I identified that metabolites influence infant weight and
length percentiles. Previous literature has suggested n-3 and n-6 FAs are associated
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with infant growth,70 and this study begins to demonstrate that these findings may be
mediated by to the metabolites of these FAs.

2.2. MATERIALS AND METHODS
2.2.1. Study Characteristics
The study's eligibility criteria for participation included mothers ≥ 19 years of age,
delivering a live infant at Nebraska Medicine. All participating maternal-infant pairs were
free of renal, metabolic, and hepatic diseases known to impair normal nutrient
metabolism. Written informed consent was obtained from all subjects after admission to
the labor and delivery unit. The study was approved by the UNMC's Institutional Review
Board (IRB #112-15-EP).

2.2.2. Maternal Dietary Intake
All participants completed the Harvard Food Frequency Questionnaire (FFQ) that
assesses dietary intake over the previous year. An advantage of FFQ compared to other
nutrient intake assessments (e.g., 24-hour recalls) is that this survey evaluates intake
over time and can be used during pregnancy.85,86 De-identified surveys were sent to the
Harvard T. H. Chan School of Public Health for quantification based on previously
established food nutrient content. Notably, the survey assessed supplement use and
reported nutrient intake with and without supplementation. This tool has been validated
in numerous adult populations, including pregnant women.85

2.2.3. Maternal and Infant Outcomes
We used participants' electronic medical records (EMR) to extract relevant
information and metrics, including maternal and infant outcomes, birth weight and length,
head circumference, and associated percentiles (Table 1). Maternal smoking status and

26
body mass index (BMI) were chosen as covariates due to previously reported
associations between these parameters and inflammation, nutrient status, and infant
outcomes.87,88

Table 1: Description of Maternal and Infant Outcomes Collected from the EMR
Gestational age
Measured in weeks
Birth weight
Measured in grams immediately following birth
Birth length
Measured in centimeters immediately following birth
Head circumference
Measured in centimeters immediately following birth
Birth weight percentile
The WHO growth standards are used to calculate birth weight
percentile. Out of 100 infants the same age, an infant in the 50th
percentile will have 50 infants smaller and 50 infants larger than
them
Birth length percentile
The WHO growth standards are used to calculate the birth
length percentile. Out of 100 infants the same age, an infant in
the 50th percentile will have 50 infants shorter and 50 infants
longer than them
Head circumference percentile The WHO growth standards are used to calculate the head
circumference percentile. Out of 100 infants the same age, an
infant in the 50th percentile for head circumference will have 50
infants with smaller heads and 50 infants with larger heads
Maternal Smoking Status
Never smoker: the mother never smoked
Current/Former smoker: the mother reported previously
smoking or smoking at the time of delivery
BMI Categorization
Not obese: BMI ≤ 30 kg/m2
Obese: BMI >30 kg/m2
Delivery mode
Vaginal
Caesarean

2.2.4. Blood Sample Collection
Maternal and umbilical cord blood samples were collected by trained nursing
personnel upon maternal admission to the hospital and at delivery. The research team
processed the specimens within 12 hours of collection, processed the specimens, and
stored plasma fractions at -80°C until metabolite analysis.

2.2.5. N-3 and n-6 FA Oxylipin Quantification Methods
The levels of lipoxygenase pathway metabolites derived from linoleic acid (LA),
dihomo-γ-linolenic acid (DGLA), arachidonic acid (AA), alpha-linolenic acid (ALA),
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eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) were quantified in
maternal and umbilical cord plasma using liquid chromatography tandem-mass
spectrometric (LCMS) approaches. Mediators assessed included those formed through
lipoxygenase actions (including 5-, 12-, and 15-LOX) with or without additional
modifications from other enzymes (e.g., COX metabolism) -see Figure 4. Tables 2 and
3 list the parent n-6 and n-3 FA nutrients and their metabolites included in the lipid panel.

Figure 4: Demonstration of Metabolites that Undergo Enzymatic Breakdown by Other
Enzymes.
Metabolites included in this study were formed through the lipoxygenase actions of
5-, 12-, and 15-LOX with or without additional modifications from other enzymes. This figure
highlights metabolites which undergo breakdown by multiple enzymes. Created with
BioRender.
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Table 2: n-6 FA Metabolites and Abbreviations
Parent Nutrient
Metabolites
LA
9-hydroxy-octadecadienoic acid
13- hydroxy-octadecadienoic acid
13- ketooctadecadienoic acid
DGLA
15-hydroxyeicosatrienoic acid
AA
5-hydroxyeicosatetraenoic acid
8-hydroxyeicosatetraenoic acid
9-hydroxyeicosatetraenoic acid
11-hydroxyeicosatetraenoic acid
12-hydroxyeicosatetraenoic acid
15-hydroxyeicosatetraenoic acid
8,15-dihydroxyeicosatetraenoic acid
5,15-dihydroxyeicosatetraenoic acid
Lipoxin A4
Leukotriene B4

Table 3: n-3 FA Metabolites and Abbreviations
Parent Nutrient
Metabolites
ALA
9-hydroxyoctadecatrenoic acid
EPA
5-hydroxyeicosapentaenoic acid
12-hydroxyeicosapentaenoic acid
15-hydroxyeicosapentaenoic acid
18-hydroxyeicosapentaenoic acid
Resolvin E1
DHA
17-hydroxydocosahexaenoic acid
7-hydroxydocosahexaenoic acid
Resolvin D1
Resolvin D2
Maresin 1

Abbreviation
9-HODE
13-HODE
13-KODE
15-HETrE
5-HETE
8-HETE
9-HETE
11-HETE
12-HETE
15-HETE
8,15-DiHETE
5,15-DiHETE
LXA4
LTB4

Abbreviation
9-HOTrE
5-HEPE
12-HEPE
15-HEPE
18-HEPE
RvE1
17-HDHA
7-HDHA
RvD1
RvD2
MaR1

Expected effect
Pro-inflammatory

Anti-inflammatory
Pro-inflammatory

Expected effect
Anti-inflammatory

2.2.5.1. Fatty Acid Extraction
FAs were extracted as described by Yang et al at the University of California
Riverside Metabolomics Facility.89 Waters Oasis-HLB cartridges (30 mg/30 μm) were
treated with ethyl acetate (1 mL), methanol (2 × 1 mL), and 95:5 v/v water/methanol
containing 0.1% acetic acid (1 mL). The metabolomics core mixed 100 μL of plasma with
7 μL of internal standard solution (stock concentration: 500 nM), 10 μL of butylated
hydroxytoluene (BHT; stock concentration: 2 mg/mL), and 120 μL of H2O: methanol
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(MeOH) (95:5) containing 0.1% acetic acid. The resulting samples (240 μL) were then
loaded onto pre-treated cartridges and washed twice with 750 μL H2O/MeOH (95:5)
containing 0.1% acetic acid. The aqueous plug was pulled from the cartridges using high
vacuum and the cartridges were then dried further under low vacuum for about 20 min.
Solid-phase extraction (SPE) cartridges were eluted into tubes with 250 μL of methanol
followed by 1 mL of ethyl acetate into 2-mL tubes containing 6 μL of 30% glycerol in
MeOH as a trap solution. The samples were dried under nitrogen and then dissolved in
70 μL of methanol containing 20 nM 1-cyclohexyl-dodecanoic acid urea (CUDA). The
samples were then vortexed for 5 min, transferred to autosampler vials with low volume
inserts, and stored at -20°C until further analysis.
2.2.5.2. Liquid Chromatography-Mass Spectrometry
Samples were analyzed for lipid mediator levels via LCMS coupled to
electrospray ionization on a triple quadrupole mass spectrometer (Waters XEVO TQXS). For analysis, 3 microliters (μL) of extract were injected into the machine. The
autosampler was cooled to 4 °C. Chromatographic separation was achieved on an
Ascentis Express column (2.1×150 mm, 2.7 μm particles; Sigma-Aldrich Supelco) at a
flow rate of 0.35 mL/min at 40°C using a gradient of 0.1% acetic acid and acetonitrileisopropanol (90:10 v/v), as described.90 All standards were dissolved in MeOH to
achieve a final concentration of 1 μM. A standard preparation was used to build a 12point calibration curve (97 pM - 200 nM). Each point included 50 nM deuterated internal
standards. Individual calibration curves were generated by plotting oxylipin standard
concentration vs. calculated response ratio (i.e., the ratio of oxylipin standard peak area
and the corresponding internal standard peak area).
The mass spectrometer was operated in multiple reaction monitoring (MRM)
mode, and electrospray ionization was performed in negative ion mode. A detailed list of
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MRM transitions is presented in Table 4. Source and desolvation temperatures were
150°C and 500°C, respectively. Desolvation gas was set to 1000 L/hr and cone gas to
150 L/hr. Collision gas was set to 0.15 mL/min. All gases were nitrogen except the
collision gas, which was argon. The capillary voltage was 2 kV in negative ion mode.
Samples were analyzed in random order. A quality control sample was analyzed every
eight injections to monitor system stability and performance. We achieved 100%
recovery

of

the

internal

standards.
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Table 4: Library of 52 Targeted Oxylipins with their Corresponding Retention Time,
Product and Metabolite m/z, and Deuterated Internal Standard Used for Quantification
Compound Name
RT (min) Precursor ion
Product ion
Internal Standard
m/z
m/z
Leukotriene B4
11.01
335.2
195.1
Leukotriene B4-d4
(±)7-HDHA
15.99
343.2273
201.2
15(S)-HETE-d8
(±)7-HDHA
15.99
343.2273
141.1
15(S)-HETE-d8
(±)17-HDHA
15.35
343.2
281.3
15(S)-HETE-d8
5-HETE
16.47
319.2
115.1
15(S)-HETE-d8
(±)8-HETE
15.91
319.2
155.1
15(S)-HETE-d8
(±)9-HETE
16.14
319.2
167.1
15(S)-HETE-d8
(±)11-HETE
15.56
319.2
167.2
15(S)-HETE-d8
(±)12-HETE
15.84
319.2
179.2
15(S)-HETE-d8
15-HETE
15.16
319.2
219.2
15(S)-HETE-d8
9(S)-HOTrE
13.14
293.2
171.1
9-HODE-d4
Lipoxin A4
8.03
351.2
115
Lipoxin A4-d5
Maresin 1
10.79
359.2
250
Maresin 1-d5
Maresin 1
10.79
359.2
221
Maresin 1-d5
Resolvin E1
4.88
349.2
195
Resolvin E1-d4
Resolvin D1
8.08
375.2
141
Resolvin D1-d5
Resolvin D1
8.08
375.2
121
Resolvin D1-d5
Resolvin D2
7.39
375.2
175
Resolvin D2-d5
Resolvin D2
7.39
375.2
233
Resolvin D2-d5
Lipoxin A4-d5
7.99
356.2
115
15(S)-HETE-d8
15.03
327.2
182
Maresin 1-d5
10.74
364.2
250
Resolvin E1-d4
4.86
353.2
197
Resolvin D1-d5
8.03
380.2
141
Resolvin D2-d5
7.35
380.2
175
Leukotriene B4-d4
10.96
339.2
197.1
Prostaglandin E2-d4
6.88
355.2
275.2
Thromboxane B2-d4
5.96
373.2
173
9-HODE-d4
14.74
299.2
172.1
9-HODE
14.65
295.2
171.1
9-HODE-d4
13-HODE
14.77
295.2
195.2
9-HODE-d4
5-HEPE
14.73
317.2
115.1
15(S)-HETE-d8
9-HEPE
14.35
317.2
149
15(S)-HETE-d8
12-HEPE
14.36
317.2
179.1
15(S)-HETE-d8
15-HEPE
13.97
317.2
219.2
15(S)-HETE-d8
5(S),15(S)-DiHETE
10.78
335.2
115.2
Leukotriene B4-d4
15(S)-HETrE
16.14
321.2
221.2
9-HODE-d4
13-KODE
15.26
293.2
113.1
9-HODE-d4
CUDA
11.31
339.2
214.3
-
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Data were processed using Skyline91 software and Microsoft Excel. Calibration
curves for each oxylipin were built using standards and deuterated internal standards.
Each curve consisted of oxylipin standard concentration vs. calculated response ratio
(the ratio of oxylipin standard peak area and the corresponding internal standard peak
area). Calibration curves were calculated by linear regression with 1/x2 weighing. The
calibration result was then corrected for dilution to determine the original oxylipin
concentration in plasma. Results falling above or below the calibration curve were
excluded from data analysis. Oxylipins with 60% or more of their samples falling under
detectable levels were categorized into not detectable and detectable, instead of being a
continuous variable.

2.2.6. Statistics
For mothers who had twins, only information from the first twin was considered in
our analysis. Descriptive statistics include means, standard deviations, medians,
interquartile range (IQR), minimums and maximums for continuous data, and counts and
percentages for categorical data. The Mann-Whitney U test was used to compare
continuous measures between dichotomous groups. The Kruskal-Wallis test was used to
compare measures between more than two groups. Fisher's exact test was used to
associate dichotomous categorical variables. Spearman correlation coefficients were
used to assess relationships between continuous variables. The eicosanoids LTB4, 9HEPE, and 8,15-DiHETE were detected in less than 40% of the samples. These
metabolites were dichotomized to detectable vs. non-detectable to identify significant
differences between the groups. McNemar's test was used to assess potential
associations between matching maternal-cord dichotomized metabolite values (i.e., ND
vs. Determinate).
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Linear regression modeling was performed on metabolites that correlated with
birth weight, length, and head circumference percentiles at the p<0.05 level in the
univariate analysis. Associations of the metabolites with these birth measures were
adjusted for obesity [>30 or ≤ 30 BMI (kg/m2)] and maternal smoking status
(current/former vs. never) in the models. Metabolites were log-transformed in the
regression analyses to meet the statistical assumptions of the models. P<0.05 was
considered statistically significant.

2.3. RESULTS
2.3.1. Baseline Characteristics
2.3.1.1. Maternal Demographics
One hundred twenty-one mother-infant pairs were available for analysis. The
mean maternal age assessed in 118 women was 29.36 years (5.88). Table 5
summarizes maternal characteristics within our cohort. Twenty-eight percent of mothers
had an obese pre-pregnancy BMI (BMI >30 kg/m2), and 22% were former or current
smokers at the time of delivery. Vaginal deliveries were performed for 74.58% of births,
and 25.42% via Caesarean Section (CS).
Median maternal daily dietary intake of total n-6 and n-3 FAs was 14.46 g/day
[7.43] and 1.72 g/day [1.01], respectively. Total n-3 FA intake includes fish oil
supplementation, ALA, EPA, and DHA. However, ALA is minimally converted into EPA
and DHA. Twenty percent of mothers reported fish oil supplementation during
pregnancy.
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Table 5: Maternal Baseline Characteristics
FA

Maternal Daily Intake of FA
Median (g/day) [IQR]

n

AA

0.15 [0.11]

103

LA

13.06 [7.91]

103

ALA

1.42 [0.75]

103

g-LA
EPA

0.010 [0.01]

103

0.020 [0.06]

103

DPA

0.020 [0.03]

103

DHA

0.090 [0.15]

103

Total Omega n-3 (includes supplementation)

1.72 [1.01]

103

Total n-6

14.46 [7.43]

103

Ratio of n-6: n-3

8.73 [1.79]

102

%

n

White

62.18

74

African American

19.33

23

Hispanic

5.88

7

Asian or Pacific islander

0.84

1

American Indian

0.84

1

Other/unknown

10.92

13

Ethnicity

%

n

2

Obesity

72.28

73

2

27.72

28

%

n

Caesarian Section (CS)

25.42

30

Vaginal

74.58

88

%

n

None

77.97

92

Current smoker (at delivery)

11.02

13

Former smoker

11.02

13

%

n

No

79.31

92

Yes

20.69

24

<30 kg/m
≥30 kg/m

Delivery Mode

Maternal Smoking Status

Fish Oil/DHA Supplementation
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2.3.1.2. Infant Demographics
Infants were, on average, born at 38.2 weeks (3.29) of gestation (Table 6). They
weighed 3.2 kg at birth and measured at 34 cm for head circumference and 49 cm for
birth length. Infants were in the ~50th percentile for birth weight, length, and head
circumference. There was no significant difference between the number of males vs.
female infants included in this study.
Table 6: Infant Baseline Characteristics
Characteristic
Gestational age, weeks
Birthweight, kilograms (kg)
Birthweight Percentile (%)
Head Circumference, centimeters (cm)
Head Circumference Percentile (%)

(n)
119
118
115
115
115

Mean (SD)
38.17 (3.29)
3.21 (0.77)
56.58 (28.86)
34.09 (2.29)
58.5 (32.26)

Median (IQR)
39.20 [2.00]
3.35 [0.80]
60.77 [45.69]
34.30 [2.60]
63.58 [57.03]

Birth Length, cm
Birth Length Percentile (%)
Sex
Female
Male

114
113
(n)
53
66

49.1 (8.06)
52.46 (33.41)
Percent (%)
44.54
55.46

49.50 [2.80]
55.90 [61.30]

2.3.1.3. Association Between Metabolite Levels and Baseline Characteristics
To begin investigating potential associations between LOX pathway SPM
metabolites and infant health, we first assessed the relationships maternal and cord
metabolite levels had with demographic and medical information. Cord plasma n-6
metabolite levels differed significantly when delivery modes were compared. Umbilical
cord samples from CS vs. vaginal deliveries had lower median levels of 9-HODE (7.26
nM vs 10.52 nM; p = 0.010), 9-HOTrE (0.35 nM vs 0.52 nM; p = 0.003), and 13-KODE
(1.05 nM vs. 1.52 nM, p = 0.039). Further, cord plasma 5,15-DiHETE was higher in CS
compared to vaginal deliveries (median: 0.24 nM vs 0.14 nM; p = 0.036). There were no
significant differences in plasma metabolite levels and infant sex.
To unveil potential relationships between difficult to quantify eicosanoids and
outcomes, LTB4, 9-HEPE, and 8,15-DiHETE were classified as detectable and non-
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detectable. There was a significant difference in AA intake by subjects with detectable
vs. non-detectable maternal LTB4 levels. Maternal intake of AA around 0.29 g/day was
associated with detectable LTB4 in maternal plasma. Further, there was a relationship
between maternal LTB4 levels and birth weight percentile. Mean birth weight percentile
was 59.71 % (n=103) in the non-detectable LTB4 group compared with 37.72% (n=13)
in the detectable LTB4 cohort. There appeared to be a relationship between BMI and the
ability to detect LTB4 levels. Higher BMI status was associated with fewer samples with
detectable LTB4 levels. However, there was no significant correlation between the
presence of cord plasma LTB4 and infant growth metrics.

2.3.2. Relationship between LOX Metabolite Levels in Maternal and
Umbilical Cord Plasma
2.3.2.1. n-6 Metabolites in Maternal and Umbilical Cord Plasma
To begin understanding the role of n-6 oxylipins at delivery, their relationship
between maternal and cord plasma was explored. I observed significant correlations in
the levels of n-6 FA metabolites between maternal and cord plasma. AA and DGLA's
metabolites were higher in cord compared with maternal plasma, whereas LA precursors
tended to be lower in cord vs. maternal specimens. Figures 4 and 5 depict n-6 precursor
levels in maternal and cord plasma. Appendix C describes median precursor levels and
highlights significant relationships. DGLA’s metabolite, 15-HETrE, had a significant,
weak positive correlation between maternal and cord plasma (rs = 0.31; p = 0.001); data
not shown.
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Figure 5: Log Scaled AA LOX Pathway Metabolite Concentrations in Maternal and
Cord Plasma at Delivery.
Spearman correlations were used to assess the relationship between
metabolite levels in maternal and cord plasma. The strongest positive correlations were
15-HETE (rs = 0.64; p = <0.001) and 5,15-DiHETE (rs = 0.75; p = <0.001). The whiskers
indicate the minimum and maximum values and display the individual samples.
Because less than 40% of the samples had detectable levels of LTB4 and 8,15DiHETE, further analysis of these metabolites was not completed.
*, p-value < 0.05; M, maternal plasma; C, cord plasma; AA, arachidonic acid, LOX,
lipoxygenase; HETE, hydroxyeicosatetraenoic acid; DiHETE, dihydroxyeicosatrienoic
acid; LXA4, Lipoxin A4; LTB4, Leukotriene B4.
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Figure 6: Log Scaled LA LOX Pathway Metabolite Concentrations in Maternal and
Cord Plasma at Delivery.
Spearman correlation demonstrated LA metabolites 13-HODE (rs = 0.22, p =
0.029) and 13-KODE (rs = 0.25; p = 0.018) were significant with low positive correlations
between maternal and cord plasma. There was no significant correlation between
maternal and cord 9-HODE (rs = 0.090; p = 0.37) plasma levels.
*, p-value < 0.05; M, maternal plasma; C, cord plasma; LA, linoleic acid; HODE,
hydroxyoctadecadienoic acid; KODE, ketooctadecadienoic acid.
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2.3.2.2. n-3 Metabolites in Maternal and Umbilical Cord Plasma
We identified EPA and DHA metabolites and found that these lipids tended to be
higher in maternal compared with cord plasma. Figures 5 and 6 show maternal and cord
metabolite levels and display the significant, positive correlations between maternal and
infant metabolites. ALA metabolite 9-HOTrE did not significantly correlated between
maternal and cord plasma (Appendix C).

Figure 7: Log Scaled EPA LOX Pathway Metabolite Concentrations in Maternal and
Cord Plasma at Delivery.
Metabolite levels are log scaled, and whiskers identify minimum and maximum
values. Spearman correlation highlighted a significant, positive correlation between maternal
and cord 5-HEPE (rs = 0.48, p = <0.001). No other significant correlations for metabolite levels
in maternal and cord. Resolvin E1-3 were not quantified in this cohort; however, they have
been found in maternal and cord plasma previously.
*, p-value < 0.05; M, maternal plasma; C, cord plasma; HEPE, hydroxyeicosapentaenoic acid;
LOX, lipoxygenase; EPA, eicosapentaenoic acid.

40

Figure 8: DHA LOX pathway metabolite concentrations in maternal and cord plasma
at delivery.
Metabolite levels were log-scaled. Spearman correlation for DHA metabolites
demonstrated 17-HDHA (rs = 0.53; p < 0.001) and 7-HDHA (rs = 0.56; p < 0.001), had
significant, moderate positive correlations between maternal and infant metabolite levels.
*, p-value < 0.05; M, maternal plasma; C, cord plasma; DHA, docosahexaenoic acid; LOX,
lipoxygenase; HDHA, hydroxydocosahexaenoic acid.

2.3.3. Metabolite Associations with Maternal Diet
The influence of maternal dietary intake was analyzed to understand the impact
of diet on metabolite levels in maternal and cord plasma. Total n-6 FA intake was
positively correlated with cord 15-HETE levels (rs = 0.26; p = 0.01), whereas the
maternal intake ratio of n-6 to n-3 was negatively correlated with maternal 15-HETE (AA
metabolite, rs = -0.24, p-value = 0.03) and 17-HDHA (DHA metabolite, rs= -0.25, p-value
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= 0.03). When analyzing the influence of DHA intake on metabolite levels, we found
DHA intake was significantly positively correlated with maternal 9-HEPE (rs = 0.36; p =
0.03), 7-HDHA (rs = 0.36; p = 0.003), and 17-HDHA (rs = 0.28; p = 0.01) plasma levels.
Total n-3 FA intake was only significantly positively correlated with cord 17-HDHA (rs =
0.22; p = 0.04). Significantly lower median n-6 metabolite concentrations were observed
in individuals who used fish oil supplements, including cord 15-HETrE (median: 1.05 nM
vs 1.50 nM, p-value = 0.032) and maternal 5,15-DiHETE (median: 0.08 nM vs 0.28 nM,
p-value = 0.027), both n-6 metabolites. Table 7 shows significant correlations between
dietary intakes and metabolite plasma levels.

Table 7: Correlations between Dietary Intakes and Metabolite Plasma Levels
Intake

Metabolite

Rho (rs)

p-value

n-6: n-3 Ratio

Maternal 15-HETE
Maternal 17-HDHA

-0.24
-0.25

0.03
0.03

Total n-6
DHA

Cord 15-HETE
Maternal 9-HEPE

0.26
0.36

0.01
0.033

Maternal 7-HDHA

0.36

0.003

0.28
0.22

0.015
0.04

Maternal 17-HDHA
Total n-3
Cord 17-HDHA
*non-significant findings were not included in this table

2.3.4. Associations between FA Metabolites and Infant Growth
2.3.4.1. n-6 FA Metabolites and Infant Growth
The relationships between infant growth and n-6 FA metabolites were initially
analyzed using Spearman correlations (Table 8). After adjustment, cord 9-HODE, 13HODE, and 13-KODE positively predicted birth length percentile. With every 1%
increase in cord 9-HODE, 13-HODE, and 13-KODE, infant birth length percentile
increased by 0.13%, 0.20% and 0.025%, respectively. However, infant birth weight
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percentile decreased by 0.041% for every 1% increase in maternal 5,15-DiHETE.
Figure 7 illustrates the relationship between the significant metabolites in the LOX
pathway.

Table 8: Significant Spearman Correlations and Linear Regression between n-6 Plasma
Metabolite Levels and Infant Growth Metrics
Spearman Correlations
Metabolite
Cord 9-HETE
Maternal 12-HETE
Maternal 15-HETE
Maternal 5,15-DiHETE
Birth Length Percentile
Cord 11-HETE
Maternal 15-HETE
Cord 9-HODE
Cord 13-HODE
Cord 13-KODE
Birth Head Circumference Percentile
Cord 9-HETE
Linear Regression
Growth Metric
Metabolite
Birth Length Percentile
Cord 9-HODE
Growth Metric
Birth Weight Percentile

Birth Weight Percentile

rs
-0.311
-0.20
-0.21
-0.34
0.22
-0.21
0.21
0.22
0.21
-0.22

p-value
0.0012
0.040
0.043
0.016
0.028
0.046
0.029
0.026
0.045
0.023

Beta (b)
0.13

p-value
0.039

Cord 13-HODE

0.20

0.0014

Cord 13-KODE

0.19

0.016

Maternal 5,15-DiHETE

-0.041

0.047
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Figure 9: Lipoxygenase (LOX) Enzymatic Breakdown of n-6 FAs and the Metabolites
Associated with Infant Growth Metrics.
Omega-6 FAs are enzymatically cleaved by phospholipase A2 (PLA2). Parent n-6 FA
can then interact with LOX enzymes to be further metabolized into oxylipins that participate in
the physiological process. Increases in cord LA metabolites, 13-KODE, 13-HODE, and 9HODE, predicted an increase in birth length percentile. In contrast, higher levels of maternal
5,15-DiHETE were associated with a decrease in birth weight percentile.
(+), beta value was positive; (-), the beta value was negative; HpODE,
hydroxyperoxyoctadecadienoic acid; KODE, ketooctadecadienoic acid; HODE,
hydroxyoctadecadienoic acid; HpETrE, hydroxyperoxyeicosatrienoic acid; HETrE,
hydroxyeicosatrienoic acid; HpETE, hydroxyperoxyeicosatetraenoic acid; HETE,
hydroxyeicosatetraenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; LT, leukotriene; Lx,
lipoxin.
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2.3.4.2. n-3 FA Metabolites and Infant Growth
We assessed potential relationships between infant growth and n-3 FA
metabolites using the Spearman correlation (Table 9). We found that the n-3 metabolites
5-HEPE and 7-HDHA in cord and maternal specimens, respectively, were associated
with infant growth after adjustment for maternal obesity and smoking status. For every
1% increase in median cord 5-HEPE (EPA metabolite), the birth length percentile
increased by about 0.12%. In contrast, the expected birth weight percentile decreased
by 0.062% for every 1% increase in maternal 7-HDHA. Figure 7 highlights the significant
metabolites in the LOX pathway. No other significant relationships between n-3
metabolites and infant growth were identified.

Table 9: Significant Correlations and Linear Regressions between n-3 Plasma Metabolite
Levels and Infant Growth Metrics.
Spearman Correlation
Growth Metric
Metabolite
rs
p-value
Birth Weight Percentile
Maternal 5-HEPE
-0.20
0.042
Maternal 12-HEPE
-0.28
0.023
Maternal 15-HEPE
-0.32
0.0089
Maternal 7-HDHA
-0.34
0.0033
Birth Length Percentile
Cord 5-HEPE
0.21
0.036
Birth Head Circumference Percentile
Maternal 7-HDHA
-0.29
0.016
Growth Metric
Birth Length Percentile
Birth Weight Percentile

Linear Regression
Metabolite
Cord 5-HEPE
Maternal 7-HDHA

Beta (b)

p-value

0.12
-0.062

0.025
0.025
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Figure 10: Lipoxygenase (LOX) Enzymatic Breakdown of n-3 FAs and the Metabolites
Associated with Infant Growth Metrics.
Omega-3 FAs are enzymatically cleaved by phospholipase A2 (PLA2) from the phospholipid
bilayer. Parent n-3 FA can then interact with the same LOX enzymes that break down n-6 to be
metabolized into oxylipins with less potent anti-inflammatory properties. Increases in cord 5-HEPE
were predictive of an increase in birth length percentile. However, increases in maternal 7-HDHA
were predictive of a decrease in birth weight percentile.
(+), beta value was positive; (-), beta value was negative; HOTrE, hydroxyoctadecatrenoic acid;
HpEPE, hydroxyeicosatetraenoic acid; HEPE, hydroxyeicosapentaenoic acid; HpHDHA,
hydroxyperoxydocosahexaenoic acid; HDHA, hydroxydocosahexaenoic acid; oxo-DHA, oxodocosahexaenoic acid.
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2.4. DISCUSSION
The main findings of my study highlight the relationship between LOX pathway
metabolites in maternal and cord plasma and the impact these metabolites have on
infant growth metrics. Metabolites 5-HEPE, 9-HODE, 13-HODE, and 13-KODE positively
predicted infant birth anthropometrics while 7-HDHA and 5,15-DiHETE negatively
predicted infant growth. To my knowledge, my studies described herein are the first to
explore the relationship between n-6 and n-3 LOX pathway metabolite exposure in utero
and fetal growth outcomes at the time of delivery.

2.4.1. n-6 FAs
AA metabolites play essential roles in the continued maintenance of pregnancy
and delivery. Interestingly, we identified a trend towards higher circulating AA metabolite
levels in cord plasma compared to maternal cord plasma. Previous studies reported
decreased parent nutrient AA in maternal plasma accompanied by increases in cord
plasma throughout pregnancy.92 Best et al. identified a similar trend in AA metabolites;
this group reported lower 8-, 9-, 11-, 12-, and 15-HETE levels in maternal blood spots at
34 vs. 14 weeks of gestation. In contrast, maternal 5-HETE levels increase significantly
throughout pregnancy93 and have been shown to induce uterine contractility.94 HETEs
have essential functions: they function as PPAR ligands owing to their capacity to bind to
nuclear receptor transcription factors. Additionally, they participate in protein kinase
signaling activation, angiogenesis, and neuronal apoptosis.25 Further, the ability of 12and 15-HETE to activate the capsaicin-sensitive receptor correlates with pain signaling
during inflammation.25 I found similar increases in AA metabolites in cord vs. maternal
plasma at the time of delivery. Arachidonic acid concentrations, the precursor for HETE
metabolites, are much higher in fetal blood and tissues compared to maternal blood,95
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but there is little evidence that placental chain elongation and desaturation account for
the observed increases in AA supplied to the fetus.
The impact of AA metabolites on pregnancy outcomes remains to be precisely
defined. Both beneficial and adverse effects have been reported. Most studies
investigated potential relationships between metabolite levels in maternal plasma
collected before delivery and maternal/infant outcomes. Goveia-Figueira et al. found that
5- and 15-HETE levels were associated with premature labor.48 Similarly, Ramsden et
al. showed that above-median 5-HETE and 15-HETE concentrations were associated
with a higher risk of preterm delivery when assessed at gestational week 14.58 Maternal
plasma samples from women with pre-eclampsia have significantly higher 5-, 8-, 12-, 15HETE and LTB4 levels compared with women having normal pregnancies and nonpregnant women. Moreover, 5-HETE, 15-HETE, and LTB4 levels were significantly
higher in plasma from women with severe vs. mild pre-eclampsia.96
Few studies have addressed the importance of LOX metabolites in maternal and
cord plasma on infant growth. Welch et al. used Bayesian modeling to demonstrate an
association between the adjusted mean concentration of 12-HETE and size for
gestational age. Among small for gestational age (SGA) cases, the adjusted mean
concentration of maternal 12-HETE was 56.2% higher than that observed in mothers
whose infants were classified as appropriate for gestational age (AGA). We found no
predictive value for maternal or cord 12-HETE on infant growth metrics but observed that
maternal plasma levels of the AA metabolite 5,15-DiHETE were negatively associated
with infant birth weight percentile at birth.
The impact of cord plasma AA metabolites on infant outcomes is not well
understood. A previous study found that in pre-eclamptic pregnancies, umbilical cord
constriction is dependent on 15-HETE levels.65 In our study, cord AA metabolites were
not significantly associated with infant growth but we observed a trend towards lower LA
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metabolite levels in cord vs. maternal plasma. LA is an essential n-6 fatty acid
metabolized into HODEs through the LOX pathway. HODEs, like HETEs, are generally
present in healthy pregnancies;25 they function as PPAR ligands and have atherogenic
properties. HODE activity is modulated by Th1 and Th2 lymphocytes with cytokine and
chemokine participation.97 Best et al. demonstrated that maternal 13-HODE significantly
decreases throughout normal pregnancy from 14 to 34 weeks of gestation, suggesting
that less metabolite is transferred to the developing fetus.93 On the other hand,
pregnancies with maternal 9-HODE levels below the median concentration tended to
have a higher risk of spontaneous preterm birth.58 Our results show that cord 13-HODE,
9-HODE, and 13-KODE are positively associated with birth length percentile. Together,
our experimental results lead us to propose that AA and LA metabolites likely regulate
events necessary for normal delivery and potentially influence fetal growth and blood
vessel development through their role as PPAR ligands. In addition, elevated HETEs
appear to be associated with pregnancy pathologies such as pre-eclampsia, impaired
infant growth, and preterm delivery.

2.4.2. n-3 FAs
EPA and DHA are n-3 FAs that compete with n-6 fatty acids for LOX pathway
enzymes to produce a class of less potent anti-inflammatory specialized pro-resolving
mediators (SPM).98 EPA is converted to HEPEs and further metabolized into the SPM
Resolvin E-series. HEPEs induce neutrophil chemotaxis, inhibit platelet aggregation, and
play a role in mouse adipogenesis.17 Resolvin E-series inhibit further inflammation and
release of cytokines and are involved in the resolution of inflammatory responses. A
previous study reported higher EPA, SPMs, and metabolites in infant cord blood after
maternal dietary n-3 supplementation.93 However, these studies did not evaluate the
relationship between metabolite levels and infant outcomes. In our study, EPA 5-HEPE
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levels in maternal and cord plasma were significantly correlated. Further, cord 5-HEPE
positively predicted infant length percentile at birth. It remains to be established whether
these correlations reflect active participation of 5-HEPE in fetal outcomes. Mechanistic
analyses have shown 5-HEPE enhances glucose-dependent insulin secretion in mouse
insulinoma cells and human intestinal carcinoma cells.

17,99

It is tempting to hypothesize

that 5-HEPE is a fetal growth factor that regulates infant growth through its effects on
insulin secretion.
Many DHA-derived resolvins are synthesized through metabolic steps catalyzed
by 15-LOX and 5-LOX. 17-HDHA is a 15-LOX intermediate and a pathway marker for
the D-series resolvins. Mozurkewich et al. demonstrated that umbilical cord 17-HDHA
was significantly increased compared with maternal levels at 12-20 and 34-36 weeks
gestation20. Best et al. observed a significant decrease in 7-HDHA levels at 34 vs. 14
weeks of gestation93. Our study supported this trend as 7-HDHA at delivery was lower in
cord plasma compared to maternal plasma. Interestingly, we found that maternal 7HDHA levels were negatively associated with infant birth weight percentile. In addition,
maternal 7-HDHA levels were significantly correlated with maternal DHA intake. Best et
al. found an increased risk of spontaneous preterm birth with higher levels of 4-HDHA in
mothers who received supplementation and had higher n-3 baseline levels. 7-HDHA is
metabolized from the same FA precursor and LOX enzyme. This association was not
seen in women who received supplementation and had moderate to low n-3 status.93 A
synthetic 7-HDHA has been identified as a PPAR ligand, potentially highlighting a
mechanistic pathway for 7-HDHA to influence infant growth.100
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2.5. CONCLUSION
This study highlights the presence and potential influence of LOX pathway
metabolites of both n-6 and n-3 FAs on infant growth outcomes at delivery. Omega-6
and n-3 metabolites have not been described in detail in maternal and cord plasma.
Therefore, this study adds to the breadth of metabolites described during pregnancy. In
addition, this begins to elucidate the potential role of LOX PUFA metabolites on infant
growth.
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CHAPTER 3: The Relationship of Placental
LOX Pathway Metabolites with Plasma
Levels and Infant Growth

52

3.1. INTRODUCTION
The extreme of altered fetal development results in intrauterine growth restriction
(IUGR). IUGR is poor fetal growth in the womb, affecting 15% of pregnancies in the U.S.
and Europe and 30-55% in other countries.101,102 The clinical presentation of IUGR is
influenced and preceded by many factors. Negative exposures during pregnancy are
linked to alterations in the intrauterine environment associated with the infant's shortand long-term complications. In the short term, fetuses experience altered fetal growth
and increased perinatal morbidity while also having a higher risk for experiencing
cardiovascular and metabolic diseases in adulthood.101 Not all insults lead to IUGR;
nonetheless, they alter fetal development and potentially affect infant health across the
lifespan.
Placental insufficiency and its associated altered fetal growth in the womb is the
primary cause of IUGR.103 Placental insufficiency reduces nutrient transport, oxygen
delivery, and secretion of hormones and other signaling molecules like n-3 FAs.
Inflammation, improper implantation, and maternal nutrition are just a few factors that
can lead to placental insufficiency.104 However, the preceding factors altering fetal
growth are often not recognized until the clinical presentation of IUGR. Therefore,
understanding the health and role of the placenta is essential to infant health and
disease.

3.1.1. The Placenta's Role in Normal and Altered Fetal Growth
The placenta is a metabolically active tissue that integrates maternal and fetal
circulation signals to regulate placental function. The placenta senses changes in
maternal circulation and responds by matching fetal growth with the ability of the mother
to supply nutrients.101–103,105 For example, in a non-human primate model, reduced amino
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acid intake by the mothers reduced the activity of important transporters. This study
demonstrates IUGR is preceded by reduced amino acid transport and suggests a
mechanism how placental changes contribute to IUGR.105 In addition, the proper
development of the placenta and its vasculature are necessary to allow for the optimal
transfer of nutrients. However, changes in the intrauterine environment can alter the
placental structure, function, blood flow, and fetal nutrient supply, contributing to
placental insufficiency. Placental insufficiency then begins to change blood flow, the
activity of critical metabolic enzymes, and the expression of nutrient transporters
necessary to transfer resources to the fetus.106 Collectively, the fetus experiences
insufficient nutrition for proper growth and development.

3.1.2. Pregnancy Associated Inflammation
The establishment of normal pregnancies relies on a balance between
inflammatory and anti-inflammatory states. The blastocyst requires inflammation to allow
for attachment to the uterine wall. At the placenta, a microenvironment is created to
influence the differentiation of cells, which release pro-inflammatory cytokines necessary
for placental cell development.13 Further, the maintenance of the pregnancy relies on
some immune response and inflammation to allow the mother to fight off infections.13,25
Finally, delivery of the infant depends on the transition from a quiescent uterine
environment to an influx of inflammatory cells into the cervix, myometrium, and
chorioamniotic membranes.25 Therefore, controlled inflammation is necessary for normal
physiological processes in pregnancy.
However, uncontrolled inflammation in the mother, placenta, or fetus affects
placental function. Inflammation is one cause of altered placental nutrient transporters
and causes dysfunction in the placental cells necessary for nutrient transport and blood
flow to the fetus.101,102,106 Syncytiotrophoblasts are responsible for nutrient transport, and
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in IUGR, these cells are thicker and have reduced transport expression.101 Extra-villous
trophoblasts (EVTs) establish blood flow between the mother and fetus (Figure 11A). In
the presence of inflammation, EVTs have reduced invading capacity and contribute to
the inflammatory environment with the release of cytokines.107,108 Vascular smooth
muscle cells (VSMC) maintain the blood flow between maternal-fetal pairs (Figure 11B);
however, inflammation causes pathological contractility, viability, and differentiation.108–
110

the

Collectively, inflammation can influence fetal growth and development by changing
placenta

and

nutrient

transfer.
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A.
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B.
Figure 11: Placental Structures Involved in Nutrient Transfer, Establishing Blood
Supply and Maintaining Blood Flow.
A) Frontal plan of chorionic villi demonstrating syncytiotrophoblasts that supply
nutrients to the fetus. Cytotrophoblasts break through the syncytiotrophoblasts to become
extra-villous trophoblasts that establish blood flow between mother and baby. B) Transverse
section of chorionic villi demonstrating vascular smooth muscle cells in fetal vessels.
Macrophages are present in the chorionic villi and basal plate of the placenta. Figures
adapted from Kaipe et al. and Baines et al. and created in BioRender.
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3.1.3. The Junction between LOX Pathway Eicosanoids, the Placenta, and
Clinical Outcomes
Maternal nutrition is a modifiable factor that can influence the early in-utero
environment and fetal growth. Changes in eicosanoid levels between maternal and
umbilical cord plasma have raised questions about the placenta as a target and
modulator of eicosanoids during pregnancy. Keelan et al. demonstrated n-3 eicosanoids
and SPMs were quantifiable, and supplementation significantly increased SPMs and
their precursors 17-HDHA and 18-HEPE.21,59 Omega-6 eicosanoids in the placenta have
been implicated in physiological and pathological outcomes. Term labor is associated
with increased levels of 11-HETE and decreased levels of 5-HETE in cord blood.25,48
However, an oxylipin in the same family,15-HETE, was increased in placentas from preeclamptic pregnancies.65 There remains a significant gap in knowledge identifying the
presence of various oxylipins in the placenta and the clinical implications on fetal growth.
Therefore, I set out to first describe the presence of oxylipins from n-6 and n-3 FAs in
placental tissue at delivery. Second, I explored the correlation between placental oxylipin
levels and plasma. Third, I also investigated the influence of n-3 and n-6 FA metabolite
levels on infant growth.

3.2. MATERIALS AND METHODS
3.2.1. Study Characteristics
Maternal-infant pairs were recruited from the labor and delivery unit at Nebraska
Medicine after Institutional Review Board approval (IRB #112-15-EP). Written informed
consent was gathered from all subjects by trained study personnel. Eligibility criteria for
participation in the study included: mothers ≥ 19 years of age, delivering at Nebraska
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Medicine, delivery resulting in a live pregnancy, and maternal-infant pairs free of
renal, metabolic, or hepatic disease that impair normal nutrient metabolism.

3.2.2 Maternal and Infant Outcomes
Maternal and infant characteristics were obtained from the EMR (Table 10).
Ethnicity was categorized as White, Black, Hispanic, Asian or Pacific Islander,
Other/Unknown or White and Non-White. The delivery mode was characterized as
vaginal or cesarean. Mothers and infants were still included in the analysis if there were
missing data for variables.
Table 10: Maternal and Infant Characteristics and Their Definitions
Maternal Characteristics
Infant Characteristics
Maternal Age (years)
Gestational Age (weeks. days)
Maternal Smoking Status
Birth Weight (kg)
Never Smoker
Mother has never
Birth Length (cm)
smoked
Current/Former
The mother reported
Head Circumference (cm)
Smoker
previously smoking or
currently smoking at
the time of delivery
Non-obese
Obese

BMI categorization
BMI < 30 kg/m2
BMI ≥ 30 kg/m2

Birth Weight Percentile (%)
Birth Length Percentile (%)
Birth Head Circumference Percentile (%)

3.2.3. Maternal Dietary Intake
The Harvard FFQ was administered to all participants to measure nutrient intake
over the past year to measure maternal dietary intake of FAs.111 The FFQ is a semiquantitative self-report survey detailing maternal daily dietary intake of various nutrients.
Individual nutrient intakes were calculated based on the known nutrient content of the
foods and computed by assigning a daily frequency weight. This tool has been validated
in pregnancy.112 The following intakes were collected: AA, LA, DGLA, ALA, DHA, and
EPA, total n-6 FA (AA, DGLA, and LA), total n-3 (ALA, DHA, EPA, and fish oil
supplementation), and the n-6: n-3 ratio. Participants were asked if they took fish oil
(EPA+DHA) supplements during pregnancy and responses were coded as yes or no.

59

3.2.4. Tissue Sample Collection
Trained nursing personnel collected maternal blood upon admittance to the
hospital and umbilical cord blood at delivery in EDTA tubes. The research team obtained
the samples within 12 hours of collection and transported the samples using lightsensitive bags to ensure FA stabilization. Blood specimens were centrifuged, and
plasma was collected and stored at -80 °C until metabolite analysis.
Human placental cross-sections were collected at random by trained research
personnel. There were no exclusion criteria for placental samples, except for placentas
already fixed in formalin. Samples were placed in a -80 °C freezer until metabolite
analysis.

3.2.5. Placental Oxylipin Quantification
The University of California-Riverside Metabolomics core facility processed the
cross-sectional placental samples. Liquid chromatography tandem-mass spectrometry
was used to determine the concentration of oxylipins. Table 11 and Table 12 summarize
the eicosanoids from the LOX enzymatic pathway that were analyzed.
Table 11: Omega-6 Precursors and Metabolites Analyzed in Placental Tissue
Parent Nutrient

Metabolite

Abbreviation

LA

9-hydroxyoctadecadienoic acid

9-HODE

13- hydroxyoctadecadienoic acid

13-HODE

DGLA

13- ketooctadecadienoic acid
15-hydroxyeicosatrienoic acid

13-KODE
15-HETrE

AA

5-hydroxyeicosatetraenoic acid

5-HETE

8-hydroxyeicosatetraenoic acid

8-HETE

9-hydroxyeicosatetraenoic acid

9-HETE

11-hydroxyeicosatetraenoic acid

11-HETE

12-hydroxyeicosatetraenoic acid

12-HETE

15-hydroxyeicosatetraenoic acid

15-HETE

8,15- hydroxyeicosatetraenoic acid

8,15-DiHETE

5,15-dihydroxyeicosatetraenoic acid

5,15-DiHETE

Lipoxin A4

LxA4

Leukotriene B4

LTB4
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Table 12: Omega-3 Precursors and Metabolites Analyzed in Placental Tissue
Parent Nutrient

Metabolite

Abbreviation

ALA
EPA

9-hydroxyoctadecatrenoic acid
5-hydroxyeicosapentaenoic acid
12-hydroxyeicosapentaenoic acid
15-hydroxyeicosapentaenoic acid
18-hydroxyeicosapentaenoic acid
Resolvin E1
17-hydroxydocosahexaenoic acid
7-hydroxydocosahexaenoic acid
Resolvin D1
Resolvin D2
Maresin 1

9-HOTrE
5-HEPE
12-HEPE
15-HEPE
18-HEPE
RvE1
17-HDHA
7-HDHA
RvD1
RvD2
MaR1

DHA

3.2.5.1. Placental Tissue Extraction
The placental tissue extraction protocol was adapted89 and 50-100 mg of
placental tissue was prepared for extraction. Ten microliters (ml) of antioxidant solution
(0.2 mg/mL of BHT and EDTA), 10 ml of surrogate solution and 400 mL of ice-cold
methanol with 0.1% of acetic acid and 0.1% of BHT were added to the thawed placental
tissue and then stored in a -80 °C freezer for 30 min. Once frozen, the samples were
homogenized with a bead mill homogenizer at 30 Hz for 10 min, and then the
homogenates were frozen overnight at -80 °C. Homogenates were centrifuged at 10,000
rpm for 10 min, and the supernatant was collected. The remaining pellets were washed
with 100 mL of ice-cold methanol with 0.1% of acetic acid and 0.1% of BHT, centrifuged,
and the supernatants of each sample were combined. Supernatants were diluted with 2
mL of H20 and loaded onto the SPE cartridges.
SPE Extraction: Waters Oasis cartridges were washed with ethyl acetate and
methanol. The solution containing H2O and methanol was used to equilibrate the
cartridges to the initial condition. Cartridges were loaded with the diluted supernatant
and washed twice with SPE solution (H2O with 20% methanol). The cartridges were then
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vacuum dried. Analytes were eluted with 0.5 mL of methanol and 3 mL of ethyl acetate
to tubes with 10 µl of trapping solution (30% glycerol in methanol), vacuum dried
(SpeedVac), and reconstituted with internal solutions. Recoveries of surrogate analytes
were above 60%, respectively.

3.2.6. Statistical Analysis
Descriptive statistics are presented as means (standard deviation) or medians
[interquartile ranges (IQR)], with minimums and maximums for continuous data and
counts and percentages for categorical data. The Mann-Whitney test was used to
compare continuous measures between dichotomous groups. The Kruskal Wallis test
was used to compare measures between more than two groups. Spearman correlation
coefficients were used to assess associations between continuous variables.
Linear regression was performed on metabolites correlated with birth weight
percentile, birth length percentile, or birth head circumference percentile at a p < 0.05 in
the univariate analysis. The model was adjusted for maternal obesity (BMI ≥ 30 or < 30
kg/m2) and smoking status (current/former vs. never).

A p < 0.05 was considered

statistically significant.

3.3. RESULTS
3.3.1. Baseline Characteristics
3.3.1.1 Maternal Demographics
There were 121 maternal-infant pairs enrolled in this study, with 43 placental
samples available for analysis. Mothers were on average 29.4 (5.88) years old, with
62.2% identifying as White, 19.3% as Black, 5.9% as Hispanic, 1% as Asian or Pacific
Islander, 1% as American Native, and 10.9% as other/unknown. Twenty-two % of
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mothers were current or former smokers, and 28% had a pre-pregnancy BMI greater
than 30 kg/m2. The number of mothers receiving a cesarean section was not significantly
different than the number of mothers with vaginal deliveries, nor did delivery mode
greatly influence placental oxylipin levels at delivery (Table 14).
Maternal dietary intakes are summarized in Table 13; mothers reported median
intakes of 14.46 [7.43] g/day of total n-6 and 1.72 [1.00] g/day of total n-3 FA. Median
maternal intakes of the three main FAs AA, EPA and DHA were 0.15 [0.11] g/day, 0.02
[0.060] g/day, and 0.09 [0.15] g/day. Twenty % of mothers identified taking fish oil
supplements during pregnancy.

Table 13: Maternal Baseline Characteristics for Continuous Variables
(n)
Mean (SD)
Median [IQR]
Maternal Age (years)

118

29.4 (5.88)

29.00 [10.00]

AA

103

0.19 (0.13)

0.15 [0.11]

LA

103

14.95 (8.66)

13.06 [0.86]

ALA

103

1.71 (1.15)

1.42 [0.74]

g-LA

103

0.020 (0.010)

0.01 [0.010]

EPA

103

0.060 (0.10)

0.020 [0.06]

DPA

103

0.030 (0.020)

0.020 [0.030]

DHA

103

0.13 (0.13)

0.090 [0.15]

Total n-3

103

1.93 (1.24)

1.72 [1.00]

Total n-6

103

16.28 (9.21)

14.46 [7.43]

The ratio of n-6: n-3

102

8.73 (1.55)

8.73 [1.79]

Maternal Daily Intakes of FA (g/day)
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Table 14: Categorical Maternal Demographics
Ethnicity
White

(n)
74

%
62.2

Black

23

19.3

Hispanic

7

5.9

Asian or Pacific Islander

1

0.8

American Indian

1

0.8

Other/Unknown

13

10.9

(n)

%

2

BMI Category

73

72.3

2

28

27.7

(n)

%

Cesarian Section (CS)

30

25.4

Vaginal

88

74.6

(n)

%

None

92

78.0

Current Smoker (at delivery)

13

11.0

Former Smoker

13

11.02

Fish Oil Supplementation

(n)

%

No

92

79.31

Yes

24

20.69

<30 kg/m
≥30 kg/m

Delivery Mode

Smoking Status

3.3.1.2. Intersection of Demographics and Metabolite Levels
To begin to understand more completely the relationships between the LOX
pathway SPM metabolites and infant health, I first assessed for relationships between
placental levels and demographic or medical characteristics (Table 15). Mothers with
obesity had significantly lower median levels of 5-HEPE and 15-HEPE relative to
mothers with a BMI less than 30 kg/m2. There were no other significant relationships
between oxylipin levels and maternal obesity. Median LTB4 levels were significantly
different between mothers who identified as Non-White (4.76 nM) compared to mothers
who identified as White (1.80 nM).
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Table 15: Significant Differences between Metabolite Levels and Demographics

LTB4

White
1.80

15-HEPE
5-HEPE

BMI <30
2.50
3.18

Ethnicity
Non-White
4.76
BMI (kg/m2)
BMI ≥ 30
1.55
1.32

p-value
0.036
p-value
0.033
0.013

3.3.1.3. Associations between Metabolite Levels and Maternal Dietary Intakes of
Precursor FA
Maternal fish oil supplementation and dietary n-6: n-3 intake ratios were
significantly correlated with placental precursor levels. Fish oil supplementation was
associated with significantly lower levels of n-6 oxylipins 5-, 8-, 9-, 11-, 15-HETE, 9HODE, LTB4, and 5,15-DiHETE levels compared to mothers that did not report fish oil
supplementation.

Maternal dietary intake ratio of n-6: n-3 FAs showed a low to

moderate positive correlation with placental precursors (5,15-DiHETE, 11-HETE, 9HETE, and 7-HDHA). Data is summarized in Table 16.

Table 16: Significant Relationships of Placental Levels Based on Maternal Intake
Fish Oil
Yes
No
p-value
Supplementation
(nM)
(nM)
5-HETE
85.60
128.89
0.041
8-HETE
28.53
50.96
0.010
9-HETE
91.20
156.65
0.005
11-HETE
32.67
52.57
0.023
15-HETE
61.38
103.89
0.022
9-HODE
41.17
52.00
0.050
5,15-DiHETE
1.17
2.56
0.006
LTB4
1.21
3.33
0.027
Significant Spearman
Levels
Precursor
5,15-DiHETE
11-HETE
9-HETE

Correlation for ratio of n-6 to n-3 Intakes and Placental Precursor
rs
0.39
0.36
0.37

p-value
0.021
0.036
0.027
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3.3.1.4. Infant Demographics
In this cohort, infants had a median gestational age of 39.2 weeks [2.00]. Infant
anthropometrics are summarized in Table 17. At birth, infants were born into the
following median percentiles for weight, head circumference, and length: 60.77 [45.69],
63.58 [57.03], and 55.90 [61.30], respectively. The number of male infants born was not
significantly different than the number of female infants. Not all baseline characteristics
were available for the 121 infants enrolled in this study.
Table 17: Infant Baseline Characteristics
Birth Anthropometrics
(n)
Gestational Age (weeks. days)
119
Birthweight, Kilograms (kg)
118
Birthweight Percentile (%)
115
Head Circumference, cm
115
Head Circumference Percentile (%)
115
Birth Length, cm
114
Birth Length Percentile (%)
113
Sex
(n)
Female
53
Male
66

Mean (S.D.)
38.2 (3.29)
3.2 (770.2)
56.6 (28.86)
34.1 (2.29)
34.09 (2.29)
49.1 (8.06)
52.46 (33.41)
Percent (%)
44.5
55.5

Median [IQR]
39.2 [2.00]
3.34 [0.80]
60.77 [45.69]
34.30 [2.60]
63.58 [57.03]
49.50 [2.80]
55.9 [61.30]

3.3.2. Metabolite Levels in the Placenta
Placental metabolite levels in the LOX enzymatic pathway were quantified and
their levels reported in Table 18.
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Table 18: LOX Pathway Metabolite Concentrations Quantified in Placental Cross-sections
Precursor Metabolite
(n) Mean (nM)
Median (nM)
Minimum Maximum
(SD)
[IQR]
(nM)
(nM)
LA
9-HODE
43 137.13 (394.80) 48.33 [63.44]
6.87
2573.62
13-HODE
43 206.77 (688.22) 55.02 [73.67]
6.57
4441.62
13-KODE
43 36.53 (114.18)
12.79 [16.75]
2.17
750.29
DGLA
15-HETrE
43 67.01 (234.35)
15.56 [13.73]
2.23
1468.09
AA
5-HETE
43 227.20 (451.80) 107.99 [78.14]]
37.45
2576.41
8-HETE
43 85.26 (177.07)
39.03 [31.77]
3.54
998.01
9-HETE
43 244.33 (437.00) 117.94 [95.96]
6.58
2387.81
11-HETE
43 112.64 (250.27) 49.34 [47.74]
5.27
1401.19
12-HETE
43 414.10 (584.03) 186.69 [345.41] 16.87
3270.71
15-HETE
43 290.02 (791.89) 98.45 [74.28]
12.92
4531.80
5,15-DiHETE 43 6.50 (19.86)
1.83 [2.04]
0.18
124.18
LTB4
43 3.38 (3.39)
1.97 [3.73]
0.10
15.76
ALA
9-HOTrE
43 3.50 (10.73)
1.12 [2.43]
0.17
70.37
EPA
5-HEPE
43 4.10 (6.17)
2.53 [2.73]
0.51
37.53
9-HEPE
43 2.52 (4.18)
1.32 [1.64]
0.25
24.95
12-HEPE
43 16.00(17.08)
9.71 [13.31]
1.18
80.96
15-HEPE
43 5.36 (12.08)
2.0 [2.49]
0.49
72.90
DHA
17-HDHA
43 110.22 (299.90) 32.81 [33.02]
5.47
1570.88
7-HDHA
43 27.96 (52.87)
16.03 [11.33]
2.51
272.40

3.3.3. The Relationship between n-6 FA Metabolite Levels in Placenta
Tissue and Maternal and Infant Plasma
The AA-derived 9-HETE, highlighted a low-to-moderate association between
increases in placental and cord plasma (Figure 12). There were no other significant
relationships identified between maternal or cord plasma and placental HETE
metabolites. Tables 19 and 20 summarize median placental, maternal, and cord
metabolite levels. Further, Spearman correlations are represented between maternalplacenta and cord-placenta.
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Figure 12: Log Scaled Metabolite Levels for 9-HETE in
Different Tissue Samples.

Spearman correlations were used to determine the
relationship between maternal (M), placental (P), and
cord (C) precursor levels. Placental levels had a
significant, positive relationship with cord plasma (rs =
0.40, p = 0.011). Whiskers are extended to the minimum
and maximum precursor levels.
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Table 19: Maternal-Placental Relationship for n-6 Metabolites
Sample
Oxylipin
(n)
Mean
Median
Min
Source
(nM)
(nM)
(nM)
(SD)
[IQR]

Max
(nM)

Spearman
Correlation
(p-value)

Maternal

rs = 0.018
(0.91)

9-HODE

Placenta
Maternal
Placenta

13-HODE

Maternal
Placenta

13-KODE

Maternal
Placenta

15-HETrE

Maternal

5-HETE

Placenta
Maternal
Placenta

8-HETE

Maternal
Placenta

9-HETE

Maternal
Placenta

11-HETE

Maternal

12-HETE

Placenta
Maternal
Placenta

15-HETE

Maternal
Placenta
Maternal
Placenta

5,15DiHETE
LTB4

107

27.75
(28.27)
43
137.13
(394.80)
107 28.9 (24.79)
43
206.77
(688.22)
105 6.26 (14.41)
43
36.53
(114.18)
115 4.03 (15.17)
43
67.01
(234.35)
105 10.89
(18.18)
43
227.20
(451.80)
114 6.56 (20.51)
43
85.26
(177.07)
114 6.86 (22.94)
43
244.33
(437.00)
113 6.65 (16.32)
43
112.64
(250.27)
115 10.23
(20.13)
43
414.10
(584.03)
99
12.9 (40.09)
43
290.02
(791.89)
54
6.54 (14.51)
43
6.50 (19.86)
Not Detectable
43
3.38 (3.39)

18.94 [19.57]

5.00

199.04

48.33 [63.44]

6.87

2573.62

20.99 [14.56]
55.02 [73.67]

6.73
6.57

152.05
4441.62

rs = -0.028
(0.87)

2.31 [2.50]
12.79 [16.75]

0.72
2.17

125.84
750.29

rs = -0.0083
(0.96)

0.72 [0.83]
15.56 [13.73]

0.14
2.23

144.82
1468.09

rs = -0.030
(0.86)

5.86 [9.51]

0.45

143.51

rs = -0.081
(0.63)

107.9 [78.14]

37.45

2576.41

1.33 [1.76]
39.03 [31.77]

0.20
3.54

176.93
998.01

rs = -0.089
(0.59)

1.06 [1.89]
117.94 [95.96]

0.11
6.58

185.18
2387.81

rs = 0.064
(0.70)

1.81 [2.55]
49.34 [47.74]

0.21
5.27

104.86
1401.19

rs =0.025
(0.88)

3.84 [6.59]

0.18

163.83

rs = 0.22
(0.18)

186.69
[345.41]
3.95 [5.62]
98.45 [74.28]

16.87

3270.71

0.13
12.92

317.45
4531.80

rs = -0.026
(0.89)

0.27 [1.31]
1.83 [2.04]

0.020
0.18

61.74
124.18

rs = 0.36
(0.28)
N/A

1.97 [3.73]

0.10

15.76
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Table 20: Placental-Cord Relationships for n-6 Metabolites
Source

Oxylipin

(n)

Mean (nM)
(SD)

Median
(nM)
[IQR]
48.33 [63.44]

Min
(nM)

Max
(nM)

Placenta

9-HODE

43

137.13
(394.80)
11.00 (5.98)

6.87

2573.62

9.83 [6.40]

2.72

33.19

206.77
(688.22)
14.61 (8.57)

55.02 [73.67]

6.57

4441.62

12.87 [8.70]

3.94

59.98

36.53
(114.18)
1.61 (0.74)

12.79
[16.75]
1.44 [0.90]

2.17

750.29

0.52

4.38

227.20
(451.80)
1.86 (1.64)

107.9 [13.73]

37.45

2576.41

1.40 [1.09]

0.47

11.60

227.20
(451.80)
10.89
(18.18)
85.26
(177.07)
2.89 (2.74)

107.9 [78.14]

37.45

2576.41

5.86 [5.30]

0.45

143.51

39.03 [31.77]

3.54

998.01

2.08 [1.36]

0.73

18.92

244.33
(437.00)
2.61 (2.03)

117.94 [95.96]

6.58

2387.81

2.24 [1.53]

0.41

13.07

112.64
(250.27)
4.24 (5.90)

49.34 [47.74]

5.27

1401.19

2.42 [2.68]

0.74

44.90

186.69 [345.41]

16.87

3270.71

8.32 [16.43]

1.20

137.46

98.45 [74.28]

12.92

4531.80

111

414.10
(584.03)
18.62
(25.16)
290.02
(791.89)
7.25 (7.99)

5.27 [5.22]

0.11

55.06

43

6.50 (19.86)

1.83 [2.04]

0.18

124.18

Cord

5,15DiHETE

68

0.54 (1.20)

0.16 [0.26]

0.03

7.81

Placenta

LTB4

43

3.38 (3.39)

1.97 [3.73]

0.10

15.76

Cord
Placenta

112
13HODE

Cord
Placenta

112
13KODE

Cord
Placenta

15HETrE
5-HETE

8-HETE

9-HETE

11HETE
12HETE

43
103

15HETE

Cord
Placenta

43
112

Cord
Placenta

43
112

Cord
Placenta

43
112

Cord
Placenta

43
105

Cord
Placenta

43
112

Cord
Placenta

43
102

Cord
Placenta

43

43

Cord
Not Detectable
** p < 0.05

Spearman
Correlation
(p-value)
rs = 0.23
(0.16)
rs = 0.29
(0.067)
rs = 0.13
(0.46)
rs = 0.23
(0.16)
rs = 0.15
(0.35)

rs = 0.19
(0.23)
rs = 0.40
p = 0.011 *
rs = 0.24
p = 0.14
rs = 0.17
p = 0.31

rs = 0.045
p = 0.78
rs = 0.13
p = 0.56
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3.3.4. The relationship between n-3 FA Metabolite Levels in Placenta Tissue
and Maternal and Infant Plasma
Table 21 and Table 22 summarize the relationships between n-3 FA metabolite
levels in the placenta and maternal or cord plasma. Placenta ALA-derived 9-HOTrE,
showed a low-to-moderate positive association with an increase in cord plasma 9HOTrE (Figure 13A). EPA precursor 5-HEPE demonstrated significant low-to-moderate
positive associations between maternal-placenta and placenta-cord levels. A
maternal increase in 9-HEPE, another EPA precursor, strongly correlated with
placental 9-HEPE levels. Figure 13B-C highlights the metabolites with significant
relationships between placental and plasma levels for EPA metabolites. Figure 13D
demonstrates an increase in placental 7-HDHA had a positive low-to-moderate
correlation with cord 7-HDHA. There were no significant correlations between 17-HDHA
in maternal and placental levels or placental and cord levels.
Table 21: Maternal-Placental Relationships for n-3 Metabolites
Oxylipin
(n) Mean (nM)
Median (nM)
Min
(SD)
[IQR]
(nM)
Maternal
Placenta
Maternal
Placenta
Maternal
Placenta
Maternal
Placenta
Maternal
Placenta

9-HOTrE

Maternal
Placenta

17-HDHA

5-HEPE
9-HEPE
12-HEPE
15-HEPE

Maternal 7-HDHA
Placenta
** p < 0.05

Max
(nM)

116
43
115
43
46
43
71
43
66
43

2.79 (4.35)
3.50 (10.73)
3.48 (17.82)
4.10 (6.17)
0.94 (2.75)
2.52 (4.18)
0.91 (1.76)
16.00 (17.08)
0.80 (1.95)
5.36 (12.08)

1.46 [1.60]
1.12 [2.43]
0.40 [0.61]
2.53 [2.73]
0.19 [0.48]
1.32 [1.64]
0.34 [0.82]
9.71 [13.31]
0.29 [0.27]
2.0 [2.49]

0.22
0.17
0.10
0.51
0.030
0.25
0.030
1.18
0.10
0.49

30.11
70.37
185.84
37.53
18.35
24.95
13.06
80.96
14.94
72.90

90
43

7.43 (22.42)
110.22
(299.90)
7.25 (18.92)
27.96 (52.87)

1.83 [2.63]
32.81 [33.02]

0.13
5.47

1.36 [2.54]
16.03 [11.33]

0.20
2.51

172.13
1570.8
8
132.54
272.40

74
43

Spearman
Correlation
(p-value)
rs = 0.16
p = 0.33
rs = 0.35**
p = 0.028
rs = 0.79**
p = 0.036
rs = 0.35
p = 0.067
rs = 0.23
p = 0.33
rs = 0.031
p = 0.88
rs = 0.38
p = 0.15
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Table 22: Placental-Cord Relationships for n-3 Metabolites
Oxylipin N
Mean (nM)
Median
(SD)
(nM)
[IQR]

Min
(nM)

Max
(nM)

Spearman
Correlation
(p-value)

Placental
Cord
Placental
Cord
Placental
Cord

9-HOTrE

Placental

12-HEPE

5-HEPE
9-HEPE

Cord
Placental
Cord
Placental
Cord

15-HEPE

Placental

7-HDHA

Cord
**p < 0.05

17-HDHA

43
103
43
112
43
38

3.50 (10.73)
0.56 (0.40)
4.10 (6.17)
0.60 (1.29)
2.52 (4.18)
0.16 (0.11)

1.12 [2.43]
0.47 [0.31]
2.53 [2.73]
0.39 [0.29]
1.32 [1.64]
0.12 [0.06]

0.17
0.090
0.51
0.10
0.25
0.070

70.37
2.67
37.53
13.41
24.95
0.54

rs = 0.38 *
p = 0.018

43

16.00 (17.08)

9.71 [13.31]

1.18

80.96
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1.56 (5.92)

0.25 [0.91]

0.040

52.49

rs = 0.025
p = 0.89

43
54
43
101

5.36 (12.08)
0.26 (0.17)
110.22 (299.90)
2.88 (3.76)

2.0 [2.49]
0.20 [0.14]
32.81 [33.02]
2.16 [1.94]

0.49
0.12
5.47
0.17

72.90
1.10
1570.88
35.03

rs = 0.42
p = 0.074
rs = 0.26
p = 0.14

43

27.96 (52.87)

16.03 [11.33]

2.51

272.40

99

1.41 (1.26)

1.16 [0.93]

0.29

10.03

rs = 0.40**
p = 0.028

rs = 0.43 *
p = 0.0050
rs = 0.37
p = 0.47
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B
A

C

D

Figure 13: Log Scaled Visual of Significantly Correlated ALA, EPA, and DHA Precursor
levels. A) Placental 9-HOTrE levels were significantly associated with cord plasma 9-HOTrE
(rs = 0.38, p = 0.018). B) Placental 5-HEPE was correlated with maternal (rs = 0.35, p =
0.028) and cord (rs = 0.43, p = 0.0050) plasma. C) 9-HEPE was strongly correlated between
maternal and placental samples (rs = 0.79, p = 0.036). D) Cord 7-HDHA increased with an
increase in placental 7-HDHA (rs = 0.40, p = 0.028). Graphs were made in prism using the
violin feature, which extended whiskers to the minimum and maximum values. p<0.05 was
considered significant.
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3.3.5. Infant Growth and LOX Pathway Precursors in the Placenta
LOX pathway precursor levels in placentas were analyzed with infant birth
anthropometrics (weight, length, and head circumference percentiles), and LTB4 was
the only metabolite to demonstrate a significant relationship. An increase in LTB4 was
weakly associated with a decrease in birth- weight, length, and head circumference
percentiles. After adjustment, LTB4 remained significantly associated with median birth
weight percentile. For every 1% increase in placental LTB4, a 0.23% reduction in birth
weight percentile would be expected. Interestingly, the relationship between birth length
and head circumference percentile trended towards significance after adjustment (Table
23).

Table 23: Placental LTB4’s Relationship with Infant Growth.
Spearman Correlations

rs

p-value

Birth Weight Percentile

-0.36

0.019**

Birth Length Percentile

-0.31

0.044**

Birth Head Circumference Percentile

-0.34

0.027**

Linear Regression

b

p-value

Birth Weight Percentile

-0.23

0.027**

Birth Length Percentile

-0.21

0.067

Birth Head Circumference Percentile

-0.22

0.074

** p < 0.05
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3.4. DISCUSSION
This present study reports placental n-3 and n-6 LOX pathway precursor levels at
delivery and their relationship with maternal and cord plasma. The quantification of n-6
and n-3 oxylipins corroborates previous studies that the placenta is involved in regulating
oxylipins. My study adds to the literature the identification of a wide array of LOX
pathway eicosanoids not previously analyzed in the placenta. Further, only certain
placental oxylipins were significantly correlated between maternal and cord plasma. The
n-6 derivative, 9-HETE, was positively correlated between placental and cord levels.
Omega-3 FA oxylipins 9-HOTrE, 5-HEPE, and 7-HDHA, had positive correlations
between placental and cord plasma. Maternal plasma was positively correlated with 5HEPE and 9-HEPE levels. LTB4 was negatively correlated with birth weight, length, and
head circumference percentiles. After adjustment for maternal pre-pregnancy BMI and
smoking status, LTB4 negatively predicted birth weight percentile. These studies add to
the current literature the relationship between tissue levels, which begins to parse out
placental diffusion of metabolites, storage of metabolites, or synthesis and metabolism of
FAs. Further, these studies suggest the placental is an important regulator of
metabolites and involved in infant health.

3.4.1. Placental n-6 FA Precursor Levels at Delivery
Previously in Ch. 2, I identified many of the HETE precursors were significantly
higher in cord plasma compared to maternal circulation. HETEs are PPAR ligands,
which bind to nuclear receptors and influence genes essential for cell differentiation and
metabolic processes.25,113 Further, HETEs participate in protein kinase signaling
activation,114 angiogenesis,115 and neuronal apoptosis.25,116 In pregnancy, LOX pathway
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derivatives are produced in the placenta and may affect the myometrium while also
regulating placental progesterone biosynthesis.42
In this study, I report cord 9-HETE had a significant low-to-moderate positive
correlation with placental 9-HETE levels. However, there was not a significant
relationship with maternal plasma. Therefore, increased 9-HETE levels in the placenta
are potentially leading to higher levels of 9-HETE being transferred to the fetus through
the umbilical cord. 9-HETE has been shown to stimulate human eosinophil and
neutrophil chemotaxis.17 At delivery, neutrophils migrate into the uterus and cervix and
release pro-inflammatory cytokines and chemokines to facilitate labor. The presence of
9-HETE in the placenta potentially illuminates its role in recruiting neutrophils for the
initiation of labor. However, altered levels of placental 5-, 8-, 12-, and 15-HETEs have
been found in pre-eclamptic pregnancies compared to normal pregnancies.35,65,66,117
Further, 15-HETE has been identified in the human umbilical cord and found to increase
the vasoconstriction of the umbilical artery.65,118 This leads to decreased blood flow and
nutrient supply to the fetus.
In addition to 9-HETE's potential role in parturition, there may be a function in
brain development and neuronal apoptosis of the fetus. AA, the parent nutrient to 9HETE, is found in significant amounts in the fetal brain.8 As stated above, HETEs have
been shown to have biological effects on neuronal apoptosis. Cell death is an essential
feature of brain development, where approximately 50% of the neuronal cells are
eliminated through neuronal apoptosis.119,120 A mouse model demonstrated that early
births could trigger neuronal cell death; however, delaying delivery did not delay cell
death. Therefore, cell death can be initiated by birth but also relies on an autonomous
developmental program.119 Due to the current studies on other HETE oxylipins, 9-HETE
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is potentially needed in parturition and fetal development; however, alteration in 9-HETE
levels could also be pathological.

3.4.2. Placental n-3 FA Precursor Levels at Delivery
Omega-3 fatty acid precursors from the LOX pathway were quantified in the
placenta and demonstrated significant positive correlations with maternal and cord
plasma. Few studies have reported oxylipin concentrations in the placenta. Keelan et al.
described omega-3 eicosanoids in the placenta of control and supplemented women and
increased 17-HDHA, 18-HEPE, and SPMs in the supplemented group compared to
controls.21 Our study adds to the limited literature on n-3 LOX pathway metabolites found
in placental tissue at delivery. Since inflammation is a major contributor to poor placenta
health and leads to adverse outcomes, identification of potentially important n-3 targets
in the placenta could assist with anti-inflammatory effects.
3.4.2.1. ALA Precursor Levels at Delivery
Little is known about 9-HOTrE in humans and has not been explored during
pregnancy. To our knowledge, this is the first study to describe 9-HOTrE in placental
tissue and highlight a relationship between cord plasma. In Ch. 2, I demonstrated there
was not a significant correlation between maternal and cord 9-HOTrE plasma levels.
However, cord and placental 9-HOTrE showed a significant, positive low-to-moderate
correlation (rs = 0.38, p = 0.018). Therefore, the placenta is potentially selectively
transferring 9-HOTrE. The parent nutrient ALA is an essential FA that must be obtained
from the diet. Its anti-inflammatory effects have been attributed to ALA's conversion to
DHA and EPA and then the production of oxylipins. However, conversion rates of ALA to
DHA and EPA are quite low.9,121 Additionally, ALA oxylipins are found in blood and
tissues at relatively high concentrations.121 ALA oxylipins potentially have a distinct
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mechanism in regulating inflammation. In obese rats, high 9-HOTrE was associated with
glomerular hypertrophy.17,122 Most recently, the presence of 9-HOTrE increased in M1like macrophages pretreated with ALA and stressed with lipopolysaccharides (LPS).
Pauls et al. suggests that ALA and its oxylipins may dampen the inflammatory
phenotype of M1 macrophages.121 The further metabolism of 9-HOTrE into 9,16-HOTrE
inhibits prostaglandin synthesis from COX1 and collagen-induced human platelet
aggregation and the production of inflammatory mediators.17,123
The connection between 9-HOTrE and pregnancy is potentially through the
regulation of macrophage activity and prostaglandins synthesis. At the maternal-fetal
interface (the placenta), macrophages are the second largest group of cells.24
Macrophages are immune cells generally characterized as M1 and M2 subtypes.
Functionally M1 macrophages are pro-inflammatory, and M2 macrophages are antiinflammatory (Figure 11).124,125 Normal pregnancy relies on the balance between M1
and M2 macrophages for various processes, such as trophoblast invasion, spiral artery
remodeling, and apoptotic cell phagocytosis. All these processes are related to the
placenta's structure, function, and health, and dysregulation in macrophage polarization
has been associated with spontaneous abortion, pre-eclampsia, and preterm birth due to
inadequate remodeling of uterine vessels and defective trophoblast invasion.24,126–128
Further, the protection of fetal growth relies on the M2 phenotype to promote maternal
immune tolerance until labor. From the few studies conducted, I hypothesize that 9HOTrE is present in the placenta to help maintain the balance between M1 and M2
macrophages, potentially influencing placental health and ultimately influencing fetal
growth.
The presence and biological activity of 9-HOTrE may also indicate activation of
the pathway that results in its metabolism into 9,16-HOTrE. As described above, 9,16-
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HOTrE had anti-aggregatory and anti-inflammatory properties by inhibiting COX-1, COX2, and the human 5-LOX pathway.123 All of these are essential mechanisms within
pregnancy.123 Cyclooxygenase is the enzyme in the synthesis of prostaglandins (PG)
that are regulators of implantation, decidualization, and parturition while also
metabolizing FA's into various pro-inflammatory mediators. COX-1 is constitutively
expressed in most tissues, whereas cytokines or inflammatory stimuli can induce COX2.129 COX-1 inhibition during pregnancy prolonged the length of gestation for full-term
and preterm labor.130 Pre-eclamptic placenta expressed significantly higher COX-2
compared to normal placentas.131 Therefore, 9-HOTrE's role in pregnancy may be
related to its ability to regulate inflammatory processes at the placenta and in the
developing fetus to allow for proper nutrient transfer and growth.
3.4.2.2. EPA as Precursors at Delivery
EPA derived metabolites in the placenta like 5-HEPE and 9-HEPE, demonstrated
relationships between maternal and cord plasma. I also observed maternal and cord
plasma 5-HEPE levels had a significant, positive correlation (Ch. 2). Similarly, Yamada
et al. demonstrated 5-HEPE extracted from Pacific krill acted as a ligand for all three
isotypes of peroxisome proliferator-activated receptors (PPARs) alpha (a), delta (d) and
gamma (g), and significantly activated PPAR g and d more than EPA.132 Studies have
shown all three isotypes are found in placental trophoblast cells and bind long-chain
eicosanoids. PPARs are major regulators of lipid and glucose metabolism, inflammation,
and angiogenesis and regulate pregnancy physiology and clinical complications.133 For
example, animal and cellular models have suggested a link between variations in PPAR
genes and birthweight and gestational duration.134 The significant, positive correlations
between placental 5-HEPE and maternal and cord plasma suggest 5-HEPE has a role at
the placenta and in fetal development, potentially through the activation of the PPAR

79
system. Another study used human umbilical vascular endothelial cells to understand
the effects of 5-HEPE on NF-E2 related factor 2 (Nrf2). Nrf2 is a transcription factor that
regulates

cell

survival,

detoxification,

and

antioxidation.135

5-HEPE

treatment

demonstrated an increase in the pathway involved in maintaining the antioxidative
capacity of cells. Surprisingly, the 5-HEPE treatment also increased the levels of
reactive oxygen species but has a dampened ability to activate leukocytes that promote
inflammatory reactions.135 More research is needed to understand the safe physiological
levels compared to those that cause poor outcomes.
Placental 9-HEPE positively correlated with maternal plasma levels; however,
maternal and cord plasma levels of 9-HEPE were not significantly correlated. 9-HEPE
acts like 5-HEPE and activates all three PPAR isotypes, but 9-HEPE has been shown to
have significantly greater PPAR system activation than 5-HEPE.132 In animal models,
PPAR activation by 9-HEPE induces adipose development in mouse preadipocytes and
glucose uptake in the myoblast.132 Therefore, 9-HEPE is potentially a more potent PPAR
system activator than 5-HEPE, with similar placental and fetal health roles.
3.4.2.3. DHA as Precursors at Delivery
Lastly, the DHA metabolite, 7-HDHA, was identified in the placenta at delivery and
had a significant, positive correlation with cord 7-HDHA levels. Previously I reported
maternal and cord 7-HDHA plasma levels were significantly correlated, with maternal 7HDHA levels negatively predicting birth length percentile. The negative relationship
between 7-HDHA and birth length percentiles seems counterintuitive as 7-HDHA is an n3 precursor often associated with beneficial anti-inflammatory properties. Best et al.
reported a significant increase of maternal 7-HDHA and 4-HDHA levels in blood spots
from 14 weeks of gestation to 34 weeks of pregnancy after supplementation.93
Unexpectedly, another study found increases in 4-HDHA from supplementation in
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women with already high n-3 FA baseline levels was associated with an increased risk of
early preterm birth.21 More recently, Zhang and colleagues created a synthetic 7-HDHA
that allowed for the isolation of racemic 7(S)-HDHA and highlighted 7(S)-HDHA as a
potential ligand for PPARa .100 PPARa deficiency is linked to miscarriages, neonatal
mortality, and a shift to a more inflammatory immune environment.133 The presence of 7HDHA in the placenta may be linked to its more anti-inflammatory effects; however, 7HDHA may also have more harmful effects, as demonstrated by its negative association
with birth length percentile and prematurity.

3.4.3. LOX Pathway Precursor and Infant Growth
Leukotriene B4 (LTB4) placental levels were negatively correlated with birth weight,
length, and head circumference percentiles. After adjustment for maternal smoking and
pre-pregnancy obesity, LTB4 negatively predicted median weight percentile at birth.
Interestingly, LTB4 was undetectable in maternal and cord plasma (Ch. 2), yet LTB4 was
quantified in placental samples. LTB4 is an AA metabolite that releases human
polymorphonuclear leukocyte lysosomal enzymes, causes chemotaxis of immune cells,
platelet aggregation, and is a PPARa ligand.17,132 In addition, LTB4 has two receptors
expressed in the placenta that can also respond to other metabolites like 12-HETE.136
LTB4 has previously been reported in term placentas, with higher levels in spontaneous
labor vs. cesarean section and significantly higher in preterm deliveries with
chorioamnionitis.137 In pre-eclamptic pregnancies, maternal serum LTB4 was higher at
19-24 weeks for pregnancies that developed pre-eclampsia and delivered preterm.138 In
the present study, fish oil supplementation was associated with significantly deceased
placental LTB4 levels than no fish oil supplementation (1.21 nM vs. 3.33 nM). Our cohort
consumed high levels of AA acid, which may provide increased substrate for LTB4. In
addition, Non-whites had significantly higher levels of LTB4 relative to whites and may
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be influenced by chronic inflammation associated with societal stress. LTB4 has also
been shown to inhibit the enzyme 11b-hydroxysteroid dehydrogenase type 2 (11bHSD2) responsible for protecting the fetus against high levels of maternal cortisol.42,139
Infant exposure to cortisol is associated with fetal growth retardation, preterm birth, and
postnatal developmental delays.140 Therefore, LTB4 is a potential biomarker and target
for treatment and prevention of negative birth outcomes.

3.4.4. Maternal Dietary Intakes and Supplementation Influence on
Precursors
Maternal intake ratio of n-6: n-3 FAs had significant positive correlations with
placental AA metabolites 5,15-DiHETE, 9-HETE, and 11-HETE. The Western Diet has
higher intakes of n-6 FAs, which would provide increased n-6 substrates for LOX and
COX enzymes. Our cohort generally had high intakes of AA, which would increase the n6: n-3 ratio. Interestingly, DHA metabolite 7-HDHA was also positively correlated with
the ratio of n-6: n-3 but due to its characterization as an n-3 I would expect there to be a
negative correlation. In supplementation studies, DHA supplementation increased 7HDHA in women with higher baseline n-3 levels. High n-6 levels are thought to reduce
the ability of n-3 FA to encounter LOX enzymes to be metabolized into oxylipins. As
expected, n-3 supplementation decreases placental n-6 oxylipin levels; however, there
was no association with 7-HDHA. Maternal diet is seemingly influencing placental
concentrations of LOX pathway precursors.
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3.5. CONCLUSION
In conclusion, we report that LOX pathway precursors are present in the placenta
at delivery and exhibit relationships between maternal and cord plasma levels. Further,
LTB4 may indicate an inflammatory intrauterine environment and serve as a predictor of
poor infant growth. However, more studies are needed to identify the role of individual
precursor levels and clinical implications of these precursors at delivery.

83

CHAPTER 4: Metabolites’ Role in
Prematurity and NICU Admission
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4.1. INTRODUCTION
Prematurity (birth before 37 weeks of gestation) is the leading cause of childhood
mortality in children under 5 years and accounts for around 10% of births worldwide and
in the US.49 In the US, advances in healthcare have improved the survival rate for
preterm infants without improving the rates of morbidity.141 Infants born prematurely face
higher rates of cerebral palsy, visual problems, and developmental delays.141–147 In
adulthood, preterm infants have been found to have an increased risk of metabolic
disease and cardiovascular dysfunction.148 The mechanisms underlying the causes of
prematurity are not well understood. Prematurity is a public health issue and our gaps in
knowledge hinder our ability to design successful preventative measures.
Inflammation caused by infection or other etiologies is a major risk factor for
prematurity.13 During premature labor, chemokines and cytokines are central mediators
of inflammation and once released orchestrate an inflammatory response.13,149 For
example, IL-1b, IL-8, and TNF-a are pro-inflammatory cytokines that activate the
myometrium and increase the levels of prostaglandins produced in tissues.13,149 In
contrast, IL-10 is an anti-inflammatory mediator that is significantly reduced in placental
tissues complicated by preterm labor and chorioamnionitis.1,13,150 Circulating cytokines
can activate matrix-degrading enzymes and neutrophil elastases that decrease the
tensile strength of the chorioamniotic membrane leading to preterm premature rupture of
membranes (PPROM).149,151 The inflammation underlying prematurity is a potential
target for developing preventative and treatment strategies.
Oxylipins from n-3 and n-6 FAs are important inflammatory regulators during
pregnancy and can influence prematurity.25,35 The best studied oxylipins are
prostaglandins and leukotrienes which are produced from the enzymatic breakdown of
AA into the prostaglandins (PG) E2 and F2a and leukotriene B4 (LTB4) .17 PGE2 and
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PGF2a increase uterine contractions, promote cervical ripening, and activate the decidua
and fetal membranes.13,48,152 These prostaglandins are elevated in amnion and the
decidua in the presence of micro-organisms, pro-inflammatory cytokines, or other
mediators. Leukotriene B4 is also increased in the amnion in preterm labor and
infections, and acts as a chemoattractant for leukocytes and increases uterine
contractions.137,153 Yet, the anti-inflammatory characteristics of oxylipins demonstrate
their ability to regulate inflammatory processes.98 More studies are needed to better
understand the physiological and pathological characteristic of oxylipins, where the
dysfunction leads to poor outcomes like preterm birth.
Most studies have focused on the role of AA and DHA metabolites during
pregnancy, leading to less availability of data for other FA metabolites such as LA, ALA,
EPA, and DGLA.20,21,35 The regulation and exposure to the diverse family of oxylipins
derived from n-3 and n-6 FAs in pregnancy could potentially play an important role in the
progression or prevention of adverse infant outcomes. However, there is currently limited
understanding of whether and how oxylipins at delivery influence biochemical and
clinical endpoints in pregnancy. The objective of this study was to profile and explore the
influence of FA oxylipins from the three major enzymatic pathways in high-risk
pregnancy outcomes- prematurity and admission to the Neonatal Intensive Care Unit
(NICU).
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4.2. MATERIALS AND METHODS
4.2.1. Study Design and Setting
Study participants were approached on the Labor and Delivery Unit at Nebraska
Medicine after IRB approval (IRB# 112-15-EP). Eligibility for this study included mothers
≥ 19 years old, blood draws less than 12 hours old, and maternal-infant pairs free of
metabolic or genetic diseases that would interfere with nutrient metabolism.

4.2.2. Maternal and Infant Outcomes
Table 24 describes maternal and infant outcomes in detail extracted from the
EMR. The primary outcome was prematurity defined as birth before 37 weeks of
gestation. The secondary outcome was admission to the neonatal intensive care unit
(NICU). Other infant characteristics included, birth weight, birth weight percentile, birth
length, birth length percentile, head circumference, and head circumference percentile.
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Table 24: Description of Maternal and Infant Outcomes Collected from the EMR.
Gestational age (weeks)
Measured in weeks
Prematurity
Birth before 37 weeks’ gestation
Neonatal Intensive Care Unit Admission Infant was admitted to the NICU after delivery
(NICU)
Birth Weight (g)
Measured in grams immediately following
birth
Birth Length (cm)
Measured
in
centimeters
immediately
following birth
Head Circumference (cm)
Measured in centimeters and measured
immediately following birth
Birth Weight Percentile
The WHO growth standards are used to
calculate birth weight percentile. Out of 100
infants the same age, an infant in the 50th
percentile will have 50 infants smaller and 50
infants larger than them.
Birth Length Percentile
The WHO growth standards are used to
calculate the birth length percentile. Out of
100 infants the same age, an infant in the 50th
percentile will have 50 infants shorter and 50
infants longer than them.
Head Circumference Percentile
The WHO growth standards are used to
calculate the head circumference percentile.
Out of 100 infants the same age, an infant in
the 50th percentile for head circumference
will have 50 infants with smaller heads and
50 infants with larger heads.
Maternal Smoking Status
Never Smoker
Mother has never smoked
Current/Former Smoker
The mother reported previously smoking or
currently smoking at the time of delivery
BMI Categorization
No-obese
BMI ≤ 30 kg/m2
Obese
BMI >30 kg/m2
Delivery Mode
Vaginal
Caesarean (CS)

4.2.3. Blood Sample Collection
Labor and Delivery unit nurses collected maternal blood at the time of admission
and umbilical cord blood at the time of delivery in EDTA tubes. Samples obtained within
12 hours of collection were transported in light-sensitive bags, centrifuged, and plasma
collected and stored at -80 °C until further analysis.
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4.2.4. n-3 and n-6 FA Oxylipins Quantification Methods in Plasma
Metabolite levels derived from linoleic acid (LA), dihomo-γ-linolenic acid
(DGLA), arachidonic acid (AA), alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA),
and docosahexaenoic acid (DHA) were quantified using lipid chromatography tandemmass spectrometry on maternal and umbilical cord plasma and placental tissue. Table
25 and Table 26 describe the n-6 and n-3 precursors and metabolites included in the
lipid panel, respectively.

Table 25: n-6 FA Metabolites Analyzed from the COX, LOX and CYP450 Pathways
COX
LOX
CYP450
Name and
Abbreviation Name
Abbreviation
Abbreviation
Prostaglandin (PG) E2
9-HODE
5,6-epoxy-eicosatrienoic acid
5,6-EET
PGD2
13-HODE
11,12-epoxy-eicosatrienoic acid
11,12-EET
PGF1a
13-KODE
14,15-epoxy-eicosatrienoic acid
14,15-EET
PGF2a
15-HETrE
5,6-dihydroxyeicosatrienoic acid
5,6-DiHET
Thromboxane B2
5-HETE
11,12-dihydroxyeicosatrienoic acid
11,12-DiHET
8-HETE
14,15-dihydroxyeicosatrienoic acid
14,15-DiHET
11b-PGE2
13,14-dihydro-PGF2a
9-HETE
20-hydroxyeicosatetraenoic acid
20-HETE
15-deoxy-?12,14Prostaglandin J2

11-HETE

9,10- epoxyoctadecenoic acid

9,10-EpOME

12-HETE
15-HETE

12,13- epoxyoctadecenoic acid
9,10- dihydroxyoctadecenoic acid

12,13-EpOME
9,10-DiHOME

8,15-DiHETE

12,13- dihydroxyoctadecenoic acid

12,13-DiHOME

5,15-DiHETE
LXA4
LTB4
LOX pathway n-6 metabolites are outlined in Ch. 2 (pg. 29)
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Table 26: n-3 FA Metabolites Analyzed from the LOX and CYP40 Pathways

LOX
CYP450
Abbreviation
Name
5-HEPE
14,15-epoxy-eicosatetranoic acid
15-HEPE
14,15-epoxy-eicosatetranoic acid
15-HEPE
14,15-dihydroxyeicosatetraenoic acid
15-HEPE
17,18-dihydroxyeicosatetraenoic acid
15-HEPE
15-HEPE
15-HEPE
LOX pathway metabolite names can be found in Ch. 2 (pg. 29)

Abbreviation
14,15-EpETE
17,18-EpETE
14,15-DiHETE
17,18-DiHETE
16,17-EpDPA
19,20-DiHDPA

4.2.4.1. Standards/Calibration Curve
All standards were combined in methanol to a concentration of 1 μM. This
standards mix was used to build a 12-point calibration curve which ranged from 97 pM to
200 nM, each point included 50 nM deuterated internal standards. Each curve consists
of oxylipin standard concentration vs. calculated response ratio (the ratio of oxylipin
standard peak area and the corresponding internal standard peak area).
4.2.4.2. Solid Phase Extraction
Samples were extracted based on methods provided by Yang et al.89 Prior to
extraction, Waters Oasis-HLB cartridges (30 mg/30 μm) were washed with ethyl acetate
(1 mL), methanol (2 × 1 mL), and 95:5 v/v water/methanol with 0.1% acetic acid (1 mL).
Serum samples were thawed on ice, then a 100 μL aliquot of sample was combined with
7 μL internal standards solution at 500 nM, 10 μL BHT at 2 mg/mL, and 120 μL of 95:5
H2O/MeOH with 0.1% acetic acid. The 240 μL treated serum aliquots were then loaded
onto the cartridges and washed twice with 750 μL 95:5 H2O/MeOH with 0.1% acetic
acid. The aqueous plug was pulled from the cartridges with high vacuum, and cartridges
were further dried with low vacuum about 20 min. SPE cartridges were eluted into tubes
with 250 μL of methanol followed by 1 mL of ethyl acetate into 2 mL tubes containing
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6 μL of 30% glycerol in MeOH as a trap solution. The samples were dried under nitrogen
and the residues reconstituted in 70 μL of methanol containing 20 nM CUDA. The
samples were then vortexed for 5 min, transferred to autosampler vials with low volume
inserts, and stored at -20 °C until analysis.
4.2.4.3. Liquid Chromatography-Mass Spectrometry
Samples were analyzed by liquid chromatography coupled to electrospray
ionization on a triple quadrupole mass spectrometer (Waters XEVO TQ-XS). For
analysis, 3 μL of extract was injected. The autosampler was cooled to 4 °C.
Chromatographic separation was achieved on an Ascentis Express (2.1×150 mm,
2.7 μm particles; Sigma-Aldrich Supelco) column using a flow rate of 0.35 mL/min at 40
°C during a 26 min gradient (0–3.5 min from 15 % B to 33 % B, 3.5–5.5 min B to 38 %,
5–7 min to 42 % B, 7–9 min to 48 % B, 9–15 min to 65 % B, 15–17 min to 75 % B, 17–
18.5 min to 85% B, 18.5–19.5 min to 95 % B, from 19.5 to 21 min to 15 % B, 21–26 min
15 % B), while using the solvents A, 0.1% acetic acid, and B, 90:10 v/v
acetonitrile/isopropanol.90
The mass spectrometer was operated in multiple reaction monitoring (MRM)
mode and electrospray ionization was performed in negative ion mode. The detailed list
of

MRM

transitions

can

be

found

in

Chapter

1

(pg.

33).

Source

and desolvation temperatures were 150° C and 500° C, respectively. Desolvation gas
was set to 1000 L/hr and cone gas to 150 L/hr. Collision gas was set to 0.15 mL/min. All
gases were nitrogen except the collision gas, which was argon. Capillary voltage was 2
kV in negative ion mode. Samples were analyzed in random order. A quality control
sample was analyzed every eight injections to monitor system stability and
performance.
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4.2.4.4. Data Processing
Data were processed using Skyline91 software and Microsoft Excel. Calibration
curves for each oxylipin were built using standards and deuterated internal standards.
Each curve consisted of oxylipin standard concentration vs. calculated response ratio
(the ratio of oxylipin standard peak area and the corresponding internal standard peak
area). Calibration curves were calculated by linear regression with 1/x2 weighing. The
calibration result was then corrected for dilution to determine the original oxylipin
concentration in serum. Data above or below the calibration curve were excluded from
data analysis. Oxylipins with 60% of the levels without detectable levels were
categorized as not detectable (ND) and detectable.

4.2.5. n-3 and n-6 FA Oxylipins Quantification Methods in Placenta
The placental extraction protocol was adapted and completed using 50-100 mg
of placental tissue.89 Tissue samples were thawed and weighed before adding 10 µL of
antioxidant solution (0.2 mg/mL of BHT and EDTA), 10 mL of surrogate solution and 400
ml of ice-cold methanol with 0.1% of acetic acid and 0.1% of BHT. The tissue samples
were then stored in a -80 °C freezer for 30 min until frozen. A bead mill homogenizer
was used at 30 Hz for 10 min to homogenize the samples the newly formed
homogenates were frozen overnight at -80 °C. Homogenates were centrifuged at 10,000
rpm for 10 min, and the supernatant was collected. The remaining pellets were washed
with 100 mL of ice-cold methanol with 0.1% of acetic acid and 0.1% of BHT, centrifuged,
and the supernatants of each sample were combined. Supernatants were diluted with 2
mL of H20 and loaded onto the SPE cartridges.
SPE Extraction: Waters Oasis cartridges were washed with ethyl acetate and methanol.
The solution containing H2O and methanol was used to equilibrate the cartridges to the
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initial condition. Cartridges were loaded with the diluted supernatant and washed twice
with SPE solution (H2O with 20% methanol). The cartridges were then vacuum dried.
Analytes were eluted with 0.5 mL of methanol and 3 mL of ethyl acetate to tubes with 10
µL of trapping solution (30% glycerol in methanol), vacuum dried (SpeedVac), and
reconstituted with internal solutions. Recoveries of surrogate analytes were above 60%,
respectively.

4.2.6. Maternal Dietary Intake
All participants completed the Harvard Food Frequency Questionnaire (FFQ) that
assesses dietary intake over the previous year. Notably, the survey assessed
supplement use and reported nutrient intake with and without supplementation. This tool
has been validated in numerous adult populations, including pregnant women and was
used to assess intake between preterm and term deliveries.85

4.2.6. Statistical Analysis
Descriptive statistics include means, standard deviations, medians, interquartile
range (IQR), minimums and maximums for continuous data and counts and percentages
for categorical data. For mothers who had twins, only information from the first twin was
analyzed for infant data. The Mann-Whitney test was used to compare continuous
measures between dichotomous groups. The Kruskal Wallis test was used to compare
measures in more than two groups. Fisher’s exact test was used to compare categorical
variables. Spearman correlation coefficients were used to assess associations between
continuous variables.
Logistical regression modelling was performed on metabolites correlated with
prematurity and NICU admission at the p < 0.05 level on univariate analysis.
Associations of the metabolites with these birth measures were adjusted for obesity (≥
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30 or < 30 BMI (kg/m2)), maternal smoking status (current/former vs. never), and race
(white vs. non-white) in the models. In NICU admission, prematurity was included as a
covariate. The metabolites were not log-transformed for the logistical regression models.
P<0.05 was considered statistically significant.

4.3. RESULTS
4.3.1. Baseline Characteristics
Overall, mothers had a median age of 29 [10] years old and there was not a
significant difference between maternal age between preterm and term birth (p = 0.49).
Maternal median BMI was 27.47 [9.57] kg/m2 with 75% of mothers having a prepregnancy BMI < 30 kg/m2. There was not a significant difference in BMI between
preterm and term deliveries (p = 0.53). Seventy-eight percent of mothers have never
smoked. Twenty-six infants were born prematurely (19%), and 38 infants were admitted
to the NICU (26.9%). Preterm infants had a median gestational age at 36.0 weeks [2.00]
compared to 39.40 [1.30] for term infants (Table 27). Maternal intakes of n-6 and n-3
FAs across prematurity and NICU admissions are presented in Table 28, with no
significant

differences

found

between

intakes.
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Table 27: Maternal and Infant Demographics Table
Overall
(n) Mean (SD)

Preterm
(n)
Mean (SD)

Maternal Age (years)

119

29.36 (5.88)

Maternal BMI (kg/m2)

119

28.41 (6.70)

Median
[IQR]
29.00
[10.00]
27.47 [9.57]

24

30.41 (5.75)

Median
[IQR]
29.00 [

24

28.88 (8.44)

Birth Age
(weeks.days)
Birth Weight (kg)
Birth weight Percentile

119

38.17 (3.29)

39.20 [2.00]

24

119
119

3.21 (0.77)
56.58 (28.86)

3.35 [0.80]
60.77
[45.69]
49.50 [2.80]

24
24

Birth Length (cm)

119

49.1 (8.06)

Birth Length Percentile

119

52.46 (33.41)

55.90
[61.30]
34.30 [2.60]

24

Birth Head Circumference (cm)

119

34.09 (2.29)

Birth Head Circumference
Percentile

119

58.5 (32.26)

None
Current/Former Smoker

92
27

78.0 %
22.02%

Yes

32

26.90%

21

No

86

72.30%

2

24

24

Term
(n) Mean (SD)
95

29.19 (5.89)

Median
[IQR]
29.00

26.94 [7.58]

95

27.02 (6.31)

25.14 [8.78]

34.46 (2.98)

36.00 [2.00]

95

39.58 (0.96)

39.40 [1.30]

2.58 (0.78)
36.91
(32.70)
48.31
(19.04)
40.57
(38.49)
31.77 (3.30)

2.54 [0.51]
32.41
[61.42]
45.70
[10.00]
38.64
[88.27]
32.50 [2.50]

95
95

3.42 (0.55)
60.01
(27.18)
49.34 (4.37)

3.43 [0.62]
61.12
[43.14]
50.20 [3.10]

55.93
(33.36)
34.65 (1.58)

67.07
[60.76]
34.70 [1.9]

34.15
[59.23]

95

62.21
(30.73)

64.23
[49.29]

76
19

63.87%
15.97%

17.18%

84

70.59%

1.69%

11

9.24%

63.58
24
36.85
[57.03]
(34.89)
Maternal Smoking
16
13.45%
8
6.72%
NICU Admission

95
95
95

95

Table 28: Comparisons of Maternal Intakes of n-6 and n-3 FAs for Prematurity and NICU Admission
Precursor
Arachidonic Acid
Linoleic Acid
Alpha-Linolenic Acid
Gamma-Linolenic Acid
Eicosapentaenoic Acid
Docosapentaenoic Acid
Docosahexaenoic Acid
Total n-3
Total n-6
Ratio of n-6: n-3
Precursor
Arachidonic Acid
Linoleic Acid
Alpha-Linolenic Acid
Gamma-Linolenic Acid
Eicosapentaenoic Acid
Docosapentaenoic Acid
Docosahexaenoic Acid
Total n-3
Total n-6
n6-n-3

Preterm
(n)
Median
15
0.20
15
14.42
15
1.64
15
0.020
15
0.040
15
0.030
15
0.13
15
1.89
15
15.70
15
8.40
NICU Admission
(n)
0.17
22
13.47
22
1.41
22
0.010
22
0.040
22
0.02
22
0.11
22
1.72
22
15.03
22
8.48

IQR
0.16
8.03
1.04
0.01
0.06
0.02
0.15
1.11
8.85
2.04
0.13
6.50
0.78
0.01
0.89
0.38
0.14
0.87
6.67
2.68

Term
(n)
Median
88
0.15
88
12.84
88
1.41
88
0.010
88
0.010
88
0.020
88
0.070
88
1.64
88
14.26
87
8.84
No NICU Admission
81
0.15
81
13.06
81
1.43
81
0.010
81
0.010
81
0.020
81
0.070
81
1.72
81
14.30
80
8.88

IQR
0.11
7.01
0.76
0.01
0.05
0.02
0.14
0.82
7.15
1.78

p-value
0.33
0.21
0.37
0.76
0.17
0.088
0.16
0.25
0.18
0.87

0.11
7.70
0.74
0.010
0.050
0.025
0.15
1.20
8.58
1.79

0.67
0.70
0.34
0.42
0.20
0.35
0.41
0.54
0.68
1.00

96

4.3.2. Relationship between Preterm and Term Deliveries and LOX n-6
Oxylipins in the Placenta, Maternal Plasma, and Cord Plasma
Table 29 summarizes median metabolite levels in tissues for preterm and term
deliveries. Median metabolite levels for maternal 15-HETE, 12-HETE, and 13-KODE
were significantly higher in preterm deliveries. However, maternal LXA4 was
significantly lower in preterm relative to term deliveries. Median cord levels of 15-HETE,
8-HETE, and LXA4 were significantly higher in premature compared to term infants.
After adjustment, n-6 metabolites from the LOX pathway did not predict prematurity.
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Table 29: Plasma and Placenta Median LOX n-6 Oxylipin Levels in Term and Preterm
Deliveries
Preterm
Term
Mann-Whitney
Oxylipin Level

(n)

Maternal 5-HETE
Cord 5-HETE
Placenta 5-HETE
Maternal 8-HETE
Cord 8-HETE
Placenta 8-HETE
Maternal 9-HETE
Cord 9-HETE
Placenta 9-HETE
Maternal 11-HETE
Cord 11-HETE
Placenta 11-HETE
Maternal 12-HETE
Cord 12-HETE
Placenta 12-HETE
Maternal 15-HETE
Cord 15-HETE
Placenta 15-HETE
Maternal Lipoxin A4
Cord Lipoxin A4
Placenta Lipoxin A4
Maternal 9-HODE
Cord 9-HODE
Placenta 9-HODE
Maternal 13-HODE
Cord 13-HODE
Placenta 13-HODE
Maternal 13-KODE
Cord 13-KODE
Placenta 13-KODE
Maternal 5,15-DiHETE
Cord 5,15-DiHETE
Placenta 5,15-DiHETE
Maternal 15-HETrE
Cord 15-HETrE
Placenta 15-HETrE
* p-value < 0.05

19
22
4
22
23
4
23
23
4
22
23
4
22
20
4
19
22
4
14
21
21
23
4
20
23
4
21
21
4
10
15
4
23
23
4

Median
(nM)
5.26
7.10
705.97
1.58
2.69
260.06
1.43
2.94
709.38
2.02
3.88
289.70
10.28
9.56
598.88
6.19
7.37
4957.27
6.38
10.36
19.78
7.44
266.42
22.26
12.5
458.74
3.16
1.65
62.43
1.74
0.30
17.12
0.92
1.47
144.12

[IQR]

(n)

8.81
17.66
1242.98
6.97
3.78
499.76
5.32
2.45
1286.43
8.16
4.27
696.13
15.87
25.2
942.35
17.34
10.47
2062.95
8.52
30.04
23.37
6.62
505.4
18.52
9.17
910
2.98
1.1
114.64
15.17
0.69
35.83
3.18
1.52
383.77

84
87
39
90
87
39
89
87
39
89
87
39
91
81
39
78
87
39
66
75
84
87

Median
(nM)
6.26
7.14
101.45
1.31
1.96
39.03
1.06
2.15
117.94
1.81
2.39
49.34
3.44
8.3
186.69
3.22
5.00
98.45
11.22
7.02
19.07
10.18

85
87

20.99
13.22

82
79
39
44
52

2.27
1.43
12.79
0.23
0.16

90
87
39

0.69
1.4
15.56

[IQR]

p-value

10.2
4.54
78.14
1.7
1.10
31.12
1.62
1.39
95.14
2.36
1.82
41.23
4.33
13.81
343
4.56
4.79
69.09
12.36
7.41
18.56
6.58
50.21
15.32
8.67
73.31
2.57
0.83
14.13
0.64
0.04
1.95
0.76
0.99
13.68

0.799
0.859
0.347
0.213
0.002 *
0.601
0.496
0.072
0.347
0.605
0.252
0.884
0.004 *
0.446
0.631
0.005 *
0.006 *
0.786
0.052 *
0.012 *
0.311
0.055
0.884
0.146
0.497
0.631
0.025 *
0.568
0.517
0.290
0.320
0.572
0.058
0.700
0.661
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4.3.3. Relationship Between NICU Admission and LOX n-6 Oxylipin Levels
in the Placenta, Maternal Plasma and Cord Plasma
AA-derivatives cord 8-HETE, maternal 15-HETE, and cord 15-HETE were
significantly higher in NICU admission compared to infants not admitted to the NICU.
However, maternal LXA4 was significantly lower in NICU admission relative to infants
not admitted. Cord 9-HODE, an LA derivative, was significantly lower in NICU
admission. Table 30 shows median levels between the two groups and their significance
levels. After adjustment, for a one nanomolar increase in maternal LXA4, a 24.6%
reduction in odds of NICU admission is expected (OR: 0.75, 95% CI: 0.58, 0.99, p =
0.038). Based on the Hosmer and Lemeshow test, the model provides an adequate fit(p = 0.54).
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Table 30: Plasma and Placental Median LOX n-6 Oxylipin Levels in NICU and Non-NICU
Admission
NICU Admission

Non-NICU Admission

Mann-Whitney

(n)

Median

[IQR]

(n)

Median

[IQR]

p-value

Maternal 5-HETE

26

5.48

6.95

76

6.30

11.36

0.40

Cord 5-HETE

28

5.44

9.55

80

7.49

4.26

0.46

Placental 5-HETE

8

145.17

711.08

35

101.45

67.31

0.43

Maternal 8-HETE

30

1.16

1.86

81

1.42

1.74

0.77

Cord 8-HETE

29

2.58

3.64

80

1.95

1.08

0.005*

Placental 8-HETE

8

38.86

295.56

35

39.03

30.15

0.99

Maternal 9-HETE

31

0.87

2.00

80

1.08

1.77

0.75

Cord 9-HETE

29

2.41

2.61

80

2.09

1.45

0.14

Placental 9-HETE

8

115.69

859.44

35

117.94

94.82

0.79

Maternal 11-HETE

30

1.44

2.81

80

1.86

2.48

0.80

Cord 11-HETE

29

3.21

4.14

80

2.38

1.87

0.072

Placental 11-HETE

8

54.87

316.2

35

49.34

38.99

0.91

Maternal 12-HETE

30

4.15

11.06

82

3.53

4.56

0.065

Cord 12-HETE

26

9.56

22.87

74

8.27

12.17

0.38

Placental 12-HETE

8

328.13

856.16

35

182.04

333.14

0.43

Maternal 15-HETE

25

5.24

7.15

71

3.19

4.86

0.023*

Cord 15-HETE

28

7.21

7.62

80

4.92

4.67

0.018*

Placental 15-HETE

8

93.18

1025.84

35

98.45

63.09

0.99

Maternal 5,15-DiHETE

12

0.90

19.17

41

0.24

0.56

0.53

Cord 5,15-DiHETE

20

0.19

0.69

46

0.16

0.15

0.65

Placental 5,15-DiHETE

8

1.86

5.90

35

1.83

1.90

0.89

Maternal Lipoxin A4

21

7.19

7.87

59

12.33

12.31

0.026*

Cord Lipoxin A4

25

9.06

7.21

70

7.22

7.23

0.095

Placental Lipoxin A4

-

-

-

-

Maternal 9 HODE

28

18.83

19.58

76

19.45

19.08

0.77

Cord 9 HODE

29

8.46

6.49

80

10.3

6.58

0.048*

Placental 9-HODE

8

53.97

288.16

35

48.33

43.21

0.82

Maternal 13 HODE

27

20.80

13.78

77

21.14

15.27

0.47

Cord 13 HODE

29

12.61

7.01

80

13.20

8.97

0.55

Placental 13-HODE

8

2.24

511.99

35

55.02

68.05

0.91

Maternal 13 KODE

30

2.31

2.69

72

2.37

2.56

0.45

Cord 13 KODE

28

1.51

0.95

71

1.45

0.81

0.52

Placental 13-KODE

8

12.09

69.84

35

12.79

13.9

0.91

Maternal 15-HETrE

31

0.69

1.30

81

0.72

0.78

0.35

Cord 15-HETrE

29

1.59

1.69

80

1.35

0.88

0.28

Placental 15-HETrE

8

14.29

153.14

35

15.56

12.60

0.96

*p < 0.05

--
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4.3.4. Relationship between Preterm and Term Deliveries and LOX n-3
Oxylipins in the Placenta, Maternal Plasma, and Cord Plasma
Table 31 shows precursor levels from term and preterm deliveries. Maternal 12HEPE, 15-HEPE and 7-HDHA metabolites were significantly higher in preterm deliveries
relative to term deliveries. Cord 7-HDHA was the only cord metabolite to demonstrate a
significant difference between the two groups (preterm: 1.54 nM vs. term: 1.07 nM), and
levels tended to be higher in prematurity. There were no significant differences found in
placental levels between term and preterm deliveries. After adjustment, n-3 LOX
pathway precursors did not reduce the odds of prematurity.

Table 31: Median LOX n-3 Oxylipin Tissue Levels within Term and Preterm Deliveries

Maternal 9-HOTrE
Cord 9-HOTrE
Placenta 9-HOTrE
Maternal 5-HEPE
Cord 5-HEPE
Placenta 5-HEPE
Maternal 9-HEPE
Cord 9-HEPE
Placenta 9-HEPE
Maternal 12-HEPE
Cord 12-HEPE
Placenta 12-HEPE
Maternal 15-HEPE
Cord 15-HEPE
Placenta 15-HEPE
Maternal 7-HDHA
Cord 7-HDHA
Placenta 7-HDHA
Maternal 17-HDHA
Cord 17-HDHA
Placenta 17-HDHA
*p < 0.05

Preterm
(n) Median
(nM)
23
1.81
20
0.36
4
4.89
23
0.56
23
0.37
4
7.18
14
0.23
13
0.13
4
5.42
18
0.73
20
0.27
4
11.97
13
0.43
7
0.2
4
14.62
13
4.72
21
1.54
4
65.97
20
2.42
23
2.54
4
367.35

[IQR]
2.25
0.41
10.66
1.48
0.55
13.81
1.14
0.06
9.37
1.61
1.22
15.42
1.25
1.22
27.81
13.82
1.41
163.67
10.1
3.94
895.55

Term
(n) Median
(nM)
91
1.32
81
0.48
39
1.08
90
0.39
87
0.4
39
2.53
32
0.17
25
0.12
39
1.28
51
0.27
61
0.25
39
9.71
53
0.28
47
0.2
39
2.00
61
1.33
78
1.07
39
16.03
68
1.83
76
2.13
39
32.51

[IQR]

p-values

1.28
0.29
1.67
0.55
0.28
2.41
0.36
0.09
1.4
0.48
0.69
13.31
0.24
0.69
1.88
1.63
0.95
11
2.22
1.63
29.52

0.113
0.089
0.369
0.079
0.763
0.268
0.488
0.877
0.202
0.011 *
0.810
0.754
0.045 *
0.587
0.661
0.009 *
0.008 *
0.490
0.210
0.220
0.369
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4.3.5. Relationship Between NICU Admission and LOX n-6 Oxylipin Levels
in the Placenta, Maternal Plasma, and Cord Plasma
Maternal 12-HEPE and cord 7-HDHA levels were significantly higher in
maternal-infant pairs with NICU admission compared no NICU admission. Table 32
demonstrates these relationships. After adjustment, n-3 LOX pathway precursor levels
did not reduce the odds of NICU admission.

Table 32: Median LOX n-3 Oxylipin Tissue Levels in NICU and Non-NICU Admission
Metabolite
NICU
Non-NICU
MannAdmission
Admission
Whitney
(n)
Median
[IQR]
(n)
Median
[IQR] p-value
Maternal 9-HOTrE
31
1.77
2.62
82
1.30
1.31
0.26
Cord 9-HOTrE
25
0.37
0.33
75
0.48
0.32
0.14
Placental 9-HOTrE
8
1.30
5.45
35
1.08
14.35 1.00
Maternal 5-HEPE
31
0.44
0.89
81
0.4
0.58
0.32
Cord 5-HEPE
29
0.38
0.42
80
0.4
4.21
0.68
Placental 5-HEPE
8
2.24
5.90
35
2.77
2.57
0.82
Maternal 9-HEPE
17
0.16
1.18
28
0.19
0.35
0.94
Cord 9-HEPE
16
0.13
0.11
21
0.12
0.04
0.83
Placental 9-HEPE
8
1.25
5.31
35
9.71
1.24
1.00
Maternal 12-HEPE
23
0.68
2.20
45
0.24
0.37
0.007*
Cord 12-HEPE
25
0.27
1.11
55
0.25
0.71
0.61
Placental 12-HEPE
8
11.16
11.39
35
9.71
14.35 0.84
Maternal 15-HEPE
17
0.32
1.33
48
0.28
0.21
0.19
Cord 15-HEPE
12
0.2
0.12
42
0.2
0.14
0.87
Placental 15-HEPE
8
1.36
14.9
35
2.07
1.63
0.46
Maternal 7-HDHA
17
1.83
13.92
56
1.32
1.59
0.076
Cord 7-HDHA
27
1.47
1.43
71
1.06
0.94
0.034*
Placental 7-HDHA
8
16.88
68.43
35
117.94
9.90
0.94
Maternal 17-HDHA
25
1.76
4.21
62
1.92
2.25
0.51
Cord 17-HDHA
28
2.5
3.94
70
2.16
1.62
0.33
Placental 17-HDHA
8
38.70
380.07 35
32.51
28.77 0.84
*p < 0.05
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4.3.6. Relationship between Preterm and Term Deliveries and COX n-6
Oxylipins in the Placenta, Maternal Plasma, and Cord Plasma
Cord PGE2 is the only precursor that demonstrated a significant difference in
plasma between preterm and term deliveries (Table 33). Term pregnancies had 1.68 nM
of PGE2 compared to 0.78 nM in cord plasma from preterm deliveries. Cord PGE2 is not
predictive of prematurity after adjustment.

Table 33: Median COX n-6 Oxylipin Tissue Levels within Term and Preterm Deliveries
Preterm

Term

Maternal PGE2

(n)
21

Median
0.18

[IQR]
1.18

(n)
60

Median
0.23

[IQR]
0.82

p-value
0.96

Cord PGE2

23

0.78

1.51

86

1.68

2.28

0.002*

Placental PGE2

4

9.97

57.44

39

27.84

26.34

0.19

Maternal PGD2

22

0.24

2.41

72

0.29

0.33

0.58

Cord PGD2

21

0.39

0.41

74

0.25

0.22

0.073

Placental PGD2

4

29.41

17.51

39

46.95

45.15

0.29

Maternal PGF2a

18

0.24

0.4

58

0.17

0.17

0.10

Cord PGF2a

23

0.94

0.97

87

0.61

0.71

0.15

Placental PGF2a

4

13.36

120.65

39

5.12

3.38

0.85

Maternal Thromboxane B2

18

0.5

0.57

87

0.35

0.58

0.19

Cord Thromboxane B2

22

3.47

4.08

85

2.92

5.81

0.51

Placental Thromboxane B2

4

13.36

25.14

39

40.47

25.89

0.069

Maternal 11B-PGE2

19

0.22

0.885

59

0.17

0.37

0.94

Cord 11B-PGE2

20

0.54

1.01

56

0.37

0.83

0.63

Placental 11B-PGE2

2

11.96

5.53

2

9.95

19.32

1.00

*p < 0.05
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4.3.7. Relationship Between NICU Admission and COX n-6 Oxylipin Levels
in the Placenta, Maternal Plasma and Cord Plasma
Maternal and cord PGF2a were higher in NICU admission. Conversely, cord
PGE2 tended to be lower in cord plasma for infants admitted to the NICU. Maternal
Thromboxane B2 trended towards significance, with higher levels in NICU admission
relative to no NICU admission. Table 34 summarizes metabolite levels from the COX
enzymatic pathways that showed significant differences between groups.

After

adjustment, COX n-6 oxylipins were not predictive of NICU admission.

Table 34: Median COX n-6 Oxylipin Tissue Levels in NICU and Non-NICU Admission
NICU Admission

No NICU Admission

p-value

Maternal PGE2

(n)
27

Median
0.17

[IQR]
0.89

(n)
53

Median
0.27

[IQR]
0.96

0.35

Cord PGE2

29

1.07

1.13

79

1.81

2.31

0.003*

Placental PGE2

8

23.67

27.87

35

26.69

27.5

0.52

Maternal PGD2

27

0.22

1.12

66

0.3

0.31

0.33

Cord PGD2

28

0.32

0.37

66

0.25

0.22

0.37

Placental PGD2

8

40.08

67.86

35

46.95

43.98

0.74

Maternal PGF2a

23

0.25

0.36

52

0.15

0.16

0.040*

Cord PGF2a
Placental PGF2a

29
8

0.94
6.22

0.73
18.66

80
35

0.57
5.00

0.72
3.38

0.013*
0.44

Maternal Thromboxane B2

27

0.50

0.57

78

0.35

0.56

0.055

Cord Thromboxane B2

29

3.47

3.71

78

2.85

5.73

0.22

Placental Thromboxane B2

8

42.34

33.4

35

37.44

30.63

0.91

Maternal 11B-PGE2

24

0.17

0.8

53

0.17

0.39

0.51

Cord 11B-PGE2

26

0.43

0.83

49

0.41

0.85

0.84

Placental 11B-PGE2
*p < 0.05

2

11.96

5.43

2

9.95

19.32

1.00
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4.3.8. Relationship between Preterm and Term Deliveries and CYP n-6
Oxylipins in the Placenta, Maternal Plasma, and Cord Plasma
Table 35 highlights the metabolites in the CYP450 enzymatic that demonstrated
significantly different levels between infants born preterm vs. term (Table 35). Maternal
20-HETE was the only maternal sample to be significantly different and was higher in
preterm deliveries relative to term deliveries. Cord metabolites 14,15-DiHET, 20-HETE,
9,10-EpOME, 12,13-EpOME, 9,10-DiHOME, and 12,13-DiHOME were significantly
lower in preterm compared to term infants. After adjustment, the cord CYP pathway
precursors 14,15-DiHET, 9,10-DiHOME, and 12,13-DiHOME were associated with a
reduction in odds of prematurity. However, cord metabolites 9,10-DiHOME and 12,13DiHOME failed the Hosmer and Lemeshow Goodness-of-Fit test. Therefore, a one
nanomolar increase in cord 14,15-DiHET is expected to reduce the odds of prematurity
by 53% (OR = 0.470, 95% CI = 0.254-0.872, p = 0.016).
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Table 35: Median CYP n-6 Oxylipin Tissue Metabolite within Term and Preterm Deliveries
Preterm
Term
p-value
(n)
Median [IQR]
(n)
Median [IQR]
Maternal 5,6-EET
7
9.7
4.34
71
8.01
8.93
0.38
Cord 5,6-EET
7
13.29
22.55
67
23
24.76
0.87
Placental 5,6-EET
4
1168.79 2351.89 39
182.98 155.26 0.22
Maternal 11,12-EET
22
0.23
0.14
81
0.34
1.78
0.22
Cord 11,12-EET
22
0.40
0.46
85
0.41
0.71
0.76
Placental 11,12-EET
4
38.56
60.62
39
12.09
8.73
0.60
Maternal 14,15-EET
23
0.39
0.40
88
0.50
3.21
0.28
Cord 14,15-EET
23
0.66
0.67
87
0.67
0.98
0.42
Placental 14,15-EET
4
48.29
73.68
39
15.96
10.8
0.60
Maternal 5,6-DiHET
23
1.14
2.31
91
1.04
0.92
0.25
Cord 5,6-DiHET
23
3.42
4.57
87
3.73
4.53
0.12
Placental 5,6-DiHET
4
44.93
96.75
39
1.01
0.81
0.60
Maternal 8,9-DiHET
23
0.57
0.46
91
0.56
7.35
0.96
Cord 8,9-DiHET
23
3.27
2.36
87
3.87
4.07
0.35
Placental 8,9-DiHET
4
42.47
86.01
39
4.66
3.17
0.69
Maternal 11,12-DiHET
23
0.50
0.24
91
0.45
1.07
0.28
Cord 11,12-DiHET
23
2.06
1.14
87
2.15
1.55
0.79
Placental 11,12-DiHET
4
21.00
37.86
39
3.32
2.11
0.54
Maternal 14,15-DiHET
23
0.79
0.43
91
0.89
4.51
0.40
Cord 14,15-DiHET
23
2.81
1.30
87
4.05
1.5
<0.001*
Placental 14,15-DiHET
4
15.80
13.2
39
5.32
3.23
0.91
Maternal 20-HETE
22
0.17
0.11
53
0.13
0.080
0.021 *
Cord 20-HETE
20
0.13
0.065
78
0.17
0.1
0.001*
Placental 20-HETE
4
0.44
0.50
39
0.25
0.15
0.49
Maternal 9,10-EpOME
23
7.68
5.69
86
10.3
5.69
0.43
Cord 9,10-EpOME
23
2.62
3.23
86
4.59
8.76
0.002 *
Placental 9,10-EpOME
4
24.58
39.68
39
8.61
6.81
0.63
Maternal 12,13-EpOME
22
10.75
7.41
86
14.55
18.75
0.29
Cord 12,13-EpOME
23
3.36
3.53
86
5.34
9.75
0.006 *
Placenta 12,13-EpOME
4
21.81
31.86
39
9.45
6.62
0.69
Maternal 9,10-DiHOME
23
4.60
4.18
91
4.54
3.70
0.79
Cord 9,10-DiHOME
23
1.32
1.37
87
1.90
0.97
0.004 *
Placental 9,10-DiHOME
4
24.58
14.28
39
8.61
1.06
0.75
Maternal 12,13-DiHOME 23
5.36
4.29
91
6.30
5.06
0.26
Cord 12,13-DiHOME
23
2.04
2.13
87
3.04
2.02
0.005 *
Placental 12,13-DiHOME 4
4.69
11
39
3.98
2.69
0.95
*p < 0.05
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4.3.9. Relationship Between NICU Admission and CYP n-6 Oxylipin Levels
in the Placenta, Maternal Plasma, and Cord Plasma
CYP metabolites in NICU admission followed a similar trend as seen in
prematurity. Maternal 20-HETE was the only maternal signal to be significantly different
between the NICU admission (0.17 nM) and non-NICU admission (0.12 nM).
Interestingly, cord 14,15-DiHET, 9,10-EpOME, 12,13-EpOME, and 9,10-DiHOME were
significantly lower in infants admitted to the NICU relative to infants not admitted to the
NICU. Table 36 shows median metabolite levels between groups.
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Table 36: Median CYP450 n-6 Oxylipin Tissue Levels in NICU and non-NICU Admission
Metabolite
Maternal 5,6-EET
Cord 5,6-EET
Placental 5.6-EET
Maternal 11,12-EET
Cord 11,12-EET
Placental 11,12-EET
Maternal 14,15-EET
Cord 14,15-EET
Placental 14,15-EET
Maternal 5,6-DiHET
Cord 5,6-DiHET
Placental 5,6-DiHET
Maternal 8,9-DiHET
Cord 8,9-DiHET
Placental 8,9-DiHET
Maternal 11,12-DiHET
Cord 11,12-DiHET
Placental 11,12-DiHET
Maternal 14,15-DiHET
Cord 14,15-DiHET
Placental 14,15-DiHET
Maternal 20-HETE
Cord 20-HETE
Placental 20-HETE
Maternal 9,10-EpOME
Cord 9,10-EpOME
Placental 9,10-EpOME
Maternal 12,13-EpOME
Cord 12,13-EpOME
Placental 12,13-EpOME
Maternal 9,10-DiHOME
Cord 9,10-DiHOME
Placental 9,10-DiHOME
Maternal 12, 13-DiHOME
Cord 12,13-DiHOME
Placental 12,13-DiHOME
*p < 0.05

NICU Admission
(n) Median [IQR]
13 9.22
14.29
12 21.51
28.75
8
213.39 1120.15
29 0.23
0.32
28 0.37
0.45
8
14.44
36.19
31 0.41
0.63
29 0.66
0.62
8
19.29
45.48
31 1.06
1.41
29 3.42
4.60
8
1.14
44.92
31 0.59
0.80
29 3.71
2.17
0
-41.7
31 0.50
0.33
29 2.06
1.45
8
14.44
19.6
31 0.86
0.58
29 2.94
2.00
8
4.87
14.43
25 0.17
0.11
24 0.14
0.095
8
0.39
0.47
31 7.68
7.29
29 2.62
3.46
8
8.10
23.8
30 11.8
9.06
29 3.36
3.39
8
8.76
21.3
31 4.60
6.50
29 1.46
1.35
8
1.64
7.45
31 5.90
5.23
29 2.15
2.13
8
3.02
4.09

Non- NICU Admission
(n) Median [IQR]
65 7.82
7.78
62 22.77
22.92
35 182.98 138.21
73 0.34
0.75
78 0.41
0.66
35 12.09
7.12
79 0.50
1.48
80 0.68
0.93
35 15.96
9.30
82 1.05
0.84
80 3.71
4.52
35 1.01
0.73
82 0.55
7.34
80 3.71
4.29
35 4.66
3.16
82 0.45
1.07
80 2.15
1.38
35 3.32
1.93
82 0.89
4.51
80 4.02
1.51
35 5.32
3.24
49 0.12
0.06
73 0.17
0.10
35 0.25
0.13
77 10.25
17.65
79 4.67
7.46
35 8.61
6.84
77 14.72
18.4
79 5.40
8.35
35 9.45
6.06
82 4.58
3.30
80 1.90
1.01
35 2.22
0.90
82 6.30
4.76
80 3.04
2.02
35 4.35
2.67

Mann Whitney
p-value
0.28
0.62
0.43
0.44
0.36
0.96
0.40
0.22
0.91
0.53
0.20
0.96
0.71
0.89
0.79
0.33
0.98
0.96
0.75
0.002 *
0.89
0.009 *
0.10
0.15
0.56
0.001 *
0.70
0.45
0.001 *
0.72
0.54
0.0080*
0.46
0.65
0.011
0.26

108

4.3.10. Relationship between Preterm and Term Deliveries and CYP n-3
Oxylipins in the Placenta, Maternal Plasma, and Cord Plasma
Table 37 illustrates significant differences between term and preterm deliveries
for n-3 oxylipins from the CYP450 pathway. There were no significant differences found
between term and preterm EPA precursors. DHA metabolites, maternal 16,17-EpDPA,
maternal 19,20-DiHDPA, and cord 19,20-DiHDPA showed significant differences
between groups. After adjustment, CYP n-3 oxylipins were not associated with
prematurity.

Table 37: Median CYP n-3 Oxylipin Tissue Metabolites within Term and Preterm Deliveries
Metabolite
Maternal 14,15-DiHETE
Cord 14,15-DiHETE
Placental 14,15-DiHETE
Maternal 17,18-DiHETE
Cord 17,18-DiHETE
Placental 17,18-DiHETE
Maternal 16 ,17-EpDPA
Cord 16,17-EpDPA
Placental 16,17-EpDPA
Maternal 19,20-DiHDPA
Cord 19,20-DiHDPA
Placental 19,20-DiHDPA
*p < 0.05

Preterm
(n)
17
22
4
23
23
0
22
23
4
23
23
4

Term
Median
2.75
5.53
6.75
2.25
5.8
0.41
0.76
7.07
1.78
3.35
2.93

[IQR]
1.48
2.85
18.66
0.68
2.65
0.12
0.12
12.53
1.08
1.05
9.39

(n)
52
85
20
91
87
23
71
82
39
91
87
39

Median
2.42
5.96
6.26
1.93
6.9
2.29
0.57
1.23
3.70
1.43
4.02
2.30

[IQR]
1.57
2.94
7.56
1.11
3.40
1.47
0.61
0.61
2.71
0.71
1.75
1.57

Mann
Whitney
p-value
0.56
0.48
0.91
0.082
0.069
0.034 *
0.30
0.46
0.049 *
0.007 *
0.98

4.3.11. Relationship Between NICU Admission and CYP n-3 Oxylipin Levels
in the Placenta, Maternal Plasma and Cord Plasma
There were no significant differences in CYP450 n-3 metabolite levels between
NICU and non-NICU admissions. Table 38 illustrates the median metabolite levels.
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Table 38: Median CYP450 n-3 Oxylipin Tissue Levels in NICU and non-NICU Admission
NICU Admission
No NICU
Mann
Admission
Whitney
Metabolites
(n) Median
[IQR] (n) Median (nM)
[IQR] p-value
(nM)
Maternal 14,1520 2.19
2.72 48 2.12
1.45 0.18
DiHETE
Cord 14,15-DiHETE
28 5.55
4.29 78 4.86
2.88 0.4
Placental 14,157
3.93
7.66 17 6.57
8.76 0.16
DiHETE
Maternal 17,1831 2.00
0.93 82 1.67
1.10 0.056
DiHETE
Cord 17,18-DiHETE
29 5.52
4.32 80 6.17
3.01 0.71
Placental 17,181
2.29
22 2.21
1.67 1.00
DiHETE
Maternal 16,17-EpDPA 29 0.20
0.51 63 0.26
0.61 0.26
Cord 16,17-EpDPA
29 0.46
0.32 75 0.54
3.01 0.17
Placental 16,17-EpDPA 8
3.68
6.18 35 3.78
2.55 0.86
Maternal 19,2031 1.32
0.82 82 1.25
0.72 0.06
DiHDPA
Cord 19,20-DiHDPA
29 3.11
2.22 80 3.76
1.61 0.389
Placental 19,208
4.83
2.31 35 2.46
1.76 0.99
DiHDPA

4.4. DISCUSSION
This study presents the relationships between n-6 and n-3 pathway metabolites
and infant outcomes at the time of delivery. The LOX, COX and CYP450 metabolites
demonstrated significant differences in metabolite levels between maternal and cord
plasma for prematurity and NICU admission. However, only cord 14,15-DiHET was
found to reduce the odds of prematurity by 53% and maternal LXA4 to reduce the odds
of NICU admission by 24.6%. Inflammation is an underlying mechanism to prematurity
and NICU admission, and the data presented here suggests 14,15-DiHET and LXA4
may be beneficial in addressing uncontrolled inflammation.

110

4.4.1. LOX n-6 Oxylipins in Prematurity and NICU Admission
LOX pathway oxylipins derived from n-6 FAs have been found to impact
prematurity. Specific n-6 oxylipins have been associated with prematurity but were not
predictive of prematurity in these studies. Omega-6 oxylipins are generally proinflammatory except for LXA4, which can have both pro- and anti-inflammatory
properties. However, maternal LXA4 reduced the odds of NICU admission. This study
highlights that an increase in 1 nM of maternal LXA4 reduces the odds of NICU
admission by 24.6%, yet the importance of LXA4 in normal and abnormal pregnancy is
not sufficiently understood. On a molecular level LXA4 increases vasodilation,
decreases neutrophil chemotaxis, and increases monocyte adhesion.154 Vasodilation of
the arterioles implies that LXA4 may be relevant for the onset of vasodilation during
normal pregnancy.69 In addition, higher levels of LXA4 have been reported at 24 weeks
of gestation.152,155 Interestingly, LXA4 has not been reported in umbilical cord blood;
however, I detected cord LXA4 levels in both NICU and non-NICU admission.156 My data
would suggest lower levels of LXA4 may initiate or progress the inflammatory response
underlying infant morbidity. Clinically, a proposed novel treatment for pre-eclampsia is
LXA4 supplementation during pregnancy due to studies demonstrating administration
not effecting the fetus.69 Therefore, supplementation with LXA4 may also help to reduce
NICU admission of infants exposed to inflammation in-utero through its ability to inhibit
the molecular signals of inflammation.157

4.4.2. LOX n-3 Oxylipins in Prematurity and NICU Admission
Omega-3 FAs are recommended during pregnancy and have been shown to
reduce the incidence of prematurity.158 However, in this study the metabolites of omega3 FAs did not reduce the odds of prematurity or NICU admission. According to Das et
al., negative pregnancy outcomes may occur despite the tissues capacity to produce
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LOX pathway oxylipins. This could be due to a deficiency in the parent nutrients, AA,
EPA and DHA, that could be the basis for the endothelial dysfunction, inflammation, and
hypertension.159 Applying this hypothesis to prematurity, potentially during preterm
pregnancies there is an upregulation of n-3 LOX pathways to combat the dysfunction;
however, there is not enough AA, EPA, and DHA to overcome the imbalance. In this
cohort, there were no significant difference in intakes between term and preterm
deliveries. Potentially, preterm deliveries in this study did not have the substrate to
combat uncontrolled inflammation.

4.4.3. COX n-6 Oxylipins in Prematurity and NICU Admission
Omega-6 FAs are metabolized through the COX pathway into inflammatory
oxylipins that are associated with poor infant outcomes when dysregulated.160
Prostaglandins (PGs) are key mediators of human parturition through induction of
myometrium contractility, cervical ripening, degrading the extracellular matrix causing
the rupture of fetal membranes.48 PGE2 causes cervical remodeling and induces
progesterone withdraw at the tissue site. PGF2a initiates parturition in humans by
modulating chemokines and cytokines that activate multiple signaling pathways. These
prostaglandins can be found in placental and umbilical cord tissue, with different regions
contributing various levels. One study suggests PGE2 and PGF2a increased as a
functional of gestational age until 36 weeks of gestation.48,160 Interestingly, no significant
differences were found in this study between preterm and term deliveries or NICU
admission. There may not be a difference due to the median age for preterm deliveries
being 36.00 weeks of gestation [2.00] compared to 39.94 weeks of gestation [1.30] for
term deliveries. Therefore, PGE2 potentially stabilized in most of the maternal-infant
pairs enrolled in this study.160
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4.4.4. CYP450 n-6 Oxylipins in Prematurity and NICU Admission
The cord plasma AA metabolite, 14,15-DiHET, was associated with a 53%
reduction in odds of prematurity after adjustment. The physiological roles of
dihydroxyeicosatrienoic acids (DiHETs) are understood mainly through the alterations in
epoxyeicosatrienoic acids (EETs), which are generally vasodilators. DiHETs are formed
through the rapid degradation of EETs by the enzyme soluble epoxide hydrolase (sHE)
and are considered less active. Interestingly, EETs facilitated uterine blood flow in the
setting of pre-eclampsia, with 14,15-DiHET increasing in urine from pre-eclamptic
pregnancies. These findings demonstrate a reduced CYP450 production and increased
degradation of EET by sHE, and have been associated as a marker of metabolic
inactivation of EET signaling.161 More recent research has begun to demonstrate that
DHETs can retain certain EET signaling capacities, such as regulating vascular smooth
muscle cells and activating the PPAR system (a and g). The PPARs a and g have been
suggested as links between gestational duration, preterm labor and birth weight. 133,134,162
14,15-DiHET’s association with a reduction in prematurity, may suggest it has a role in
regulating pathological pregnancy outcomes through its activation of the PPAR system.

4.4.5. CYP450 n-3 Oxylipins in Prematurity and NICU Admission
Omega-3 metabolites formed through the CYP450 pathway were not associated
with prematurity or NICU admission. There remains a large gap in knowledge about n-3
derivatives from the CYP450 pathway. Best et al. demonstrated 19,20-EpDPA increased
significantly in maternal plasma between 20 weeks of gestation and 34 weeks of
gestation after omega-3 supplementation. However, the supplementation and placebo
group did not have significantly different 19,20-EpDPA levels at 34 weeks of gestation.
From the same large study (Omega-3 fats to Reduce the Incidence of Prematurity),
Ramsden et al. found similar results between 14 weeks and 24 weeks of gestation. In
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addition, they explored plasma oxylipins as predictors of prematurity independent of
supplementation. CYP450 oxylipin 19,20-EpDPA did not predict prematurity.58 My
research did not analyze 19,20-EpDPA but a similar EPA derivative- 16,17-EpDPA.
16,27-EpDPA was also not predictive of prematurity. As mentioned previously, maternal
intake of precursors was the same across infant outcomes. Prematurity and NICU
admission are thought to have more inflammation and need for these metabolites.
However, if there is not enough original substrate to create these metabolites, then the
inflammation goes uncontrolled. There may be important relationships that are not
visible due to the nature of the data.159 Therefore, this research shows the presence of
the metabolites and continued research into CYP450 n-3 metabolites role in pregnancy
is necessary.

4.5. CONCLUSION
Oxylipins present at delivery from the LOX and CYP450 pathways may begin to
help identify treatment strategies with specific metabolites to reduce the risk of poor
infant outcomes. Larger studies including earlier deliveries are necessary to highlight
other metabolite relationships potentially not demonstrated here.
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CHAPTER 5: Vascular Smooth Muscle
Cells’ and Extra-villous Trophoblasts’
Expression of GPR18 in Preterm and Term
Placentas
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5.1. INTRODUCTION
Placental vascular functioning is essential to maintain maternal-fetal health and
prevent adverse perinatal outcomes, including intrauterine growth restriction, preeclampsia, and preterm delivery.109,163–165 Placental malperfusion has been identified as
the most common placental pathology associated with adverse neonatal outcomes in
over 20,000 births.163 In preterm placentas, inflammation/infection was discovered in
over 25% of deliveries. However, the mechanistic alterations in placental development
leading to impaired vascular function are not well understood.
Early modulators of placental vascular development are extra-villous trophoblasts
(EVTs) derived from the fetus, while vascular smooth muscle cells (VSMCs) maintain
blood flow and blood vessel function. EVTs invade maternal decidual spiral arteries to
increase blood flow from the mother to the fetus. Inflammatory stimuli reduce EVTs’
invading capacity and stimulate them to release inflammatory cytokines. Dysfunction of
these cells contributes to adverse perinatal outcomes, including preterm birth.166–168
Furthermore,

placental

VSMC

changes,

including

differentiation,

viability,

and

contractility, are predictors for reduced circulation, ischemia, and adverse neonatal
outcomes like intrauterine growth restriction, pre-eclampsia, and prematurity.108–110 Yet,
the underlying mechanisms leading to these placental malformations and how to protect
against them are unclear.
In addition to n-3 fatty acids' benefits in fetal development, they have been
reported to have advantages in cardiovascular functioning and VSMC regulation in
adults with previous heart disease, including hyperlipidemia and

previous heart

attacks.169–171 One mechanism behind the benefits of n-3 FAs is thought to be their
enzymatic metabolism into anti-inflammatory mediators called specialized pro-resolving
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mediators (SPMs). In cardiovascular disease-related events, injury exposes the
underlying endothelial cells which leads to platelet aggregation, coagulation proteins,
leukocyte migration and adhesion, and VSMC activation. The activation of VSMCs leads
to migration and proliferation of cells leading to the development of a compromised
vessel. Studies suggest SPMs are part of an endogenous homeostatic pathway that act
directly on vascular cells to reduce inflammatory signals, leukocyte adhesion, and the
migration and proliferation of cells. For example, the SPM resolvin E1 reduces infarct
size in rats subject to ischemia/reperfusion injury and resolvin D1 prevents heart muscle
fibrosis.172,173 SPMs exert their anti-inflammatory and pro-resolution activity through
binding to G-protein-coupled receptors (GPR) and initiating or altering intracellular
signaling. However, the effects of SPMs on the placenta are not well understood.
The placenta is a vascular organ, with VSMCs located in fetal vessels in the absence
of pathology and in maternal arteries in the presence of pre-eclampsia. Despite SPMs
benefits on cardiovascular smooth muscle cells, there remains a knowledge gap on the
interaction and role of SPMs at the maternal-fetal interface. Previous studies indicate
placental tissue expresses the SPM GPR receptors FPR2 and CMKLR1.68,69,174 More
recently, GPR18, the receptor for resolvin D2, has been identified in placental EVT and
VSMCs and confirmed the hypothesis that the placenta is a target for SPM RvD2. In
addition, in-vitro cell cultures identified alterations in the physiological responses by the
cells to RvD2 treatment and subsequent inflammatory exposure.175 However, the
relationship between GPR18 expression and infant outcomes has not been studied. To
investigate the potential role of GPR18 expression in the propagation of adverse infant
outcomes, I studied the relationship between GPR18 expression levels and prematurity
in VSMC and EVT.
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5.2. MATERIALS AND METHODS
5.2.1. Study Characteristics
This study received Institutional Review Board approval (IRB #112-15-EP) from
the University of Nebraska Medical Center. Eligibility for participation in the study
included mothers age ≥ 19 years of age, delivering at Nebraska Medicine, viable
pregnancy, and mothers free of renal, metabolic or hepatic disease that impair normal
nutrient metabolism. Infants with diagnosed inborn errors of metabolism and congenital
anomalies were not included in the study. After admission to the labor and delivery unit,
written informed consent was obtained from the mothers by trained research personnel.

5.2.2. Maternal and Infant Characteristics Used in Study
5.2.2.1. Demographics
Maternal demographics included maternal age, body mass index (kg/m2),
smoking status (never vs. current/former smoker), delivery mode, and race (white vs.
non-white). Infant characteristics were gestational age and sex.
5.2.2.2. Clinical Covariates
Maternal covariates included chorioamnionitis, pre-eclampsia, and maternal
intake of n-3 and n-6 FAs.
5.2.2.3. Outcomes
Infant prematurity, birth before 37 weeks of gestation, was the primary outcome
assessed in this study.
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5.2.3. Maternal Dietary Intake
All participants completed the Harvard Food Frequency Questionnaire (FFQ) that
assesses dietary intake over the previous year. Notably, the survey assessed
supplement use and reported nutrient intake with and without supplementation. This tool
has been validated in numerous adult populations, including pregnant women and was
used to assess intake between preterm and term deliveries.85

5.2.4. Blood and Fresh Placental Sample Collection
Trained nursing personnel collected maternal blood upon admittance to the
hospital and umbilical cord blood at delivery in EDTA tubes. The research team obtained
the samples within 12 hours of collection and transported the samples using lightsensitive bags to ensure FA stabilization. Blood specimens were centrifuged, and
plasma was collected and stored at -80 °C until metabolite analysis.
Human placental cross-sections were collected at random by trained research
personnel. There were no exclusion criteria for placental samples, except for placentas
already fixed in formalin. Samples were placed in a -80 °C freezer until metabolite
analysis.

5.2.5. Oxylipin Quantification Methods
Oxylipins 7-HDHA and 17-HDHA were chosen for this study due to their
breakdown into the GPR18 ligand and potential indirect influence on, RvD2.5 Liquid
chromatography-tandem mass spectrometry was used to quantify metabolite levels. The
quantification methods are described in previous chapters (Ch. 2, pg. 27 and Ch. 3, pg.
60)
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5.2.6. Placental Tissue Collection and Processing
5.2.6.1. Immunohistochemistry
Placental cross-sections were placed in 10% formalin for at least 96 hours and
then embedded in paraffin. Traditional glass slides were prepared by obtaining 4
microns (m) thick tissue sections. Once the glass slides were prepared, IHC staining for
GPR18 was performed using standard autostaining protocols on a Ventana Discovery
Ultra autostainer. Twenty-three slides were stained with GPR18 from Thermo Fischer
Scientific (polyclonal; 1: 75 dilution) and 28 were stained with GPR18 from Abcam
(polyclonal; 1: 100 dilution). The placental pathologist visually identified VSMCs and
EVTs within the slides. A VENTANA iScan HT scanner digitalized the slides at a single
focal plane level with x40 magnification. Twenty-six of the cases were in BIF format and
the last 40 cases were saved in TIFF format because of better compatibility with QuPath.
5.2.6.2. Analysis of Vascular Smooth Muscle and Extra-villous Trophoblast
VSMCs and EVTs were analyzed to quantify the intensity (low vs. medium vs.
high) and the percentage (0%-100%) of cells displaying low, medium, or high intensity of
GPR18 immunoreactivity. Expression is defined as cells expressing any type of GPR18
staining (negative or positive). Intensity is the extent of the antibody staining and is
recorded as low, medium or high. Tissue slides with less than ten blood vessels for
VSMC or 100 EVT cells, as determined by the clinical placental pathologist, were
excluded from the analysis. VSMC and EVT were annotated (digitally marked) using
VENTANA Image Viewer software (version 3.1.3; Roche, Indianapolis, IN, USA), a webbased application by BioImagene.
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5.2.6.3. QuPath Scoring Method:
a. QuPath 0.2.2 was used on a 64-bit processor windows computer. The digital image
files were opened into the QuPath software. The image type of brightfield (H-DAB)
was selected with x40 magnification and 0.25 mm pixels. The image type was
changed from H and E to DAB for IHC analysis to reflect the chromogen used for
immunostaining. The x40 magnification offered smaller pixels and more detail.
b. The pre-annotated digital images from VENTANA Image Viewer were used as a
reference for selecting the regions of interest in QuPath. The polygon tool was used
to annotate and analyze the VSMC and EVT stained with GPR18 (Figure 14). VSMC
and EVT were annotated and analyzed separately.

Figure 14: QuPath annotation of EVT cells staining for GPR18
This figure is demonstrating the use of QuPath’s polygon
tool to select EVTs staining for GPR18.
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c. The optimal stain separation was determined before running the analyses by first
estimating stain vectors. This method was performed by choosing to follow these
steps: select "analyze" à "estimate stain vectors" à select "auto" at the bottom of
the pop-up screen in QuPath
d. Cell analysis and positive cell detection were used to perform the analysis with the
setup parameters shown in Table 39.
Table 39: EVT Nucleus Parameters
EVT
Background radius
8 µm
Median filter radius
1.5 µm
Sigma
3 µm
Minimum area
10 µm2
Maximum area
400 µm2

VSMC
8 µm
1.5 µm
3.5 µm
10 µm2
400 µm2

e. Select "Cell: DAB OD mean" when using a selective antibody with both membranous
and cytoplasmic staining, as was the case in this study.
f.

The single threshold option was inactivated to allow for multiple intensity analysis.
The cutoff thresholds for 1+, 2+ and 3+ were determined before the analysis by one
pathologist using QuPath heat maps (Table 40).
Table 40: Intensity Threshold Parameters for EVT and
VSMC Measured Using Optical Density
Threshold +1
0.05
Threshold +2

0.10

Threshold +3

0.20

g. After clicking "run," the software performed the digital analysis. Under annotations
measurements, the histogram demonstrating the cell DAB OD mean reflects the
range of expression. Figure 15 illustrates the range of expression for the positive
cells.
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Figure 15: Illustrates a histogram from the analysis of VSMC expression of
GPR18. The x-axis displays the optical density values for GPR18 intensity for each
VSMC cell identified in the tissue sample.
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h. The annotations were then merged to get the total number of positive cells
categorized as 1+ (low), 2+ (medium), and 3+ (high). The percentage of cells with
low, medium, and high GPR18 expression was calculated by taking each category
divided by the total number of positive cells. For example, the percent of cells with
low GPR18 was calculated by taking [(the number of +1)/ (the number of +1, +2, and
+3)] *100.
i.

Figure 16 shows representative images of the categorization of cells within tissue
samples.

Figure 16: Merged QuPath Annotation of EVT GPR18 into Low
(yellow), Medium (orange), High (red), and Negative (blue) for
Tissue Sample.
After QuPath analyzes the optical density for the specified cell
type, the annotations are merged to categorize intensity as low,
medium, high or no expression.
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5.2.7. Statistical Analysis
Descriptive statistics included means, standard deviations, medians, and
interquartile range (IQR) for continuous data and counts and percentages for categorical
data. Means were reported for continuous data that were normally distributed including
maternal and gestational age and maternal BMI. Medians were used to describe
continuous data that was not normally distributed (maternal intakes and GPR18
expression levels). To evaluate the relationship between intakes and GPR18 expression,
each subject was categorized as having either a low, medium or high expression level of
GPR18. Once each sample had an assigned category, intakes were compared between
each group. For example, if subject 205 had the following expression intensity for GPR
18, 10% of cells had low expression, 50% had medium expression, and 40% had high
expression, then the tissue sample was categorized as having medium expression. The
Mann-Whitney test compared continuous measures between dichotomous groups, and
the Kruskal Wallis test compared measures between groups with more than two groups.
Spearman correlation coefficients were used to assess associates between continuous
variables. Confounders were determined by assessing for significant relationships with
GPR18 expression levels in the larger population. Logistical regression would be
adjusted for statistically significant confounders. P < 0.05 was considered statistically
significant. Subjects were included in the analysis with missing values for variables.
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5.3. RESULTS
5.3.1. Demographics
Fifty-two maternal-infant pairs were enrolled in the study. Maternal age averaged
38.14 ± 3.38 years old, with a mean BMI of 28.67 ± 7.00 kg/m2. Infants were on average
38.14 ± 3.38 weeks old at the time of delivery, with birth weight, -length, and -head
circumference in the 50th percentile. Eleven infants (20.37%) were born prematurely
(<37 weeks of gestation). Table 41 highlights the demographics for the maternal-infant
pairs enrolled in the study.
Table 41: Maternal and Infant Demographics and Clinical Characteristics
(n)
Mean (SD)
Median [IQR]
Gestational Age (week. days)
48
38.14
(3.38)
39.25
[2.00]
Birthweight (kg)

48

3.20

(3.38)

3.32

[0.78]

Birthweight %
Birth HC (cm)
Birth HC %
Birth Length (cm)
Birth Length %
Maternal Age (years)
Maternal BMI (kg/m2)
Placental Weight (g)

48
48
48
48
48
52
38
21

(27.91)
(3.01)
(32.59)
(4.95)
(32.23)
(7.90)
(7.00)
(173.07)

No
Yes
Vaginal
C-section
No
Yes
No
Yes
No
Yes
Female
Male
White
Non-White

65.06
34.30
52.82
48.90
44.60
27.50
27.44
378.00
%
60.80%
39.20%
78.40
21.60
76.50
23.50
28.10
23.50
84.30
15.70
39.20
60.80
44.00
56.00

[48.64]
[2.60]
[57.95]
[3.70]
[58.04]
[9.00]
[9.93]
[246.40]

NICU Admin

56.29
33.48
51.92
48.30
49.79
26.87
28.66
412.90
(n)
31
20
40
11
39
21
43
8
43
8
20
31
22
28

Delivery Mode
Fish Oil/DHA Supplementation
Placental Chorioamnionitis
Pre-eclampsia
Sex
Race
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5.3.2. GPR18 Expression in VSMCs between Term and Preterm Deliveries
There were 10 placentas available from premature vs. 41 placentas from term
deliveries. VSMCs in preterm placentas demonstrated significant differences in low and
medium GPR18 intensities. VSMCs in placentas from preterm deliveries had a 2-fold
higher percentage of cells with low GPR18 expression than term. Further, this meant a
2-fold lower expression of medium staining VSMC. High expression in term placentas
approached significance and demonstrated a seven-fold higher median percentage
compared to preterm (p = 0.066). Table 42 shows the mean and median expression
levels, while Figure 17 illustrates the differences between groups.

Table 42: Percentage of Cells with Low, Medium, or High Expression Levels in VSMC
Preterm

Term

Low

Mean (SD)
64.85 (26.16)

Median [IQR]
70. 12 [53.26]

Mean (SD)
38.15 (27.60)

Median [IQR]
36.00 [ 31.43]

p-value
0.019*

Medium

29.68 (19.15)

28. 28 [36.90]

46.85 (21.35)

48.31 [19.82]

0.032*

High

5.47 (7.55)

1.27 [14.89]

15.00 (16.21)

9.12 [25.34]

0.066

*p < 0.05
SD: standard deviation
IQR: interquartile range

127

Median of Expression Percentage (%) of VSMC

VSMC GPR 18 Expression Intensity
between Term and Preterm Placentas

80

✱
Preterm

p = 0.019

Term

70.12

✱

60

p = 0.032
48.31

40

36.00
28.28

n.s.

20

p = 0.066
9.12

1.27

0
Low

Medium

High

Expression Intensity

Figure 17: Differences in Percentage of VSMC GPR18 Expression
Intensity between Term and Preterm Deliveries.
Cells staining for GPR18 were categorized as having low, medium, or
high intensity. The percentage of cell staining for low, medium, and high
for each tissue sample were compared between placentas from term and
preterm deliveries.
*p < 0.05; n.s., non-significant

5.3.3. EVT GPR18 Expression and Intensity in Term and Preterm Placentas
There were 10 placentas from preterm and 41 placentas from term deliveries
available for analysis of GPR18 in EVTs. Expression intensity was not significantly
different between term and preterm placental samples. Table 43 describes the median
levels, and Figure 18 illustrates expression levels between the two groups.
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Table 43: Percentage of Cells with Low, Medium, or High Expression Levels in EVT
Intensity Level

Preterm

Term

Mean (SD)

Median [IQR]

Mean (SD)

Median [IQR]

p-value

Low

29.76 (12.28)

30.77 [16.69]

30.60 (20.25)

27.22 [27.34]

0.92

Medium

41.09 (14.94)

43.03 [18.26]

40.88 (20.16)

34.61 [14.98]

0.23

High

29.16 (22.84)

21.44 [36.19]

28.52 (22.95)

26.18 [44.62]

0.94

EVT GPR 18 Expression Intensity
between Term and Preterm Placentas

Preterm

n.s.

50

Term

p = 0.23
43.03

n.s.

Median Percentage (%) of EVT Cells

40

p = 0.92

34.61

30.77

n.s.
p = 0.94

30

27.22

26.18
21.44

20

10

0
Low

Medium

High

Expression Intensity Level

Figure 18: Differences in Percentage of EVT GPR18 Expression Intensity between
Term and Preterm Deliveries.
Cells staining for GPR18 were categorized as having low, medium, or high
intensity. The percentage of cell staining for low, medium, and high for each tissue
sample were compared between placentas from term and preterm deliveries. There were
no significant (n.s.) differences identified between the two groups.
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5.3.4. Omega Intakes and GPR18 Expression Levels
Maternal EPA and DHA intakes were not different between expression levels for
VSMC and EVT after Bonferroni correction. Table 44 demonstrates intakes across
GPR18 expression categories in VSMCs. EPA initially showed a significant differences,
but after Bonferroni correction, there were no significant differences (Table 45). In Table
46, intakes for EVT GPR18 expression categories are displayed DHA initially showed a
significant difference between groups, but this disappeared after Bonferroni correction
(Table

47).

Table 44: Omega-3 Intake Levels Across Expression Categories in VSMC
Intakes (mg/day)

Expression
Intensity
Categorization

(n)

Mean (SD)
mg/day

Median
[IQR]
mg/day

Total Omega-3 FA
including
supplementation

Low

11

1,997.30 (1,142.09)

1,590 [2090.00]

Medium
High
Low

24
5
11

1875.40 (806.71)
2,472.00 (1,882.41)
79.10 (113.71)

1740.00 [1372.50]
2,470.00 [3,155.00]
40.00 [90.00]

Medium

24

21.30 (25.59)

10.00 [20.00]

High
Low
Medium
High

5
11
24
5

126.00 (164.71)
167.30 (172.75)
80.80 (75.35)
190.00 (137.30)

70.00 [250.00]
90.00 [210.00]
60.00 [88.00]
210.00 [260.00]

EPA

DHA

Table 45: Kruskal-Wallis Pairwise Comparison of VSMC’s GPR18
Expression Categorizations and EPA

High-Low
High-Medium
Low-Medium

4.57
12.57
8.00

0.16
0.073
1.00
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Table 46: Omega-3 Intake Levels Across Expression Categories in EVT
Median
Expression Intensity
Mean (SD)
Intakes (mg/day)
(n)
[IQR]
Categorization
mg/day
mg/day
Total Omega-3 FA
including
Low
7
2024.30 (938.01)
1,890.00 [785.00]
supplementation
Medium
14
2021.40 (927.57)
2,175.00 [1,570.00]
EPA

DHA

High

17

1,730.00 (1,253.63)

1,440.00 [500.00]

Low

7

50.00 (81.45)

10.00 [35.00]

Medium

14

72.10 (13.39)

25.00 [30.00]

High
Low
Medium

17
7
14

24.70 (34.12)
13.43 (20.25)
14.00 (11.00)

10.00 [10.00]
40.00 [900.00]
90.00 [800.00]

High

17

76.50 (88.53)

50.00 [40.00]

Table 47: Kruskal-Wallis Pairwise Comparison of EVT’s GPR18 Expression
Categorizations and DHA

Category Comparison
High-Low
High-Medium
Low-Medium

H
-3.41
-10.27
-6.86

p-value
1.00
0.061
1.00

5.3.5. Associations Between DHA Metabolites and GPR18 Expression in Placental
Cells
Figure 20 illustrates the pathway of a metabolite and its interaction with GPR18.
Both cord 7- and 17-HDHA were correlated with intensity levels in VSMC and EVT
(Figures 21-22). Increases in cord 7- HDHA were positively correlated with low intensity
but negatively associated with the number of cells with medium and high GPR18
intensities. Cord 17-HDHA only demonstrated a significant negative correlation with
VSMC staining for medium GPR18 expression. Cord 7- and 17-HDHA levels negatively
correlated with high intensity staining EVTs, while having a moderate to a strong
relationship with low-intensity staining. Placental 7-HDHA showed a negative association
with low intensity staining GPR18 VSMC; however, only seven samples were available.
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A.

Figure 20: Schematic of maternal blood metaboliteàplacenta with receptor à and then
cord blood metabolite
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B.
Figure 20: Schematic of Metabolites in Blood Traveling from Mother to Fetus and Areas
of Interaction with the GPR18 Receptor.
(A) Maternal metabolites travel through the uterine arteries (1), through the maternal
spiral arteries into the intervillous space (2), and enter through the fetal blood vessels located
in the chorionic villi (3). Once metabolites have entered the fetal circulation, they travel
through the umbilical vein to the fetus (4). Waste products from the fetus are exchanged and
travel through the umbilical arteries into fetal veins within the chorionic villi (5). The waste is
released into the intervillous space and transported back to the mother through uterine veins
(6).
(B) As maternal metabolites are moving through maternal spiral arteries into the
intervillous space (2), RvD2 can interact with the GPR18 receptor to initiate downstream
pathways. Fetal capillaries take up the nutrients for transfer to the fetus. Vascular smooth
muscle cells are located within the fetal blood vessels and have GPR18 expression (3). RvD2
can interact with the receptor to influence an anti-inflammatory environment. Figure was
created in BioRender and adapted from Kaipe et al. and Baines et al.

Figure X: Spearman Correlations between DHA Metabolites and VSMC GPR18 Intensity
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Figure 21: Spearman Correlations Demonstrating the Relationship between Percentage of VSMC with Low, Medium, and High
GPR18 expression in Tissue Samples and Metabolite Levels in Plasma and Placenta.
Cord 7-HDHA levels had moderate-to-strong relationships with low and medium intensity. Due to expression level being a
percentage, high intensity was negatively correlated. Maternal 17-HDHA showed a weak correlation with the percentage of VSMC with
Medium GPR18 staining.
*p < 0.05
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Figure X: Spearman Correlations between DHA Metabolites and EVT GPR18 Intensity
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Figure 22: Spearman Correlations Demonstrating the Relationship between Percentage of EVT Cells with Low, Medium, and
High GPR18 Expression in Tissue Samples and Metabolite Levels in Plasma and Placenta.
Increases in the proportion of cells with low GPR18 was associated with a strong, positive correlation with cord 7-HDHA levels,
which led to having a strong, negative correlation with the percentage of EVTs with high-intensity.
*p < 0.05
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5.4. DISCUSSION
Previously, my lab has demonstrated SPM RvD2 increased in maternal and cord
plasma in the setting of prematurity. These findings led us to explore the placenta as a
potential target for SPMs. My lab found that GPR18 is, in fact, expressed in the placenta,
with expression in VSMC and EVTs. The investigations outlined in this chapter identify a
potential dysregulation of GPR18 expression intensity in VSMCs within preterm
compared to term placentas. In addition, the SPM intermediates that produce GPR18's
ligand RvD2 showed a possible relationship with VSMC and EVT expression intensity.
These findings suggest that SPMs are upregulated during preterm gestation to reduce
inflammation, but dysregulation at the maternal-fetal interface potentially prevents SPMs
from exerting beneficial anti-inflammatory effects. Dysregulated inflammation then
contributes to high-risk fetal health outcomes, including prematurity.
Placental malperfusion and inflammation/infection were identified in preterm
placentas in an investigation of over 20,000 births, including 4,000 preterm births.163
Malperfusion was the most identified pathology found in preterm placentas, at over 50%.
At the same time, regions of inflammation were found in 25% of preterm placentas. The
pathological findings in preterm placentas and previous studies demonstrating vascular
dysfunction in the presence of inflammation suggest that an inflammatory placental
environment may contribute to placental vascular dysfunction, influencing adverse
neonatal outcomes, including prematurity. Fetal-derived EVTs are early modulators of
placental vascular development. EVT invades maternal decidual spiral arteries to
increase blood flow from mother to fetus, and in the presence of inflammation, EVTs
have reduced invasive capacities and release pro-inflammatory cytokines.107 These
findings suggest a mechanism by which an inflammatory placental environment may
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contribute to placental vascular dysfunction and ultimately preterm birth.166,167 In this
capacity, expression of GPR18 in EVT to confer RvD2 responsiveness could provide a
protective benefit for these cells, making them less responsive or affected by
inflammatory stimuli. Interestingly, in these investigations, EVT expression levels of
GPR18 did not differ significantly between term and preterm births. Further, as EVT
expression intensity increased, cord 7- and 17-HDHA levels were significantly
associated with lower levels. The presence of the metabolites 7- and 17-HDHA indicate
activation of the SPM D series pathway.165,176,177 Therefore, lower metabolite levels in
cord plasma could show increased metabolism of the intermediates into D-series
resolvins at the placenta. Further investigations are needed to fully understand the
differences in metabolite levels in EVT in the setting of prematurity.
Under healthy conditions, placental vasculature exists at near maximal
vasodilation.
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Inflammation can lead to vascular dysfunction through changes in

VSMC differentiation, viability, and contractility, which are predictors for reduced
circulation, ischemia, and adverse pregnancy and neonatal outcomes.108–110 Previous
investigations in my lab demonstrated that human umbilical cord smooth muscle cells
(HUSMC) had sustained expression of GPR18 under varied inflammatory stimuli (LPS
and cytomix cocktail). After RvD2 treatment, HUSMC were less responsive to LPS
stimuli as measured by IL-6 inflammatory cytokine release and altered cytoskeletal
dynamics that did not affect collagen contraction that could negatively impact flow.175
These investigations demonstrate GPR18’s role in the health and maintenance of
VSMCs.
In this investigation, placentas from preterm deliveries had a two-fold higher
median percentage of VSMCs staining for low-intensity GPR18 expression. As
expected, this meant a two-fold decrease in the proportion of cells staining for medium
GPR18 expression. The median percentage of high intensity staining cells was higher in
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term deliveries and trended towards significant. Therefore, in the setting of prematurity,
there may be a down-regulation of GPR18 in VSMCs contributing to placental
malperfusion through RvD2’s inability to maintain healthy viability, contractility, and
differentiation.108–110 Interestingly, maternal intakes of EPA and DHA did not significantly
influence VSMC GPR18 expression intensity. However, as seen in EVTs, cord
metabolite levels were positively correlated with low and medium intensity and
negatively associated with high-intensity GPR18 expression. Maternal 17-HDHA did
show a positive relationship with the proportion of VSMCs with medium GPR18
expression. As mentioned, prematurity had lower levels of medium staining cells, but
higher maternal 17-HDHA for the cohort was associated with an association with
medium expression. One hypothesis could be that mothers with lower plasma 17-HDHA
might not have enough intermediate metabolites to upregulate GPR18, contributing to
poor VSMC health and poor outcomes.
Identification of GPR18 in placental vasculature highlights a possible mechanism
for the actions of RvD2 to regulate placental health, which could be a potential
therapeutic target. Various studies have identified elevated SPM intermediates in
maternal and cord blood and placental tissues and demonstrate maternal fish oil
supplementation enhances intermediate levels. In this study, there were no significant
differences between intakes and GPR18 expression levels. This is potentially due to the
low reported intakes of DHA, EPA, and total n-3 FAs in this cohort, which may lead to
reduced availability of intermediates in the blood to influence receptor expression.
However, one study found 17-HDHA (resolvin D series intermediate) levels increased
throughout pregnancy, and in the context of maternal supplementation with EPA or
DHA-containing fish oil, maternal 17-HDHA increased compared to mothers receiving
placebo.20 Supplementation has also been shown to increase placental DHA, 18-HEPE
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(resolvin E series intermediates), and 17-HDHA. SPMs RvD1, RvD2, and protectin D1
trended towards significance.21 In women and pregnant mice, RvD1 was associated with
term delivery compared to preterm delivery through DHA-mediated inhibition of
inflammasome activation in trophoblast.179 Another study identified EPA-derived RvE3
as a potential therapeutic agent in preterm birth in mice treated with lipopolysaccharide
(LPS).61 Some studies have shown the anti-inflammatory effects of RvD2 reduce pain
through the regulation of pro-inflammatory and Akt/GSK signaling pathways. Therefore,
future studies are needed to understand the downstream pathways activated in
pregnancy by GPR18 to assess its potential as a therapeutic target to prevent
prematurity.

5.5. CONCLUSION
This study's strength was the ability to analyze GPR18 expression and intensity
in the context of prematurity and metabolite levels during pregnancy. For the future,
larger sample sizes are needed to improve understanding of the relationship between
metabolite levels and receptor expression in the setting of preterm and term births.
Negative cell expression was not recorded for this study, so I could not make
observations between negative and positive expressions. This will be included in future
studies along with qPCR to quantify expression with co-labeling markers for VSMC and
EVTs.

139

CHAPTER 6: Let’s Bring It All Together
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6.1. DISCUSSION
Maternal nutrition is a major environmental factor that alters intrauterine fetal
growth and development and may have life-long consequences.180 This theory is known
as the Developmental Origins of Health and Disease (the Barker hypothesis), which
posits that early insults can permanently program fetuses during pregnancy. The fetus
adapts to the intrauterine environment influenced by the maternal nutrient supply
through structural and functional modifications of organs and tissues to ensure survival.
Clinical and experimental studies demonstrate early developmental exposures can lead
to

cardiovascular,

pulmonary,

metabolic,

and

psychological

diseases

during

adulthood.181,182
Omega-6 and n-3 FA eicosanoid levels influence metabolic processes while also
being influenced by maternal intakes. The oxylipin levels in the umbilical cord blood are
affected by maternal metabolite levels, placental transfer of oxylipins, and the
competitive inhibition between n-6 and n-3 precursors and intermediates. Maternal diet
content and the storage and makeup of FAs in the body can affect the state of
inflammation due to the roles of these metabolites in the inflammatory cascade.
Unregulated inflammation at any point in pregnancy is an early life exposure that can
impact the infant's development and increase their risk of adult disease.150 Therefore,
the overall objective of this dissertation was to identify specialized pro-resolving
mediators (SPMs) and their intermediates (oxylipins) as possible targets to modulate
inflammation that can alter fetal growth and contribute to adverse infant outcomes.
My overall hypothesis was n-3 FA metabolites protect against inflammatory
stimuli and promote healthy fetal development. The application of metabolomics to study
infant growth was used to identify maternal nutrient availability at delivery. This then
allowed for an investigation into areas of dysregulation that may impact birth outcomes
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like birth measurements, prematurity, and NICU admission. I began to test this
hypothesis by working towards the following specific aims: 1) quantifying a diverse panel
of oxylipins in maternal plasma, cord plasma, and placental tissue at the time of delivery.
From there, I explored how tissue levels related to each other and infant outcomes. 2) I
examined prematurity's influence on SPM-responsive cellular targets at the maternalfetal placental interface. These specific aims better define the role of n-3 and n-6
metabolites in the context of infant outcomes and contribute to the overall objective of
this dissertation work.

6.1.1 Review of Data
The data suggest n-6 and n-3 SPM intermediate levels are associated with infant
growth and birth outcomes. Chapters 2 and 3 describe the oxylipins present from the
LOX enzymatic pathway at delivery and their relationships between tissue levels. In
Chapter 2, infant birth weight and length percentiles were predicted by maternal and
cord plasma levels of n-3 and n-6 FAs. Surprisingly, cord n-6 oxylipins 9-HODE, 13HODE, and 13-KODE positively predicted infant birth length percentiles. On the contrary,
maternal n-6 oxylipin 5,15-DiHETE negatively predicted birth weight percentiles. For n-3
FA derivatives, cord 5-HEPE positively predicted birth weight percentiles. However,
maternal 7-HDHA negatively predicted birth weight percentiles. Chapter 3 identified
placental LTB4 levels- an AA derivative- negatively predicted infant birth weight
percentiles. Chapter 4 begins to examine the influence of all three enzymatic pathways
on high-risk birth outcomes- prematurity and NICU admission. Cord 14,15-DiHET
reduced the odds of prematurity, while maternal LXA4 reduced the odds of NICU
admission. Data in Chapters 1-3 suggests the clinical protective roles of oxylipin
intermediates on infant outcomes. Lastly, Chapter 5 highlights prematurity as a potential
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influence on cellular signaling. VSMCs in preterm placentas demonstrated an increased
number of cells with low GPR18 expression compared to term placentas. In turn, the
percentage of cells with medium GPR18 expression was lower in prematurity. High
GPR18 expression in VSMCs trended towards being significantly higher in term
compared to preterm placentas. Maternal diet and its relevance are addressed in each
of these chapters.

6.1.2. Interpretation of Results
Most literature has focused on the parent nutrients, n-3 and n-6 FAs, as early-life
exposure. Omega-3 FAs are associated with reduced prematurity, NICU admission, and
improved gestational length.79(p3),179,183 Generally, n-6 FAs and the ratio of n-6 to n-3 FAs
are implicated in poor infant outcomes.45(p3),84(p3) Previous studies focused on one or two
sources of oxylipins in pregnancy. For example, some studies exclusively investigate
oxylipins levels in maternal or cord plasma, while others have studied maternal and cord
together. In this cohort, samples were collected for maternal blood, cord blood, and
placental tissue. In addition, the studies available for maternal plasma are collected at 36
weeks of gestation or earlier; however, this dissertation include samples from delivery.
Lack of diversity in the oxylipins studied and samples from across gestation are
hindering the complete understanding of oxylipin levels in maternal plasma, cord
plasma, or placental samples. The research presented expands the breadth of
metabolites present at measurable concentrations and provides levels in each tissue
type allowing for significant relationships to emerge. The following text describes my
data and how it relates to the current literature.
The current literature is not robust in the metabolites present during pregnancy,
and therefore their impact on infant growth has not been determined. First, I will begin to
fill this gap by discussing the role maternal metabolites had on infant growth metrics in
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the context of the current research available on infant development. Maternal 5,15DiHETE and 7-HDHA negatively predicted infants' birth weight percentiles. 5,15-DiHETE
is an AA derivative and would be expected to have an adverse impact. Previously,
Welch et al. characterized maternal plasma eicosanoids across gestation and
highlighted differences in levels for infants born small for gestational age (SGA, ≤ 10th
percentile), appropriate for gestational age (AGA, > 10th to ≤ 90th percentile, controls),
and large for gestational age (LGA, ≥ 90th percentile). This study found SGA status was
strongest in the AA-LOX pathway,

and the derivative 12-HETE had an adjusted

population mean level that was 56.2% higher among SGA cases than AGA controls.184
Although not significant, trends were also seen for the n-6 LA-LOX pathway metabolites.
HODEs had positive associations with SGA status that ranged from 21-25% higher than
controls. The authors point out increased LOX activity is often associated with
inflammation-mediated outcomes; however, the results remained consistent after
excluding women with comorbidities.117,185,186 My data would support Welch's hypothesis
that women who deliver SGA may have higher LOX-related inflammation than women
who have babies AGA.
Surprisingly, 7-HDHA, a DHA oxylipin, also negatively predicted birth weight
percentiles. As an n-3 FA derivative, I hypothesized 7-HDHA would have positive
impacts on infant growth. In addition, maternal intakes of 7-HDHA were significantly
associated with maternal plasma 7-HDHA levels. Preliminarily, the effect of 7-HDHA
during pregnancy may be gleaned from studies examining the results from the Omega-3
fats to Reduce the Incidence of Prematurity (ORIP) randomized control trial study. A
cohort of 48 participants -12 cases of preterm birth and 36 match term controlsdemonstrated DHA supplementation increased DHA-derived 4-HDHA. Participants with
concentrations above the median for DHA-derived 4-HDHA at 14 weeks of gestation had
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a higher risk of spontaneous preterm birth, independent of supplementation. In addition
to 4-HDHA, other 5-LOX derivatives over the median levels demonstrated an increased
risk of prematurity. The metabolite 7-HDHA was not investigated in this study but is also
a 5-LOX derivative, potentially highlighting 7-HDHA as harmful to the intrauterine
environment. Infant birth weight has been the most common health outcome used to
determine if the intrauterine environment influences fetal development. The research
presented here suggests HETEs, and potentially 7-HDHA are affecting the environment
within the womb. Over the long term, these metabolites could be programming the fetus
for future complications like metabolic and cardiovascular disease in adulthood.
Second, I described the influence of umbilical cord metabolites on infant growth
and how that relates to previous studies. In my research, cord metabolites 9-HODE, 13HODE, and 13-KODE positively predicted birth length percentiles. The role of cord
HODEs on infant birth length is not well reported. The available research has studied
cord HODEs in the context of gestational age. In an evaluation of metabolites in term
births, Gouveia-Figueria et al. found that full-term pregnancy (39 0/7 weeks through 40
6/7 weeks) was associated with increased levels of 11-HETE and 15-HETrE relative to
early term (37 0/7 weeks through 38 6/7 weeks). However, late-term births (41 0/7
weeks through 6/7 weeks) had decreased levels of 5-HETE compared to full-term
births.48,187,188 Roger et al. observed cord levels of HETEs were significantly associated
with gestational age.

The authors hypothesize the production of LOX pathway

metabolites is regulated through intrauterine growth processes, and deficiencies in
bioactive lipids in infants born early could contribute to an inappropriate response to
inflammation.57 Further, Frano et al. found elevated levels of 9-HODE, 13-HODE, and
13-KODE were positively related to bronchopulmonary dysplasia and its severity.189
More research is needed to understand these seemingly contradictory results. HODEs
have essential roles in cardiac development and act as PPAR g. These studies suggest
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potential

metabolic

immaturity

influencing

dyslipidemia

and

altered

metabolic

requirements at early gestational ages.57,189 The results from this dissertation and the
research explained above offer insight into the composition of cord blood across
pregnancy, which begins to describe the intrauterine environment and fetal exposures.
Third, I presented the placenta's influence on fetal development and metabolite
levels. Placenta LTB4 was associated with a 0.23% reduction in birth length percentiles
and a trend towards an impact on birth length percentiles and head circumference
percentiles. In context with maternal supplementation with fish oil, LTB4 was significantly
lower in mothers who reported supplementation (1.21 nM) relative to mothers who did
not (3.33 nM). Keelan et al. identified n-3 oxylipins and SPMs in the placenta, with 17HDHA being the most abundant. Supplementation also increased 17-HDHA and 18HEPE levels relative to controls.21 The initial steps in producing SPMs rely on LOX and
CYP450 enzymes which generate 17-HDHA and 18-HEPE, respectively. Taken
together, LTB4 may be early exposure to infants and influence growth; however,
upregulation of SPMs and their intermediates through increased intake could potentially
regulate this exposure.
Prematurity and NICU admission are high-risk outcomes associated with a poor
intrauterine environment linked to short- and long-term health consequences. Cord
14,15-DiHET reduced the odds of prematurity. Maternal LXA4, a known antiinflammatory oxylipin, reduced the odds of NICU admission. However, no significant
differences were found between maternal intakes and prematurity or NICU admission.
Oxylipins play a diverse role in health and disease, and recently certain metabolites
have been implicated in pathology leading to prematurity. Increased PGs E2 and F2a are
associated with cervical remodeling and uterine contractions contributing to preterm
labor.13,160 At 24 weeks gestation, LOX pathway derivatives 5-HETE and 4-HDHA over
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the median were associated with a higher risk of spontaneous preterm birth.58 Therefore,
my general hypothesis was n-6 metabolites would increase the odds of prematurity and
NICU admission, while n-3 metabolites would do the opposite. Yet, data from my
dissertation demonstrated most of the n-6 metabolites were not predictive of prematurity
or NICU admission. Metabolites contribute in various ways to pregnancy and negative
outcomes.
In addition to the relationship between metabolites and prematurity, I found that
receptor expression at the cellular level and prematurity are potentially related. VSMCs
in placentas from preterm deliveries had downregulation of GPR18 expression.

My

study adds to the literature that downregulation of GPR18 expression in VSMC may also
occur in prematurity.
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SPMs and their intermediates bind to GPRs to affect

downstream pathways, but GPR18 in human placental VSMCs and EVTs had not been
reported until recently.175 GPR18 is expressed in immune cell types, including spleen
thymus, peripheral blood leukocytes, lymph nodes, among others.191,192 Previously, my
lab reported the expression and differential intensity of GPR18 staining in cross-sections
of placental VSMCs and EVTs. Placental trophoblast cells such as HTR-8, JAR, JEG-3,
and BeWo also exhibited protein-level expression of GPR18. Human umbilical artery
smooth muscle cells treated with the RvD2 ligand increased GPR18 membrane
expression and reduced the release of pro-inflammatory mediators after exposure to
LPS and cytomix cocktail. In mice and rat models imitating human disease, lower
GPR18 expression on PMNs in the setting of sepsis was related to increased severity
and worse prognosis.193 In rats that experienced an ischemic/reperfusion (I/R) injury,
endogenous RvD2 was produced, and downregulation of GPR18 expression occurred.
Exogenous RvD2 was able to recover GPR18 levels in neurons and endothelial cells in
addition to lowering pro-inflammatory cytokines, edema, and infarct area size.194 In an
obese mice model with a chronic low-grade inflammatory status, RvD2 and its precursor
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DHA upregulate GPR18 expression. GPR18 expression is altered in various disease
states, and administration of its ligand RvD2 has demonstrated its ability to recover
receptor expression.
The biological effects of GPR18 are determined by the downstream pathways
initiated from the receptor's activation. Studies have started to demonstrate that the
RvD2-GPR18 axis may enhance cyclic adenosine monophosphate (cAMP) or the
phosphorylation of cAMP Response Element-Binding Protein (CREB), extracellular
signal-regulated kinases (ERK1/2), and signal transducer and activator of transcription 3
(STAT3).195 Dysregulation of ERK1/2 and cAMP have been described in placental
trophoblast function and uterine contractions.107,196 One theory could be that the low
expression of GPR18 in prematurity does not allow for the enhancement of cAMP, which
has been shown to promote smooth muscle cell and myometrial relaxation.196
Interestingly, significant differences were found between GPR18 in VSMCs but not EVTs
in preterm vs. term births. Therefore, low GPR18 in VSMCs located in the villi could be
causing increased pressure which would enhance the reactive oxygen species leading
to an inflammatory intrauterine environment. This shift could then cause preterm labor
and delivery. A growing body of evidence has highlighted abnormal placental function as
the underlying mechanism that facilitates pre-eclampsia, IUGR, and preterm
birth.102,105,197 Therefore, determining the significance of low GPR18 expression in
preterm placental VSMCs is essential to understanding the biological meaning and how
to mitigate it.
My studies would suggest further investigation of LXA4 and 14,15-DiHET as
potential metabolites with protective effects and possible use in treatment to reduce the
adverse outcomes associated with prematurity and NICU admission. Another avenue
would be to target GPR18 expression through the administration of RvD2. Previous
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studies demonstrated the increase in GPR18 in umbilical cord VSMC membrane
expression following RvD2 treatment, which would support the use of RvD2 in at-risk
populations.175

6.2. CLINICAL APPLICATION
The research begins to outline potential metabolites beneficial to infant growth
and development while also highlighting oxylipins that may be biomarkers of a poor
intrauterine environment. Analyzing all three tissues from the mother, placenta, and fetus
gives a better picture of oxylipin presence, regulation, and exposures. Results of this
study, along with the literature review, clearly indicate a need for an advanced
understanding of oxylipins across pregnancy.
With the current knowledge, women would be encouraged to eat balanced meals
with the recommended DHA + EPA intake while consuming n-6 fatty acids due to their
roles highlighted in infant weight. If supplementation is needed, baseline levels of
omega-3 fatty acids must be taken before recommendations can be made. Another
possibility would be supplementation with intermediates that are known to be broken
down into beneficial bioactive metabolites. For example, supplementation with 17HDHA, which would bypass DHA being metabolized into 7-HDHA, might reduce
inflammation and improve vascular functioning. This study and others have shown that
not all n-3 metabolites are beneficial, and maternal FA status is essential.
LXA4 has already begun to be considered a clinical treatment option. Cell and
animal studies have demonstrated the different roles of LXA4 in the various stages of
pregnancy and its ability to modulate inflammation and pregnancy outcomes.198
Findings from this study suggest LXA4 levels at delivery reduced the odds of NICU
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admission. Therefore, LXA4 may apply to pregnant women at risk for poor maternal-fetal
outcomes.

6.3. FUTURE RESEARCH
This study provides a comprehensive set of data for oxylipin levels present at
delivery in maternal plasma, cord plasma, and placental tissue. However, additional
information to supplement this study would include experiments exploring the regulation
of inflammation through cell culture studies, animal studies, and continued observational
and potential clinical interventions.
Cultured placental trophoblast cells and VSMCs should continue to explore the
mechanistic pathways activated during pregnancy. Currently, we are working to isolate
primary placental trophoblasts, but another process that may be useful is placental
explants. Placental explant cultures allow for the study of production and release of
secretory components, cell interactions, proliferation, growth and differentiation, and
more. Now that the GPR18 expression has been confirmed in the placenta and
expression altered by prematurity, explants could offer the ability to study preterm
placenta function, growth, and expression of GPR18 when stressed with an
inflammatory stimulus. Further, using cell lines to explore GPR18 knock-out would offer
baseline data on GPR18's role in vascular smooth muscle cells and extra-villous
trophoblasts.
Animal models exploring the administration of SPMs and their precursors would
offer data regarding the functional outcomes of the metabolites. Previous research
studied the administration of RvE3 to prevent prematurity after exposure to an
inflammatory stimulus.199(p1) Therefore, I would begin to expand this research using the
metabolites identified in this dissertation to treat mice and study mechanistic and
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functional outcomes. Mechanistically, I would identify pathways that are altered in knockout models as well as exogenous treatment. To understand the larger impact of these
pathways, I would use metabolites as an intervention at different points of pregnancy to
assess for alterations in implantation, placental development, and fetal outcomes,
including prematurity and infant growth and development. Further, this model would
allow mice to be followed longitudinally to determine the long-term impacts of treatment
with these metabolites and assess for adult disease.
Once mice models have provided important information, I would begin to assess
the use of sheep to model exposure and treatment with these metabolites. Sheep
models more closely resemble human gestation and allow for the fetal influence
maternal exposures at different time points during pregnancy have on offspring growth.
Animal studies are necessary to understand the importance of specific metabolites, the
consequences of exposures at other time points, and how nutrition relates.
Human longitudinal observational studies with multiple time points are needed
because the studies in this dissertation and many of the available studies lack the
continuity between maternal, placental, and cord samples across pregnancy. Without
longitudinal observations, a linear relationship for metabolites is assumed. However, FAs
and their eicosanoids follow a U-shaped curve, and sampling from only a few points
does not allow the relationships across pregnancy to be studied.184 In addition to
increased blood sampling, collection of maternal intake, n-3 and n-6 FA plasma
concentrations, and maternal-infant outcomes would provide an in-depth look into
metabolites during pregnancy. Furthermore, analysis of chemokines and cytokines
within the plasma and placental tissue in context with metabolites would help understand
how inflammation and these metabolites contribute to the inflammatory cascade.
Once cell cultures and animal models have formed a strong foundation for our
understanding of these metabolites, I would propose the metabolites identified in this
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dissertation work be added to the biomarkers that are used to identify disease. In
addition, the metabolites demonstrated to have beneficial effects on infant growth and
outcomes should be investigated as a target for interventions. Previous animal models
have shown that RvD2 treatment improved sepsis, and decreased obesity-induced
inflammation and cerebral injury. One study has shown that RvD3 administration
reduced prematurity in mice as well. Therefore, the next step would be to understand
how these SPMs and their intermediates can be harnessed to improve an inflammatory
intrauterine environment and reduce fetal exposures during development.

6.4. STRENGTHS AND LIMITATIONS
There are multiple strengths to this study. First, we had a diverse cohort of
maternal-infant pairs, including samples and clinical information on 23 preterm infants.
Few studies have conducted an extensive panel of n-6 and n-3 metabolites within
maternal plasma, cord plasma, and placental tissue to observe full maternal-infant
transfer dynamics. Second, we collected maternal and infant characteristics and
assessed n-3 and n-6 FA intake levels. Third, to my knowledge no other study has been
completed researching the different expression levels of GPR18 in preterm vs. term
deliveries. This highlights a potential link between oxylipins contribution to inflammation
and vascular remodeling. The effects of oxylipins on inflammation and cardiovascular
activity promote a mechanistic link for preterm birth.
Limitations of this study include not having longitudinal samples from early
pregnancy to delivery. This prevents me from determining if oxylipins are increased due
to higher production, decreased degradation, or both. Further, I did not explore the
influence of n-6 oxylipins production on n-3 oxylipin levels. Due to the nature of
observational studies, there may be multiple factors leading to altered fetal development.
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The data described in this dissertation must be understood in the larger context.
Therefore, current data does not allow for an understanding of how they regulate each
other and the productions of SPMs.
Reporting error is a limitation for maternal and infant outcomes. Maternal
outcomes such as pre-pregnancy BMI, smoking status, and dietary intake are selfreported. In addition, smoking status does not distinguish between frequency or forms of
smoking. Infant measurements are collected by trained nursing staff but may vary
depending on measuring tape placement.

6.5. CONCLUSION
LOX pathway n-3 and n-6 FA metabolites were quantified in maternal plasma,
umbilical cord plasma, and placental tissue at the time of delivery. Levels demonstrated
significant correlations between tissue samples and with maternal intakes. LOX pathway
metabolites in maternal, cord, and placental tissue influence infant growth metrics. LOX
and CYP450 oxylipins reduced the odds of NICU admission and prematurity,
respectively. Prematurity may contribute to, initiate or be the mechanism that leads to
reduced GPR18 expression in VSMCs. Future research is needed to identify the specific
pathways and benefits conferred to the developing infant.
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Appendix A. Parental Consent – Clinical Biomedical
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Appendix B. Harvard Food Frequency Questionnaire
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Appendix C. Maternal and Cord Plasma
Maternal and Cord Oxylipin Concentrations and Correlations between Maternal and
Cord Levels
Metabolite
Source
Median Levels
Rho (rs)
p-value
(nM) [IQR]
11_HETE
Maternal
1.81 [2.55]
0.41
<0.001 *
Cord
2.42 [2.68]
12_HEPE
Maternal
0.34 [0.82]
0.0046
0.97
Cord
0.25 [0.91]
12_HETE
Maternal
3.84 [6.59]
0.26
0.0089 *
Cord
8.32 [16.43]
13_HODE
Maternal
20.99 [14.56]
0.22
0.029 *
Cord
12.87 [8.70]
13_KODE
Maternal
2.31 [2.50]
0.25
0.018 *
Cord
1.44 [0.90]
15_HEPE
Maternal
0.29 [0.27]
0.14
0.40
Cord
0.20 [0.14]
15_HETE
Maternal
3.95 [5.62]
0.65
<0.001 *
Cord
5.27 [5.22]
15_HETrE
Maternal
0.72 [0.83]
0.31
0.0011 *
Cord
1.40 [1.09]
17_HDHA
Maternal
1.83 [2.63]
0.53
<0.001 *
Cord
2.16 [1.94]
5_15_DiHETE
Maternal
0.27 [1.31]
0.75
<0.001 *
Cord
0.16 [0.26]
5_HEPE
Maternal
0.40 [0.61]
0.48
<0.001 *
Cord
0.39 [0.29]
5_HETE
Maternal
5.86 [9.51]
0.49
<0.001 *
Cord
5.86 [5.30]
7_HDHA
Maternal
1.36 [2.54]
0.56
<0.001 *
Cord
1.16 [0.93]
8_HETE
Maternal
1.33 [1.76]
0.42
<0.001 *
Cord
2.08 [1.36]
9_HEPE
Maternal
0.19 [0.48]
0.36
0.080
Cord
0.12 [0.06]
9_HETE
Maternal
1.06 [1.89]
0.37
0.0001 *
Cord
2.24 [1.53]
9_HODE
Maternal
18.94 [19.57]
0.091
0.37
Cord
9.83 [6.40]
9_HOTrE
Maternal
1.46 [1.60]
0.19
0.065
Cord
0.47 [0.31]
Lipoxin_A4
Maternal
10.29 [11.73]
0.12
0.31
Cord
7.67 [7.61]
*p < 0.05
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Appendix D. QuPath Protocol Used for Analyzing Receptor Expression for
Vascular Smooth Muscle Cells and Extra-villous Trophoblasts
1. Open QuPath software and download the image you want to analyze.

2. Click on image. Go to Image type and change from Brightfield (H&E) to
brightfield (H-DAB). Click OK
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3. Click annotations and choose other

4. Then start the annotations. Choose the polygon tool (or click P on the keyboard)
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5. In the annotations tab on the left, click shift and highlight all your polygons. (or
click select all at the bottom of left panel)

6. Then go to Analyze (this step helps to increase quality of staining in image)
- Preprocessing
- Estimate stain vector
- Click Yes
- Click auto and ok
- Set name for stain vectors: H-DAB default and click OK
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7. Click analyze. Choose Cell Detection and then Positive cell detection

8. Positive cell detection
a. Setup parameters.
i. Choose Optical density sum
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ii. Requested pixel size: 0.2 um
b. Nucleus parameters. For EVT

c. Intensity parameters. Don’t change anything
d. Cell parameters. Don’t change anything
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e. General parameters. Don’t change anything
f. Intensity threshold parameters
i. Uncheck “include cell nucleus”
ii. Score compartment: Cell DAB OD mean

For EVT:
Threshold 1+ value: 0.05
Threshold 2+ value: 0.1
Threshold 3+ value: 0.2
i.

Uncheck single threshold
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9. Click Run. The system will run the analysis
10. Look for the analysis results. Click the first grid.

11. Click show detection measurements.
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Don’t need to do this part. This was used for determining thresholds
12. If you want to fill the detections. Click with the 3 filled figures.

Return to Steps Here
13. Click show histograms

14. Change to Cell DAB mean
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15. Go to objects and click annotations “merge selected”
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16. Then go to measure and click “show annotation measurements”

17. Will get the total number of 1+, 2+ and 3+ intensities. Do the percentages. [(Num
+1/Num Detected)*100]

Take screen shoots. Because saving will give you all the analysis. I will screen shoot
the Histogram and some maps.
18. Don’t save the changes
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EVT Positive cell detection

< 0.05 negative
0.05-0.1: +1
0.1-0.2: +2
> 0.2: +3
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